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CARDIOVASCULAR DISEASE AND THE ROLE OF INFLAMMATION 
AND HAEMOSTASIS 
Cardiovascular diseases are the main cause of death in industrialized countries, 
and they accounted for 35% of the total mortality in 2001 in the Netherlands 1. 
Cardiovascular diseases can be divided into two categories: venous diseases and 
arterial diseases. Venous diseases include deep venous thrombosis and 
pulmonary embolism, and arterial diseases include myocardial infarction (MI), 
peripheral occlusive disease and stroke. An important underlying cause of 
arterial events is often atherosclerosis, which is a disease of the arterial wall. 
Atherosclerosis is a progressive disease and may start at an early age. It is 
characterized by the deposition of cholesterol and minerals in the vessel wall of 
arteries, resulting in the formation of atherosclerotic plaques. During the 
progression of atherosclerosis a series of changes to the plaques occurs, in 
which invasion of inflammatory cells such as macrophages and lymphocytes 
into the plaque play a key role and weaken the structure of the plaque. 
Advanced lesions may rupture, which immediately initiates blood coagulation, 
resulting in the formation of a blood clot or thrombus. If the thrombus blocks 
the local blood flow, this will severely limit the oxygen supply to the 
downstream tissue, which then can cause myocardial infarction (MI) or stroke. 
Several lifestyle factors, such as smoking, nutritional habits and physical 
activity influence the process of atherosclerosis and other (subsequent) 
cardiovascular diseases (reviewed by Ross 2 and by Lusis 3). 
Factors that contribute to the development of cardiovascular disease have been 
investigated in many epidemiological studies. These studies have led to the 
identification of now well-established cardiovascular risk factors such as 
smoking, hypertension, elevated plasma cholesterol levels, diabetes, an 
increased body mass index (BMI) and a low level of physical activity 4,5. The 
traditional risk factors that are associated with metabolism (e.g. increased BMI, 
elevated cholesterol-, triglyceride-, lipoprotein-, insulin- or glucose levels, 
hypertension) often cluster in an individual, and they are together referred to as 
the metabolic syndrome (reviewed by Reilly and Rader 6). Nowadays there is 
much interest in the metabolic syndrome and in the importance of obesity in 
particular, as the number of overweight people has reached epidemic 
proportions in parts of the Western world 7. 
The traditional risk factors are important determinants of cardiovascular 
disease, but they cannot explain the entire risk, indicating that additional 
factors are also important 8. These other factors that can contribute to the risk 
of cardiovascular disease include the plasma levels of blood coagulation factors 
and inflammatory factors 9-11. 
Cardiovascular disease has a genetic component 12,13. There are many common 




levels of proteins important in coagulation, inflammation or metabolism, and 
these polymorphisms might contribute to the risk of cardiovascular disease. In 
addition, there is evidence that the effect of genetic variation may be 
particularly strong in the presence of specific environmental factors (reviewed 
by Humphries et al 14). Common variations in cardiovascular disease genes 
under the influence of specific external factors are the subject of this thesis. In 
addition to the common polymorphisms, rare genetic disorders with severe 
cardiovascular consequences also exist, but they are beyond the scope of this 
thesis. 
A strong relationship is present between cardiovascular disease and 
inflammation. Elevated plasma levels of inflammatory factors such as 
interleukin-6 (IL6), C-reactive protein (CRP) and fibrinogen are associated with 
an increased risk of atherosclerosis and coronary events 10,11,15-17. These 
inflammatory factors (IL6, CRP and fibrinogen are also called acute-phase 
proteins) play a dual role. On the one hand, their plasma levels reflect the 
severity of underlying atherosclerosis, which can be regarded as an 
inflammatory process 2. On the other hand, these factors may contribute 
directly to the progression of the disease 18-20. 
Blood coagulation is counteracted by fibrinolysis, and the regulation of both 
processes is strongly interrelated. Blood coagulation and fibrinolysis together 
are called the haemostatic balance (Figure 1). Blood coagulation is a defense 
mechanism of the body that stops bleeding, and the main functions of 
fibrinolysis are to prevent the obstruction of blood vessels and to remove the 
clot after wound healing. The process of blood coagulation is the result of a 
cascade of activation of the various clotting factors, leading to the formation of 
thrombin. Thrombin cleaves the soluble fibrinogen molecule, resulting in the 
formation of insoluble fibrin fibers, which form the blood clot together with the 
platelets. Fibrinolysis is the process of clearance of the fibrin clots, and a central 
step in fibrinolysis is the degradation of fibrin by plasmin. Plasmin is formed 
after the cleavage of its precursor plasminogen by plasminogen activators, and 
this process is controlled by plasminogen activator inhibitor-1 (PAI-1). Several 
studies have shown that the hypercoagulable state resulting from increased 
plasma levels of factors that promote coagulation or inhibit fibrinolysis are 
associated with an increased risk of arterial cardiovascular disease (reviewed by 
Folsom 21). 
Inflammation and coagulation are interconnected in several ways. For instance, 
inflammation can directly promote blood coagulation by increasing the 
expression of tissue factor, which initiates the extrinsic coagulation pathway. 
Another example is the coagulation factor thrombin, which can induce 
inflammatory responses (reviewed by Esmon 22,23). These examples illustrate 




































Figure 1: The blood coagulation cascade and the fibrinolytic system. A simplified 
overview of the haemostatic system is shown. For the sake of clarity, negative and positive 
feed-back systems have not been indicated. 
FIBRINOGEN 
THE FIBRINOGEN MOLECULE AND THE FIBRINOGEN GENES 
Fibrinogen is a glycoprotein that is present in plasma at concentrations of 2-4 
g/l. The liver is the source of fibrinogen. The fibrinogen molecule is composed 
of two sets of three different polypeptide chains: two Aα chains, two Bβ chains 
and two γ chains, and the chains are interconnected by disulphide bridges. In 
the last step of the coagulation cascade, thrombin cleaves off small peptides 
(the so-called fibrinopeptides A and B) from the amino terminal segments of 
the fibrinogen Aα and Bβ chains, which turns the soluble fibrinogen molecule 
into an insoluble fibrin monomer. The fibrin monomers polymerize and form 
fibrin polymers, which are cross-linked by factor XIIIa, leading to a network of 
fibrin fibers. Each fibrinogen chain is encoded by a separate gene, and the 
fibrinogen gene cluster comprises approximately 50 kb and is located on 
chromosome 4. Transcription of the three fibrinogen chains is tightly 
coordinated and in vitro studies have shown that synthesis of the β chain is 
rate-limiting in HepG2 hepatoma cells, which is the reason why much emphasis 




However, there are indications that elevated α or γ chain production may also 
increase the assembly of the mature fibrinogen molecule in HepG2 cells 25. 
Elevated plasma fibrinogen levels are a strong risk factor for cardiovascular 
disease 15,26. Fibrinogen is a coagulation factor, but also an acute phase reactant, 
and plasma fibrinogen levels strongly increase upon intense inflammatory 
stimuli such as strenuous exercise, trauma, infection, or surgery 27-29. In 
addition, fibrinogen levels are mildly increased in subjects that are exposed to 
mild and chronic inflammatory stimuli, such as smoking and progressive 
atherosclerosis 30-32. As an acute phase reactant, elevated fibrinogen levels are a 
marker of the severity of the inflammatory process of atherosclerosis, which is 
an explanation for the association between plasma fibrinogen levels and 
cardiovascular risk. However, there are also indications that fibrinogen may 
have a causal role in cardiovascular disease. Fibrinogen is found in the 
atherosclerotic plaque where it can contribute to the progression of 
atherosclerosis, for example by increasing the chemotaxis of smooth muscle 
cells or affecting the stability and structure of the plaque 18,33,34. In addition, 
studies with transgenic mice carrying the human apolipoprotein (a) [apo (a)] 
gene, have also indicated a causal role for fibrinogen in vascular disease. Apo 
(a) is the protein component of lipoprotein (a), which is a major factor in the 
development of atherosclerosis. In mice expressing human apo (a) but lacking 
fibrinogen, the development of atherosclerotic lesions was reduced by 80%, 
compared to control mice expressing fibrinogen and human apo (a). This again 
indicates a role for fibrinogen in the generation of atherosclerosis, and suggests 
that fibrinogen provides a binding site for apo (a) 19. 
The main inflammatory inducer of fibrinogen is the cytokine interleukin-6 
(IL6). Hepatocytes in culture respond to IL6 administration with a strong 
increase in fibrinogen production, and plasma IL6 levels are closely correlated 
with fibrinogen levels in vivo 35-38. The expression of the three fibrinogen genes 
is coordinately regulated, and the promoter regions of all three fibrinogen genes 
contain similar regulatory sequences. All three fibrinogen promoters contain 
IL6 responsive elements (IL6 REs) with the sequence CTGGGA, that have been 
proven to be functional, but for which the molecular mechanism is still under 
debate. Both the Aα and Bβ chain promoters contain a binding site for CCAAT-
box/enhancer-binding protein (C/EBP, also known as nuclear factor for 
interleukin-6 expression (NF-IL6) or liver-enriched activating protein (LAP)), 
and an hepatocyte nuclear factor-1 (HNF-1) element. Finally, in the Bβ and γ 
chain genes also sequences responsive to glucocorticoids have been identified 
(Figure 2) 39-43. In the fibrinogen β gene promoter, the IL6 RE and the C/EBP 
binding site are both required for the IL6 response of the gene. C/EBPβ has 
been shown to bind to the C/EBP element, but until now no transcription 
factors binding to the IL6 RE or to adjacent sequences have been identified, 
leaving the molecular mechanism of the IL6 response of the fibrinogen β gene 
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Figure 2: Schematic representation of the regulatory elements in the human 
fibrinogen α, β and γ chain gene promoters. Locations relative to the transcription 
start site are shown. Identification of the HNF-3 site in the fibrinogen β promoter is 
described in chapter 2 of this thesis, and the HNF-3 site depicted in the fibrinogen α 
promoter is a putative HNF-3 site. 
GENETIC VARIATION OF THE FIBRINOGEN β GENE AND PLASMA LEVELS OF 
FIBRINOGEN 
Fibrinogen plasma levels are partly genetically determined, and a recent study 
of twins estimated the heritability of fibrinogen plasma levels at 45% 45. Several 
genetic variations have been described in all three fibrinogen genes 46,47. The 
-455G/A polymorphism in the fibrinogen β promoter has been studied most 
often, and the -455A allele has been associated with elevated habitual plasma 
fibrinogen levels in many studies 48-54. Because elevated plasma levels of 
fibrinogen are associated with an increased risk of arterial cardiovascular 
disease, the relationship between polymorphisms in the fibrinogen gene and 
arterial disease has also been investigated. Although the association between 
fibrinogen plasma levels and genetic variation is fairly consistent, the 
relationship between polymorphisms in the fibrinogen β gene and arterial 
disease turns out to be much weaker (meta-analysis by Boekholdt et al 55 and 
reviewed by Folsom 21). However, there is evidence that the effect of genetic 
variation on plasma fibrinogen levels may be much more relevant under 
specific circumstances, and the presence of an interaction between genetic 
variation in the fibrinogen β promoter and inflammation has been suggested. 




and the response of fibrinogen levels to inflammatory triggers. These studies 
consistently report a stronger rise in fibrinogen levels in -455A allele carriers 
than in GG homozygotes, after exposure to strong acute phase stimuli such as 
trauma, strenuous exercise and surgery. However, it should be noted that the 
sample size of most of these studies has been small 27-29,56. 
Change from G to A at position -455 in the fibrinogen β promoter abolishes a 
recognition site for the restriction enzyme HaeIII site, and therefore 
determination of this polymorphism is simple. In the first studies on the 
relationship between fibrinogen plasma levels and genetic variation, positive 
results were obtained for the easily detectable -455G/A variation, and therefore 
this polymorphism has been investigated in the vast majority of the 
epidemiological surveys up until now. However, the -455G/A variation is in 
complete linkage disequilibrium with several other polymorphisms in 
Caucasians, including the -1420G/A, -993C/T, and -148C/T variations in the 
promoter region of the fibrinogen β gene (Figure 3) 57. Due to this allelic 
association, any of these other polymorphisms (or even a linked polymorphism 
located outside the promoter region of the fibrinogen β gene) could be 
responsible for the effects observed to be associated with the -455G/A alleles. 
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Figure 3: Schematic representation of the promoter regions of the fibrinogen 
β chain and PAI-1 genes. The locations of the common polymorphisms are indicated. 
PLASMINOGEN ACTIVATOR INHIBITOR-1 
THE PLASMINOGEN ACTIVATOR INHIBITOR-1 PROTEIN AND GENE 
Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with a molecular 
weight of 50 kD and it is a member of the serine protease inhibitor (serpin) 





hepatocytes, endothelial cells, fibroblasts, and smooth muscle cells produce 
PAI-1, but the relative importance of the contribution of these cell types to PAI-
1 plasma levels in vivo is still unclear. Expression of PAI-1 is mediated by 
several factors such as hormones 58,59, the cytokines TNF-α, IL-1 and TGF-β 60-
62, and several other factors including very low density lipoprotein (VLDL), fatty 
acids and glucose 63-65. PAI-1 exists in two forms in plasma, and the active form 
is stabilized by binding to vitronectin. PAI-1 controls fibrinolysis by a rapid 
inhibition of tissue-type plasminogen activator (t-PA), which is the major 
physiological activator of fibrinolysis, and increased PAI-1 levels result in 
impaired fibrinolytic capacity 66. Elevated PAI-1 levels have been associated 
with cardiovascular disease in several epidemiological studies 21,67,68. Elevated 
PAI-1 levels reflect a decreased fibrinolytic state and there is also evidence that 
PAI-1 can contribute causally to the development of cardiovascular disease. In 
transgenic mouse studies, wild-type mice developed thrombosis over two times 
faster than mice deficient in PAI-1, after injury to the carotid arteries 69. 
Elevated PAI-1 levels are associated with the features of the metabolic 
syndrome (e.g. elevated BMI, hypertension, hyperinsulinaemia, lipid disorders 
and increased cytokine levels, reviewed by Juhan-Vague and Alessi 70). This 
indicates that elevated PAI-1 levels, cardiovascular disease and several 
traditional cardiovascular risk factors are strongly related and may even 
represent different aspects of the same phenomenon. 
GENETIC VARIATION OF THE PAI-1 GENE AND PLASMA LEVELS OF PAI-1 
The heritability of PAI-1 levels has been estimated at 50-60% 21,71. Similarly as 
described above for the fibrinogen β gene, also in the PAI-1 gene several 
common genetic polymorphisms have been identified that are associated with 
the plasma levels of the protein 72. Because of this association and the fact that 
elevated plasma levels of PAI-1 are associated with an increased risk of arterial 
disease, the relationship also between the PAI-1 polymorphisms and arterial 
cardiovascular disease has been investigated. The -675(4G/5G) polymorphism 
in the promoter region of the PAI-1 gene has been investigated on many 
occasions. The -675(4G) allele has been associated with elevated plasma PAI-1 
levels, and occasionally also with an increased risk of cardiovascular disease 73-
77.  As is also the case for fibrinogen, the relationship between polymorphisms 
and plasma protein levels is fairly consistent, but the relationship between 
polymorphisms and arterial disease is again much weaker (meta-analysis by 
Boekholdt et al 55 and reviewed by Folsom 21). 
For PAI-1 also there is evidence that genetic variation in the promoter region of 
the gene may modulate the response of the gene to environmental triggers. 
There are indications that PAI-1 promoter genotype can influence the 
relationship between PAI-1 plasma levels and metabolic factors such as levels of 
triglycerides, insulin and plasma lipoproteins 72,78,79, but there are also studies 




Another common polymorphisms in the promoter region of the PAI-1 gene is 
the –844A/G variation, which is also located in the promoter region and is in 
strong, but not complete linkage disequilibrium with the -675(4G/5G) 
polymorphism (Figure 3) 82. 
THIS THESIS 
Evidence is emerging that genetic variation can not only change the constitutive 
protein expression, but may also influence the response of genes to external 
triggers, thereby possibly influencing the susceptibility of an individual to 
cardiovascular disease. 
In addition, it has been shown repeatedly that elevated fibrinogen plasma 
levels, and PAI-1 plasma levels are risk factors for cardiovascular disease. 
The aim of this thesis was to identify functional polymorphisms in the 
fibrinogen β and PAI-1 promoters, to determine their interaction with 
environmental factors, and to elucidate the underlying mechanisms. 
This thesis includes results of population-based association studies on the 
relationship between genetic variation and plasma protein levels, and the 
results of in vitro functional assays explaining the molecular mechanisms. 
In chapter 2 functional in vitro assays investigating the regulation of 
fibrinogen β promoter activity are described. A new binding site for the 
transcription factor HNF-3 is identified and its importance for the regulation of 
fibrinogen β promoter activity by the pro-inflammatory cytokine IL6 is 
illustrated. The activity of this HNF-3 binding site is influenced by genetic 
variation, which is explained in more detail in the next chapter. In chapter 3, 
the effect of fibrinogen β promoter haplotype on IL6-induced and basal 
fibrinogen β transcriptional activity is demonstrated using in vitro functional 
assays, and the -148C/T polymorphism is identified as the functional variation. 
The effect of the -148C/T variation on the response of the fibrinogen β 
promoter to IL6 is explained by the effect of this polymorphism on the activity 
of the newly identified HNF-3 element. Chapter 4 describes the results of a 
small in vivo association study. The interindividual variation in response by 
fibrinogen-, C- reactive protein- and IL6 plasma levels to a standardized 
inflammatory trigger is quantified in healthy individuals, and the contribution 
of genetic variation in the IL6 and fibrinogen β promoters to this 
interindividual variation is explored. Chapter 5 describes population-based 
association studies and in vitro functional assays, both on the effect of genetic 
variation in the PAI-1 promoter on PAI-1 expression levels. In the association 
studies we observed a significant relationship between PAI-1 promoter 
haplotype and PAI-1 antigen levels in lean individuals. However, no direct 





vitro. Chapter 6 includes a description of the associations of several 
environmental and genetic factors with PAI-1 plasma levels, in a population of 
healthy Dutch individuals. In chapter 7 the results described in this thesis are 
discussed and related to insights from the literature. 
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for a novel role of HNF-3 transcription factors 
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ABSTRACT 
Inflammation is an important process in the development of cardiovascular disease 
and therefore understanding the inflammatory response of cardiovascular risk 
factors is essential. Elevated plasma fibrinogen levels are an independent risk 
factor for cardiovascular disease, and the most important inducer of fibrinogen 
expression is the inflammatory mediator interleukin-6 (IL6). The aim of the 
present study was to gain more understanding of the hepatic acute phase response 
of fibrinogen. Using reporter gene assays and mutation analysis, we identified a 
functional HNF-3 binding motif located at –159/-151 in the fibrinogen β promoter. 
This HNF-3 site is essential for the full response of the gene to IL6, but is not 
required for basal promoter activity. EMSA experiments with HepG2 nuclear 
extracts revealed that HNF-3β binds to the HNF-3 site. Furthermore we show with 
functional assays that the activity of the IL6-responsive C/EBP site, located at 
-133/-125, is dependent on the integrity of the adjacent HNF-3 site and vice versa. 
The dependency of C/EBPβ on the functional HNF-3 site can explain the necessity 
of this HNF-3 site in the IL6 response. In this study we show the involvement of 
HNF-3 in cytokine-induced gene response, which is a new function for this family 





Inflammation is an important process in the development of cardiovascular 
disease, and increased plasma levels of several acute phase proteins including 
fibrinogen are consistently associated with an increased risk of cardiovascular 
disease 1-5. Inflammatory factors play a dual role. On the one hand their plasma 
levels reflect the severity of inflammatory processes in the vessel wall, and on 
the other hand inflammatory factors can contribute directly to the development 
of disease. Fibrinogen is found in the atherosclerotic plaque where it can 
contribute to the progression of atherosclerosis, for example by increasing the 
chemotaxis of smooth muscle cells 6 and affecting the stability and structure of 
the plaque 7-9. Because of the relationship of fibrinogen to atherosclerosis and 
cardiovascular events, much attention has been paid to the regulation of 
fibrinogen levels, both under basal and inflammatory conditions. 
The mature fibrinogen molecule is composed of 3 pairs of polypeptide chains: 
two α chains, two β chains and two γ chains, and in vitro functional studies 
showed that synthesis of the β chain is rate-limiting 10. Fibrinogen is expressed 
by the liver. Fibrinogen levels can strongly increase in response to intense acute 
phase stimuli such as trauma, surgery, or strenuous exercise, and fibrinogen 
levels are chronically elevated in the presence of mild (inflammatory) stimuli 
such as smoking or severe atherosclerosis 11-13. Interleukin-6 (IL6) is the main 
mediator of acute phase-induced fibrinogen synthesis, and sequences 
responsive to IL6 are present in the promoter regions of the genes coding for 
the three fibrinogen chains. In the promoter region of the fibrinogen β gene, 
several DNA sequences that are required for full IL6-induced expression have 
been identified; an hepatocyte nuclear factor-1 (HNF-1) site at approximately 
85 nucleotides upstream of the transcription start site, a CCAAT box/ 
enhancer-binding protein- (C/EBP) binding site, and an IL6 responsive 
element (IL6 RE) 14-16. The C/EBP binding site and the IL6 RE are located 
adjacent to each other at approximately 125 nucleotides upstream from the 
transcription start site. C/EBPβ (also named LAP or NF-IL6) has been 
identified as a transcription factor important in mediating the IL6 response of 
many liver acute phase genes (reviewed by Poli 17) and the binding of C/EBPβ to 
the fibrinogen β promoter has been demonstrated 15. The IL6 RE is located 4 
base pairs upstream of the C/EBPβ site, and it has been shown repeatedly that 
sequence changes in this element result in the loss of response of the gene to 
IL6 14-16. However, no transcription factor binding to this IL6 RE has been 
identified yet leaving the regulation of the hepatic IL6-induced fibrinogen β 
expression partly obscure. 
We here report the identification of a novel hepatocyte nuclear factor-3 (HNF-
3) binding site in the fibrinogen β promoter. This HNF-3 site is located just 
upstream of the IL6 RE and the C/EBP binding site, and it is directly involved 
in the hepatic IL6 response of the fibrinogen β gene. The newly identified HNF-
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3 site and the previously described C/EBP site mutually affect each other and 
this can explain the importance of this HNF-3 site for IL6-induced fibrinogen β 
expression. A direct involvement of HNF-3 (also named FoxA) in cytokine-




The human hepatoma cell lines HepG2 (American Type Culture Collection) and 
HuH7 18 were maintained in Dulbecco’s Modified Eagle’s medium (DMEM, 
Invitrogen) supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin (Bio Whittaker Europe) and 10% foetal bovine serum (FBS, 
Invitrogen). 
PGL3-FIBRINOGEN β PROMOTER REPORTER GENE CONSTRUCTS 
1800 bp of the promoter region of the fibrinogen β gene (-1788 to +8, taking 
position 1500 in Genbank accession number X05018 as +1, the transcription 
start site) was amplified by PCR on genomic DNA. In this PCR reaction 200 µM 
of each dNTP, 10 pmol of each primer (forward primer: 5’-TCT TAC GCG TGA 
AGA ATG CCA ATC AGA GTA-3’, reverse primer: 5’-TCA TCT CGA GTA GAC 
TTA ACT GAG AGA TCT TCA-3’), 3.5 U of High Fidelity polymerase (Roche) 
and 50 ng of genomic DNA in a total volume of 50 µl was used. The PCR 
conditions were 94°C for 5 min followed by 35 cycles of 94°C for 1 min, 51°C for 
1 min, 72°C for 4 min, and a final extension at 72°C for 5 min. PCR products 
were digested with MluI and XhoI (the restriction sites introduced are 
underlined in the primer sequences) and cloned into the MluI and XhoI sites of 
pGL3- basic (Promega), resulting in the pGL3-FGB wild-type construct. The 
putative HNF3 site at –159/-151 in the fibrinogen β promoter was mutated by 
site-directed mutagenesis (QuikChange® Site-Directed Mutagenesis Kit, 
Stratagene) as described by the manufacturer, using 10-30 ng of pGL3-FGB 
wild-type construct as template and the mutagenic primers with sequences 5’- 
GCA ACA TCT TCC CAG CAA AGC TGA AGT ACT TGT CAT ACA AC -3’ and 5’- 
GTT GTA TGA CAA GTA CTT CAG CTT TGC TGG GAA GAT GTT GC –3’. This 
resulted in a pGL3-basic-derived fibrinogen β promoter construct with the core 
of the putative HNF3 site at –159/-151 changed from TATTTACTT to 
GAAGTACTT (pGL3-FGB HNF3 mut). The identity of the clones was verified by 
sequencing. In addition to the constructs described above, constructs designed 
to study the C/EBP site at -133/-125 were also used. These constructs were 
already available at our institute and are described elsewhere 16. These pGL3-




or a 400 bp fibrinogen β promoter fragment with the core C/EBP site at –133/-
125 changed from GTTGCTTAA to GTTTAGTAA (pGL3-FGB C/EBP mut). The 
sequences of the region spanning from -165 to -115 of the newly created 
constructs (including 1800 bp promoter fragments), and the available 
constructs (including 400 bp promoter fragments), are shown in Table 1. 
VECTORS EXPRESSING TRANSCRIPTION FACTORS 
Vectors expressing HNF-3α, HNF-3β, HNF-3γ and C/EBPβ (pCDNA3.1-
HNF3α, pCDNA3.1-HNF3β, pCDNA3.1-HNF3γ, pSCT-C/EBPβ, all from rat 
origin) and their empty counterparts (pCDNA3.1-, pSCT-) were a kind gift from 
Dr. P. Holthuizen (Department of Physiological Chemistry, University of 
Utrecht, the Netherlands). 
Table 1: Wild-type and mutant fibrinogen β promoter sequences 
 
 






Consensus sequence 15,20 




 3’-YTYRKTTAT-5’           5’-CTTGCNNAA-3’ 
 
 
Mutations created in fibrinogen β pGL3-basic constructs 
 
pGL3-FGB HNF3 mut 




pGL3-FGB CEBP mut 





Sequences of oligonucleotides used in EMSAs 
 
Fib β wild-type oligo  5’-TATGACAAGTAAATAAGCTTTGCTGG-3’ 
 3’-ATACTGTTCATTTATTCGAAACGACC-5’ 
 
Fib β HNF3 mut oligo  5’-TATGACAAGTACTTCAGCTTTGCTGG-3’ 
 3’-ATACTGTTCATGAAGTCGAAACGACC-5’ 
 
HNF3 consensus oligo 
 
 




                   5’-VAWTRTTKRYTY-3’ 
 
The sequence of the wild-type fibrinogen β promoter, the consensus sequences of HNF-3 
and C/EBP binding sites, the mutations in the reporter gene constructs, and the complete 
sequences of the oligonucleotides used in EMSA experiments are shown. Note that different 
HNF-3 consensus sequences have been described, the one present in the fibrinogen β 




The role of HNF-3 in fibrinogeen β  gene regulation 
ANTIBODIES 
Polyclonal antibodies directed against HNF-3β (M-20 sc-6554X) and HNF-3γ 
(N-19 sc-5361X) were obtained from Santa Cruz Biotechnology, and antibodies 
directed against HNF-3α (2000007) were obtained from Geneka. 
Luciferase-reporter gene assays 
TRANSFECTION CONDITIONS 
HepG2 and HuH7 cells were plated in 24-wells plates in DMEM with 10% FBS 
at a density of 1.0 *105 cells per well. After allowing the cells to attach overnight, 
the medium was replaced with serum-free medium supplemented with 0.1% 
human serum albumin (HSA, Cealb®). After 2 h, cells were transfected using 
FuGene 6 (Roche), according to the manufacturer’s protocol. 200 ng of pGL3 
construct, 4 ng of pRL-tk (Renilla luciferase expression construct, Promega) 
were used per well. If applicable, vector expressing HNF-3α, HNF-3β, HNF-3γ, 
C/EBPβ, or a molar equivalent of empty expression vector as control were 
added. The total amount of DNA was kept at 400 ng per well with carrier DNA 
(herring sperm, Invitrogen). The effect of the empty expression vectors on 
fibrinogen β promoter activity and on the Renilla luciferase expression was 
determined for all conditions tested in this study, and no effects of the empty 
control vectors were detected. For each construct at least two independent DNA 
preparations were used, and all DNA preparations were transfected at least 
twice in triplicate. 24 hrs after transfection the medium was replaced with 
DMEM + 0.1% HSA, containing IL6 concentrations ranging from 0 to 2.5 
ng/ml (recombinant human IL6, Pepro Tech). 
LUCIFERASE ASSAY 
After culturing the cells for 24 hrs in the presence of IL6, cells were washed 
with 500 µl phosphate-buffered saline (PBS) and subsequently lysed for 15 
minutes on a rotary platform at room temperature with 100 µl Passive Lysis 
Buffer (PLB, Promega). The Firefly luciferase reporter and Renilla luciferase 
internal control activities were measured in 10 µl lysate, using the Dual-
Luciferase® Reporter Assay System (Promega). Luminescence was measured 
using a luminometer (Berthold). 
Electrophoretic Mobility Shift Assay (EMSA) 
PREPARATION OF NUCLEAR EXTRACTS 
HepG2 cells were cultured under serum-free conditions (DMEM P/S + 0.1% 
HSA) for 24h prior to preparation of the nuclear extracts. For the preparation 
of nuclear extracts of IL6-stimulated cells, cells were incubated with 5 ng/ml 
IL6 for 15 minutes. Cells were washed and lysed, and nuclear extracts were 




supplemented with protease inhibitor cocktail (CompleteTM Mini, Roche), and 
with phosphatase inhibitors (Na-orthovanadate, final concentration 250 µM; β-
glycerophosphate, final concentration 25 mM). The protein concentration in 
the nuclear extracts was estimated using the BCA micro kit (Pierce), and the 
samples were stored at –80°C for future use. 
OLIGONUCLEOTIDES 
Double stranded 26 bp oligonucleotides including the wild-type HNF-3 site (Fib 
β wild-type) or the mutated HNF-3 site (Fib β HNF3 mut) were designed. In 
addition, a double stranded 21 bp HNF-3 consensus oligonucleotide was 
designed according to the consensus sequence provided by Locker et al 20 
(Table 1). Pairs of complementary oligonucleotides were annealed at equimolar 
amounts and radioactively labelled at the 5’ ends with γ-32ATP (Amersham 
Pharmacia Biotech) using T4 polynucleotide kinase (Invitrogen). The double-
stranded and labelled oligonucleotides were purified using MicroSpin G-25 
Columns (Amersham Pharmacia Biotech), and stored at –20°C for future use. 
BINDING REACTION AND ELECTROPHORESIS 
For each binding reaction, 3 µg of nuclear extract was pre-incubated for 30 
minutes on ice with 5 µg poly dIdC (Amersham Pharmacia Biotech ) in a 12 µl 
reaction mixture containing 10 mM Hepes (pH 7.9), 100 mM KCl, 25 mM 
MgCl2, 1 mM dithiothreitol, 0.05 mM EDTA, 0.1% (v/v) NP40, 10% (v/v) 
glycerol, 0.03 mg/ml BSA, 250 µM Na-orthovanadate and 25 mM β-
glycerophosphate. Subsequently, the labelled oligonucleodides were added to 
the pre-binding reactions and this mixture was incubated for another 30 
minutes on ice. After this and if applicable, 3 µg of antibody directed against the 
HNF-3 isoforms was added to the binding reaction and incubated for an 
additional 30 minutes on ice. Competition assays were performed by adding a 
100-fold molar excess of unlabelled double-stranded oligonucleotides to the 
radioactive oligonucleotides, prior to their addition to the binding reaction. The 
reaction products were loaded onto 5% non-denaturing polyacrylamide gels 
and run in 0.25x TBE (1x TBE = 0.1M Tris, 0.09M Boric Acid, 0.001M EDTA). 
Gels were blotted on Whatmann paper and bands were visualized by 
autoradiography. 
STATISTICAL METHODS 
Firefly luciferase activity was normalized for transfection efficiency using 
Renilla luciferase activity as the internal standard. These normalized luciferase 
activity levels were expressed as a percentage of the normalized luciferase 
activity of the pGL3-FGB wild-type construct at baseline. Normalized 
expression levels of the wild-type fibrinogen β promoter constructs were 
compared with the normalized expression levels of the mutant constructs using 
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RESULTS 
A nearly perfect HNF-3 consensus sequence was identified after a search for 
putative transcription factor binding sites with MatInspector Professional 21. 
This putative HNF-3 site is located at position -159/-151 in relation to the 
transcription start site in the fibrinogen β promoter, just upstream of the 
C/EBP binding site and the IL6 RE (Table 1). This region of the fibrinogen β 
promoter is highly conserved during mammalian evolution, as an alignment of 
human, mouse and rat sequences indicated (data not shown). Because of our 
interest in the possible role of this site in the regulation of the IL6 response of 
fibrinogen, the functionality of this putative HNF-3 site was investigated. 
All HNF-3 family members transactivate the fibrinogen β promoter 
The pGL3-FGB wild-type construct including 1800 bp of the proximal 
fibrinogen β promoter was transfected into HepG2 cells in the presence of one 
of the overexpressed HNF-3 isoforms, and the luciferase activity was 
determined. The fibrinogen β promoter responded strongly to all HNF-3 
isoforms. Promoter activity increased 2-fold in the presence of HNF-3α, 9-fold 
in the presence of HNF-3β and up to 5-fold in the presence of HNF-3γ, when a 
maximum of 500 pg of vector expressing the HNF-3 isoforms was cotransfected 
(Figure 1). This demonstrates that the fibrinogen β promoter is activated by 
overexpression of HNF-3 isoforms, which may be explained by the presence of 
a functional HNF-3 site in the first 1800 bp of the fibrinogen β promoter. 
Identification of an HNF-3 responsive site at –159/-151 in the fibrinogen β 
promoter 
To explore whether the putative HNF-3 site at position –159/ -151 is functional, 
the core sequence of this site was changed from TATTTACTT to GAAGTACTT 
by site-directed mutagenesis, and the mutant luciferase constructs were 
transfected into HepG2 cells. No important effect of mutation of the HNF-3 site 
on basal expression was observed (Figures 1, 3a and 4a). Cotransfection 
experiments with vectors expressing the HNF-3 isoforms revealed that 
mutation of the putative HNF-3 site resulted in a significant loss of response of 
the promoter to overexpressed HNF-3. After mutation, the fibrinogen β 
promoter did not respond to HNF-3α any more, the maximal response to HNF-
3β had decreased from 9-fold to 3-fold, and the maximal response to HNF-3γ 
had decreased from 5-fold to 3-fold (Figure 1). These results from experiments 
with mutant constructs show that the HNF-3 site at –159/-151 in the fibrinogen 
β promoter is functional, but apparently not essential for basal promoter 
activity. Similar results were obtained in another liver-derived cell line, HuH7. 
However, the response of the fibrinogen β promoter to overexpressed HNF-3 






pg HNF-3 expression vector/ well
 
Figure 1: Transactivation of wild-type and mutant fibrinogen β promoter 
variants by HNF-3 isoforms and identification of a functional HNF-3 site at 
-159/-151. Fibrinogen β promoter reporter gene constructs were transfected into HepG2 
cells, in the presence of increasing amounts of HNF-3α, HNF-3β or HNF-3γ expression 
vector. Differences in activity between the wild-type and HNF-3 mutant were significant at 
all HNF-3α and at all HNF-3β concentrations, and at concentrations above 50 pg of HNF-
3γ expression vector (p<0.005 in all these cases). Normalized luciferase activities are 
expressed in relation to baseline activity of the wild-type promoter construct and means (± 
SDs) of triplicate transfections are shown. 
HNF-3β binds to the –159/-151 sequence in the fibrinogen β promoter 
To detect nuclear proteins binding to the HNF-3 responsive site in the 
fibrinogen β promoter, electrophoretic mobility shift assays were performed 
(Figure 2). When oligonucleotides representing the wild-type HNF-3 element 
(Fib β wild-type), the mutant HNF-3 element (Fib β HNF3 mut) or an HNF-3 
consensus site were incubated with HepG2 nuclear extracts, binding of a 
nuclear complex to the HNF-3 consensus oligonucleotide (lane 1) and to the 
fibrinogen β wild-type oligonucleotide (lane 3) was observed. However, no 
binding of nuclear proteins to the fibrinogen β mutant oligonucleotide was 
observed (lane 8). The complex on the fibrinogen β wild-type oligonucleotide 
disappeared when 100-fold excess of cold HNF-3 consensus oligonucleotide 
was added, showing that the nuclear protein binding the –159/-151 sequence in 
the fibrinogen β promoter also recognizes this HNF-3 consensus sequence (lane 
4). The mobility of the complex was retarded when an antibody directed against 
HNF-3β was added (lane 6), but not when antibodies directing against HNF-3α 
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(lane 5) or HNF-3γ (lane 7), were added. These results show that in HepG2 
nuclear extracts, the protein binding to the HNF-3 responsive site at –159/-151 














Figure 2: Binding of HNF-3β to the HNF-3 site at –159/-151 in the fibrinogen 
β promoter. Labelled oligonucleotides representing the HNF-3 site in the wild-type 
fibrinogen β promoter (lane 3, 4, 5, 6, 7), the mutated HNF-3 site in the fibrinogen β 
promoter (lane 8), or the HNF-3 consensus oligonucleotide (lane 1) were incubated with 
nuclear extracts derived from HepG2 cells cultured under basal conditions. 100-fold molar 
excess of cold HNF-3 consensus oligonucleotide was added in lane 4, and antibodies 
against HNF-3α (lane 5), HNF-3β (lane 6) and HNF-3γ (lane 7) were used, and lane 2 was 
left empty. The locations of HNF-3 and the supershifted complexes (ss) are indicated by 
arrows. 
Integrity of the HNF-3 site is important for IL6-induced fibrinogen β 
promoter activity 
The HNF-3 site identified at –159/-151 is located next to previously described 
IL6 responsive sequences, and therefore the function of the HNF-3 site in IL6-
induced fibrinogen β promoter activity was studied. The addition of 2.5 ng/ml 




bp of the proximal wild-type fibrinogen β promoter resulted in an increase of 
12-fold of basal promoter activity (Figure 3a). The promoter variant with the 
mutated HNF-3 site however, responded to this IL6 concentration with a 
smaller increase of 5-fold only. Also at lower IL6 concentrations, mutation of 
the HNF-3 site reduced the IL6 response of the fibrinogen β promoter 
approximately by a factor of 2.5. These results show that this HNF-3 site is 
important for IL6-induced fibrinogen β promoter activity. Similar results were 
obtained in HuH7 cells, although the overall response to IL6 of the fibrinogen β 




Figure 3a: The HNF-3 site at –159/-151 in the fibrinogen β promoter is required 
for the full response of the fibrinogen β promoter to IL6. Fibrinogen β promoter 
reporter gene constructs were transfected into HepG2 cells, and cells were subsequently 
treated with IL6. At all IL6 concentrations, the IL6-induced activity of the wild-type 
promoter was significantly higher than the induced activity of the HNF-3 mutant promoter 
(p<0.0003 in all these cases). Normalized luciferase activities are expressed in relation to 
baseline activity of the wild-type promoter construct, and means (± SDs) of triplicate 
transfections are shown. 
Binding of HNF-3β under IL6-induced conditions 
To investigate whether IL6 influences the binding of HNF-3β to the fibrinogen 
β promoter, electrophoretic mobility shift assays were performed with basal 
(lanes 1, 3 and 4) and IL6-treated (lanes 5 to 7) HepG2 nuclear extracts (Figure 
3b). The binding of a single complex to the fibrinogen β wild-type 
oligonucleotide (Fib β wild-type) was observed under basal (lane 3) and IL6-
induced conditions (lane 5). 
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Figure 3b: Binding of HNF-3β to the HNF-3 site at –159/-151 in the fibrinogen 
β promoter under IL6-induced conditions. Labelled oligonucleotides representing 
the HNF-3 site in the wild-type fibrinogen β promoter (lane 3, 4, 5, 6, 7) or the HNF-3 
consensus oligonucleotide (lane 1) were incubated with nuclear extracts (NE) derived from 
HepG2 cells cultured under basal conditions (lane 1, 3, 4) or in the presence of IL6 (lane 5, 
6, 7). 100-fold molar excess of cold HNF-3 consensus oligonucleotide was added in lane 6, 
and antibodies against HNF-3β were used in lane 4 and 7. Lane 2 was left empty. The 
locations of HNF-3 and the supershifted complexes (ss) are indicated by arrows. 
The complex binding under IL6-induced conditions disappeared when 100-fold 
excess of cold HNF-3 consensus oligonucleotide was added (lane 6) and was 
retarded after the addition of an antibody directed against HNF-3β (lane 7), 
identifying this nuclear complex as HNF-3β. These results were similar to what 
was observed under basal conditions, so there was no qualitative effect of IL6 





Interaction between the HNF-3 and C/EBP sites 
To investigate whether the HNF-3 site and the C/EBPβ site interact, 
transfection experiments were performed with both the wild-type and the 
mutated fibrinogen β promoter constructs in the presence of overexpressed 
C/EBPβ. The wild-type fibrinogen β promoter responded strongly to 
overexpressed C/EBPβ, but mutation of the HNF-3 site severely reduced the 
responsiveness of the fibrinogen β promoter to C/EBPβ (Figure 4a). When 250 
pg of vectors expressing C/EBPβ were cotransfected, the presence of the 
mutated HNF-3 site decreased the maximal response from 7-fold to 3-fold. A 




Figure 4a: The HNF-3 site and the C/EBP site in the fibrinogen β promoter 
interact with each other. Fibrinogen β promoter reporter gene constructs were 
transfected into HepG2 cells. Constructs including 1800 bp of the fibrinogen β promoter 
(wild-type or HNF3 mutant) were transfected together with increasing amounts of C/EBPβ 
expression vector. At all C/EBPβ expression vector concentrations, the C/EBPβ-induced 
activity of the wild-type promoter was significantly higher than the induced activity of the 
HNF-3 mutant promoter (p<0.0003 in all these cases) 
This shows that the response of the fibrinogen β promoter to C/EBPβ is 
dependent on the integrity of the HNF-3 site at –159/-151. However, mutation 
of the HNF-3 site strongly decreases the response to C/EBPβ but does not 
completely abolish the response. This indicates that the HNF-3 site is very 
important for the C/EBP response, but is not an absolute requirement. 
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Figure 4b: The C/EBP site and the HNF-3 site in the fibrinogen β promoter 
interact with each other. Constructs including 400 bp of the fibrinogen β promoter 
(wild-type or C/EBP mutant) were transfected together with increasing amounts of HNF-3β 
expression vector, and the differences in activity between the wild-type promoter and the 
C/EBP mutant were significant at all HNF-3β expression vector concentrations (p<0.005). 
(left panel). Constructs including the wild-type or C/EBP mutant fibrinogen β promoter 
(400 bp fragments) were transfected in the presence of IL6 or overexpressed C/EBPβ. The 
wild-type promoter responded significantly more strongly than the C/EBP mutant to 500 
pg of cotransfected C/EBPβ expression vector (p=0.002), and to 2.5 ng/ml IL6 (p=0.01) 
(right panel). Normalized luciferase activities are expressed in relation to baseline activity 
of the wild-type promoter constructs, and means (±SD) of triplicate transfections are 
shown. 
Subsequently, we examined whether an intact C/EBP site at position -133/-125 
is necessary for the response of the gene to HNF-3β. In these experiments, 
pGL3-basic-derived constructs including 400 bp of the proximal fibrinogen β 
promoter were used, and these constructs were already available at our institute 
16. In the presence of 1000 pg of HNF-3β expression vector, the activity of the 
wild-type fibrinogen β promoter increased 2-fold, whereas the activity of the 
fibrinogen β promoter with the mutated C/EBP site was barely induced by 
HNF-3β (Figure 4b, left panel). Similar results were obtained at lower HNF-
3β concentrations. This shows that the HNF-3 response of the fibrinogen β 
promoter requires a functional C/EBP site at -133/-125. To summarize, these 





Finally, additional transfection assays were performed to confirm the 
previously reported requirement of the C/EBP site for the IL6 response of the 
fibrinogen β promoter 14,15. The activity of the wild-type promoter increased 5.5-
fold upon cotransfection of 500 pg of C/EBPβ expression vectors and 4-fold in 
response to 2.5 ng/ml IL6 (Figure 4b, right panel). The promoter with the 
mutated C/EBP site however, responded to C/EBPβ with an increase in activity 
of only 2.5-fold and did not respond to 2.5 ng/ml IL6, underlining the 









Figure 5: HNF-3β, C/EBPβ and IL6 synergistically enhance fibrinogen β 
promoter activity. Reporter gene constructs including 400 bp of the wild-type fibrinogen 
β promoter were transfected into HepG2 cells, in the presence or absence of 500 pg of 
HNF-3β expression vector, and/ or 250 pg of C/EBPβ expression vector, and/ or 2 ng/ml 
IL6. Normalized luciferase activities are expressed in relation to baseline activity and 
means (±SD) of triplicate transfections are shown 
Synergistic effects of HNF-3β, interleukin-6 and C/EBPβ on fibrinogen β 
promoter activity 
To study the combined effect of HNF-3β, IL6 and C/EBPβ on the fibrinogen β 
promoter, the pGL3-basic constructs including 400 bp of the wild-type 
fibrinogen β promoter were used 16. The activity of the fibrinogen promoter 
increased 2.5-fold in the presence of 500 pg vectors expressing HNF-3β, and 
increased 13-fold in response to 2 ng/ml IL6 (Figure 5). However, when HNF-
3β and IL6 were added simultaneously, the activity of the fibrinogen β 
promoter increased 40-fold, showing that HNF-3β and IL6 synergistically 
enhance fibrinogen β promoter activity. For C/EBPβ and IL6 a similar effect 
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was observed. The addition of C/EBPβ alone (250 pg expression vector) 
resulted in a 10-fold increase of promoter activity, but when added together 
with IL6, fibrinogen β promoter activity increased 60-fold. Also for HNF-3β 
and C/EBPβ a synergistic effect was observed, as the addition of HNF-3β and 
C/EBPβ together increased promoter activity 20-fold. Finally, when HNF-3β, 
C/EBPβ and IL6 were all present, fibrinogen β promoter activity increased 85-
fold compared to the basal expression level. Synergistic stimulation of IL6-
induced fibrinogen β promoter activity indicates that both C/EBPβ and HNF-3β 
are important components of the transcriptional complex regulating the IL6 
response of the fibrinogen β gene. 
DISCUSSION 
In this study, we identified a new functional HNF-3 site at –159/-151 in the 
fibrinogen β promoter and we demonstrated its involvement in the IL6 
response of the gene. The transcription factor C/EBPβ, which is activated by 
IL6, plays a central role in the IL6 induction of the fibrinogen β gene (reviewed 
by Poli 17). We observed that the integrity of the HNF-3 site identified is 
required in order to obtain full response of the promoter to C/EBPβ, which 
could explain the importance of the HNF-3 site in the IL6 response of the 
fibrinogen β promoter. In addition, we observed that C/EBPβ and HNF-3β 
synergistically activate the fibrinogen β promoter. Our results indicate that 
HNF-3 is most likely part of the transcriptional complex controlling the IL6 
response of the fibrinogen β promoter. 
Because of our interest in the inflammatory response of the fibrinogen β gene, 
we have focused on the HNF-3 site adjacent to IL6 responsive sequences. 
However, there may be other functional HNF-3 sites present in the fibrinogen β 
promoter that have not been identified yet. Our initial in silico promoter 
analysis did indeed reveal several possible HNF-3 binding motifs and our 
experimental results also imply the presence of a functional HNF-3 element 
beside the site at -159/-151. We observed that the long (1800 bp) fibrinogen β 
promoter fragments responded much more strongly to overexpression of HNF-
3 than the short (400 bp) promoter fragments, which could be explained by an 
additional HNF-3 site in the long fragment (compare Figure 1 and Figure 4b). 
Secondly, the response of the promoter to HNF-3 was strongly reduced by the 
mutation of the HNF-3 site at -159/-151, but not completely abolished. This is 
again an indication of the presence of an additional HNF-3 element further 
upstream in the fibrinogen β promoter. In theory, this latter observation might 
also be explained by a reduced but not completely abolished affinity of the 
HNF-3 site by mutation. However, this hypothesis is counteracted by our 
results from EMSA experiments, showing that after the introduction of this 




indicating that the HNF-3 site was indeed completely disrupted by the 
mutation we created. Therefore, our results indicate the presence of an 
additional HNF-3 site present between -400 and -1800 bp in the fibrinogen β 
promoter. 
Functional C/EBPβ-binding motifs have been characterized in the promoters of 
numerous acute-phase genes, including haptoglobin, C-reactive protein, serum 
amyloid A, fibrinogen α and fibrinogen β. The activity of C/EBPβ is mainly 
regulated by its phosphorylation status, and interleukin-6 is able to activate 
C/EBPβ by phosphorylation. Phosphorylation of C/EBPβ leads to increased 
transactivating potency, thus conferring early acute phase signals to the 
promoters of C/EBP-regulated acute phase genes (reviewed by Poli 17). The 
HNF-3 transcription factors (HNF-3α, -3β, and -3γ) are regulators of genes 
important in inflammation and development, and in contrast to C/EBP, HNF-3 
expression is regulated at the transcriptional level. Cytokine-responsive 
C/EBPβ and C/EBPδ proteins induce the HNF-3β promoter upon activation by 
cytokines, and can pass delayed interleukin-6 and interleukin-1 stimulation on 
to HNF-3β responsive promoters 22. It has been shown in vitro that HNF-3, but 
not C/EBP, can bind to its binding site in compacted chromatin and open the 
local nucleosomal domain. The ability of HNF-3 to open chromatin is mediated 
by a high affinity DNA-binding site, and a C-terminal domain of the protein 
which binds histones 23. The synergistic enhancement of fibrinogen β promoter 
activity by HNF-3 and C/EBP that we observed in our experiments, suggests 
that HNF-3 and C/EBP cooperate. The different mechanisms of promoter 
activation by HNF-3β and C/EBPβ, briefly described above, may provide a 
hypothesis for this cooperation. HNF-3 could make the IL6 responsive 
sequences in the DNA accessible for IL6-activated transcription factors such as 
C/EBPβ, which then activate the promoter. Cooperation between HNF-3 and 
C/EBP is in line with previous reports, in which synergistic enhancement of 
target promoters by HNF-3 and C/EBPβ has been described 24. In addition, 
HNF-3 has also been shown to synergize with other transcription factors 
including STAT3 and p53 25,26. 
In this study we show that mutations in the HNF-3 binding sequence 8 bp 
upstream of the IL6 RE result in a strongly decreased IL6 response, and we 
confirm that mutations in the C/EBP element located 4 bp downstream of the 
IL6 RE also lead to a reduced IL6 response. In addition, a common C to T 
polymorphism is located at position -148, three base pairs downstream of the 
HNF-3 binding site, and there is evidence that this polymorphism affects 
fibrinogen β promoter activity 27. Between the HNF-3 site at position –159/ -151 
and the C/EBP site at position –143/-137, an IL6 RE is located (Table 1). 
Mutations in this IL6 RE result in loss of IL6 response of the fibrinogen β 
promoter 14-16. This shows that the entire highly conserved DNA sequence from 
-160 to -125 in the fibrinogen β promoter is involved in the regulation of 
fibrinogen β gene expression, and more specifically in the IL6 response of the 
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gene. So far, no transcription factor binding to the IL6 RE has been identified. 
The IL6 RE may bind a transcription factor of its own, or it may be required for 
a correct positioning of the HNF-3 and C/EBP sites in relation to each other, or 
both. The fact that a possible third transcription factor has never been found 
might be explained by the fact that this factor may only bind in the 
simultaneous presence of HNF-3 and C/EBPβ. Since EMSA experiments are 
usually performed with an excess of oligonucleotide, the complex containing 
the three transcription factors will not be formed in such experiments.  
The DNA sequence of the IL6 RE in the human fibrinogen β promoter is 
identical to the sequence of the three IL6 REs in the human fibrinogen γ 
promoter, and it has been shown recently that signal transducer and activator 
of transcription-3 (STAT3) binds to each of the three IL6 REs in the fibrinogen 
γ promoter 28. Therefore STAT3 could be an interesting candidate for binding to 
the IL6 RE in the fibrinogen β promoter, and similar cooperative interaction of 
different sites such as we at present propose for the fibrinogen β promoter may 
also be important for the fibrinogen γ promoter. 
 
Sequence of the CRP promoter (-81 to –40 in relation to the tss) 
5’- CAATGTTGGA AAATTATTTA CATAGTGGCG CAAACTCCCT –3’ 
                                        
 
Sequence of the fibrinogen α promoter ( -163 to –126 in relation to the tss) 
5’- GGAAG CAAACAAGCT GAGGGGAATT GAGCAAGAAT TTCTG –3’ 





Figure 6: Putative HNF-3 sites in the fibrinogen α and C-reactive protein 
promoters. The fibrinogen α promoter and C-reactive protein promoter sequences 
include putative HNF-3 sites adjacent to cytokine-responsive C/EBPβ sites 29,30. 
The role of HNF-3 in the IL6-regulated gene response that we describe, could 
be shared by other acute phase genes. Indeed, inspection of promoter regions of 
several other acute phase genes revealed that the C-reactive protein promoter 
and the fibrinogen α promoter have putative HNF-3 sites located within a few 
base pairs from cytokine responsive C/EBPβ elements 29,30 (Figure 6), 
indicating that the involvement of HNF-3 in the IL6 response may in fact be a 




To summarize, we have identified a functional HNF-3 site at position –159/-151 
in the fibrinogen β promoter that is important for interleukin-6-induced 
fibrinogen β promoter activity. The necessity of HNF-3 in the IL6 response can 
be explained by the dependency of the adjacent IL6-responsive C/EBP site on 
this HNF-3 site. This work contributes to the understanding of the regulation of 
the hepatic acute-phase response of fibrinogen β, and it demonstrates a new 
function for HNF-3. 
ACKNOWLEDGEMENTS 
We thank Dr. P. Holthuizen for providing the transcription factor expression 
vectors. Furthermore we would like to thank Mrs. H. Richardson for the 
English correction. 
REFERENCES 
(1)  Smith EB, Alexander KM, Massie IB. Insoluble "fibrin" in human aortic intima Quantitative 
studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density 
lipoprotein. Atherosclerosis. 1976;23:19-39. 
(2)  Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischemic heart disease: 
principal results from the Northwick Park Heart Study. Lancet. 1986;2:533-537. 
(3)  Yarnell JW, Baker IA, Sweetnam PM et al. Fibrinogen, viscosity, and white blood cell count 
are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative 
heart disease studies. Circulation. 1991;83:836-844. 
(4)  Koster T, Rosendaal FR, Reitsma PH, Vandenbroucke JP, Briët E. Factor VII and fibrinogen 
levels as risk factors for venous thrombosis. Thromb Haemost. 1994;71:719-722. 
(5)  Folsom AR. Hemostatic risk factors for atherothrombotic disease: An epidemiologic view. 
Thromb Haemost. 2001;86:366-373. 
(6) Naito M, Hayashi T, Kuzuya M et al. Effects of fibrinogen and fibrin on the migration of 
vascular smooth muscle cells in vitro. Atherosclerosis. 1990;83:9-14. 
(7)  Koopman JL, de Maat MPM. Fibrinogen structure and thrombosis. In: Schafer AI, ed. 
Molecular mechanisms of hypercoagulable states. Austin, Texas, USA: Landes Bioscience; 
1997:125-140. 
(8)  Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces 
vascular accumulation of apolipoprotein(a) and development of atherosclerosis in 
apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA. 1998;95:12591-12595. 
(9)  Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol. 
1999;31:741-746. 
(10) Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. J Biol Chem. 
1990;265:6389-6393. 
(11) Schuit AJ, Schouten EG, Kluft C et al. Effect of strenuous exercise on fibrinogen and 
fibrinolysis in healthy elderly men and women. Thromb Haemost. 1997;78:845-851. 
(12) Scarabin PY, Aillaud MF, Amouyel P et al. Associations of fibrinogen, factor FVII and PAI-1 
with baseline findings among 10,500 male participants in a prospective study of myocardial 
infarction. Thromb Haemost. 1998;80:749-756. 
 44
 
The role of HNF-3 in fibrinogeen β  gene regulation 
(13) Erren M, Reinecke H, Junker R et al. Systemic inflammatory parameters in patients with 
atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 
1999;19:2355-2363. 
(14) Anderson GM, Shaw AR, Shafer JA. Functional characterisation of promoter elements 
involved in regulation of human Bβ-fibrinogen expression. J Biol Chem. 1993;268:22650-
22655. 
(15) Dalmon J, Laurent M, Courtois G. The human β fibrinogen promoter contains a hepatocyte 
nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol. 1993;13:1183-1193. 
(16) Gervois P, Vu-Dac N, Kleemann R et al. Negative regulation of human fibrinogen gene 
expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT 
box/enhancer-binding protein β. J Biol Chem. 2001;276:33471-33477. 
(17) Poli V. The role of C/EBP isoforms in the control of inflammatory and native immune 
functions. J Biol Chem. 1998;273:29279-29282. 
(18) Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell 
lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42:3858-
3863. 
(19) Slomiany BA, Kelly MM, Kurtz DT. Extraction of nuclear proteins with increased binding 
activity. BioTechniques. 2000;28:938-942. 
(20) Locker J. RNA polymerase II transcription controls of animals: DNA binding sites and 
transcription factors. In: Locker J, ed. Transcription Factors. John Wiley & Sons; 1996:12-55. 
(21) Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast 
and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic 
Acids Res. 1995;23:4878-4884. 
(22) Costa RH. Hepatocyte nuclear factor 3/forkhead protein family. In: Tronche F, Yaniv M, 
eds. Liver gene expression. Paris, France: R.G. Landes Company; 1994:183-205. 
(23) Cirillo LA, Lin FR, Cuesta I et al. Opening of compacted chromatin by early developmental 
transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002;9:279-289. 
(24) Antes TJ, Levy-Wilson B. HNF-3β, C/EBPβ, and HNF-4 act in synergy to enhance 
transcription of the human apolipoprotein B gene in intestinal cells. DNA Cell Biol. 
2001;20:67-74. 
(25) Lee KC, Crowe AJ, Barton MC. p53-Mediated repression of alpha-fetoprotein gene 
expression by specific DNA binding. Mol Cell Biol. 1999;19:1279-1288. 
(26) Waris G, Siddiqui A. Interaction between STAT-3 and HNF-3 leads to the activation of 
liver-specific hepatitis B virus enhancer 1 function. J Virol. 2002;76:2721-2729. 
(27) Green FR. Fibrinogen polymorphisms and athero-thrombotic disease. Ann N Y Acad Sci. 
2001;936:549-559. 
(28) Duan HO, Simpson-Haidaris PJ. Functional analysis of IL-6RE on the human γ-fibrinogen 
promoter. J Biol Chem. In press. 
(29) Liu Z, Fuller GM. Detection of a novel transcription factor for the Aα fibrinogen gene in 
response to interleukin-6. J Biol Chem. 1995;270:7580-7586. 
(30) Kleemann R, Gervois PP, Verschuren L et al. Fibrates down-regulate IL-1-stimulated C-
reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkB - C/EBP-beta 
complex formation. Blood. 2002. 
(31) Overdier DG, Porcella A, Costa RH. The DNA-binding specificity of the hepatocyte nuclear 
factor 3/ forkhead domain is influenced by amino-acid residues adjacent to the recognition 






The fibrinogen β -148C/T promoter polymorphism 
modulates the response of the gene to 
interleukin-6 by influencing the activity of the 
adjacent hepatocyte nuclear factor-3 (HNF-3) site 
Maartje Verschuur, Maureen de Jong, Hans L. Vos and Moniek P.M. de Maat 




Functional analysis of fibrinogen β promoter variations 
The fibrinogen β -148C/T promoter polymorphism 
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influencing the activity of the adjacent hepatocyte nuclear 
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ABSTRACT 
Elevated fibrinogen levels are an important risk factor for the development of 
cardiovascular disease, and genetic variation in the fibrinogen β gene partially 
determines plasma fibrinogen levels. The A allele of the -455G/A polymorphism is 
associated with elevated habitual plasma fibrinogen levels and with a stronger 
inflammatory response of fibrinogen levels. However, it is unclear whether the 
-455G/A polymorphism is causal, or just a marker of the functional allele, which is 
characterized by -1420A, -993T, -455A and -148T in Caucasians. The aim of our 
study was to identify the functional variation in the fibrinogen β promoter and to 
elucidate the molecular mechanism. Luciferase reporter gene assays in hepatoma 
cells revealed that only the transition from C to T at -148 affected promoter activity. 
It resulted in a decrease of ± 30% in basal expression and a decrease of ± 50% in 
IL6-induced expression, and the differences between the two alleles was highly 
significant. We show with cotransfection experiments and gel-shift assays that the 
-148C/T polymorphism influences the HNF-3 site at -159/-151. It has been shown 
that the functionality of the binding site for the (IL6-activatable) transcription 
factor C/EBPβ depends on the integrity of this HNF-3 site, and this explains the 
influence of the -148C/T variation on fibrinogen β promoter activity. In conclusion, 
we provide evidence that the -148C/T variation in the fibrinogen β promoter is 






Epidemiological studies have consistently shown that an elevated plasma 
fibrinogen level is a risk factor for cardiovascular disease 1,2. Elevated plasma 
fibrinogen levels are associated with an increased risk of ischaemic heart 
disease 1,3, and fibrinogen is found in atherosclerotic plaques 4. Furthermore, an 
increased plasma fibrinogen level is associated with an increased risk of venous 
thrombosis 5. Therefore, much interest has been shown in factors that 
determine fibrinogen levels. 
Human fibrinogen is composed of 3 pairs of polypeptide chains: two α 
chains, two β chains and two γ chains. Each of these proteins is encoded by a 
separate gene, and the three fibrinogen genes together form a 50 kb cluster on 
the long arm of chromosome 4. Fibrinogen is synthesized in the liver and its 
expression is mainly regulated at the level of transcription. There is evidence 
that in humans transcription of the gene encoding the β chain is rate-limiting 6. 
Fibrinogen is a strong acute-phase reactant, and inflammatory stimuli such as 
strenuous exercise, smoking and trauma result in increased fibrinogen levels 7-
12. The main inducer of fibrinogen in the acute-phase response is interleukin-6 
(IL6) 13-16. Several papers have been published describing the molecular 
mechanism of the acute phase response of fibrinogen. The IL6 response of the 
fibrinogen β promoter is mediated by an IL6-responsive element (IL6 RE) 
located at -143/-137, a C/EBPβ binding site located at –133/-125 17-19, and also 
an HNF-3 site located at –159/-151, as we have recently demonstrated 
(chapter 2). 
The relationship between genetic variation of the fibrinogen β chain and plasma 
fibrinogen levels has been studied on many occasions. The A allele of the 
fibrinogen β -455G/A variation has consistently been associated with elevated 
habitual fibrinogen levels 20-25, and an interaction between the -455G/A 
polymorphism and acute-phase stimuli has been reported repeatedly as well 
(reviewed by Humphries et al 26). Subjects with at least one A allele respond to 
trauma, surgery or strenuous exercise with a stronger rise in fibrinogen levels 
than -455GG homozygotes, and in most of these reports a critical role is 
attributed to the inflammatory mediator IL6 27-30. Besides the -455G/A 
polymorphism, there are several other polymorphisms in the promoter of the 
fibrinogen β gene. In the promoter region, the -1420G/A, -993C/T and -148C/T 
variations are in complete linkage disequilibrium with -455G/A in Caucasians 
31,32. Thus Caucasian carriers of the -455A allele also have -1420A, -993T and 
-148T, and any of these variations therefore could influence fibrinogen levels. 
Knowing the functional variation(s) is important from an epidemiological point 
of view, as these polymorphisms are not always coinherited in other ethnic 
groups 33. Furthermore, identifying the functional variations and understanding 
the mechanism are essential for insight into the variation between individuals 
with respect to their response to inflammation. 
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The first aim of our study was to assess the contribution of genetic variation of 
the fibrinogen β promoter to IL6-induced and basal fibrinogen β promoter 
activity, and to identify the functional variant(s). The second aim of this study 
was to elucidate the molecular mechanism responsible. Our results show that 
the -148C/T variation in the fibrinogen β promoter is functional both under 
IL6-induced and basal conditions. The -148C/T variation influences the 
response of the promoter to HNF-3 and C/EBPβ, providing a molecular 




The human hepatoma cell lines HepG2 (American Type Culture Collection) and 
HuH7 34 were maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen) supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin (Bio Whittaker Europe) and 10% foetal bovine serum (FBS, 
Invitrogen). 
PGL3-FIBRINOGEN β PROMOTER REPORTER GENE CONSTRUCTS 
1800 bp of the promoter region of the fibrinogen β gene (-1788 to +8, taking 
position 1500 in Genbank accession number X05018 as +1, the transcription 
start site) was amplified by PCR on the genomic DNA of individuals carrying 
different alleles of the -455G/A polymorphism. In this PCR reaction 200 µM of 
each dNTP, 10 pmol of each primer (forward primer: 5’-TCT TAC GCG TGA 
AGA ATG CCA ATC AGA GTA-3’, reverse primer: 5’-TCA TCT CGA GTA GAC 
TTA ACT GAG AGA TCT TCA-3’), 3.5 U of High Fidelity polymerase (Roche) 
and 50 ng of genomic DNA in a total volume of 50 µl was used. The PCR 
conditions were 94°C for 5 min followed by 35 cycles of 94°C for 1 min, 51°C for 
1 min, 72°C for 4 min, and a final extension at 72°C for 5 min. PCR products 
were digested with MluI and XhoI (the introduced restriction sites are 
underlined in the primer sequences) and cloned into the MluI and XhoI sites of 
pGL3-basic (Promega), upstream from the firefly luciferase gene. Finally, four 
pGL3-basic constructs each containing 1800 bp of the fibrinogen β promoter 
with a different promoter haplotype were obtained: pGL3-FGB haplo a, pGL3-
FGB haplo b, pGL3-FGB haplo c, and pGL3-FGB haplo d (Table 1). To be able 
to discriminate between the effects of the variants unique to haplotype d 
(-1420A, -993T, -455A, -148T), artificial promoter haplotypes were constructed. 
By exchanging the BsaBI-MluI restriction fragment (which spans the region 
from -1788 to -269 relative to the transcription start site) between pGL3-FGB 




148T and pGL3-FGB haplo d’-148C) were derived (Table 1). All constructs were 
sequenced to verify the identity of the polymorphic sites and to make sure that 
no PCR artefacts had been introduced. In addition, the identity of the 
fibrinogen β promoter haplotype constructs was confirmed on several occasions 
between transfection experiments. For this, restriction digests were used, as the 
change from G to A at -455 abolishes a HaeIII site and the change from C to T 
at -148 abolishes a HindIII site. 
VECTORS EXPRESSING TRANSCRIPTION FACTORS 
Vectors expressing the three HNF-3 isoforms and C/EBPβ (pCDNA3.1-HNF3α, 
pCDNA3.1-HNF3β, pCDNA3.1-HNF3γ, pSCT-C/EBPβ, all from rat origin) and 
their empty counterparts (pCDNA3.1-, pSCT-), were a kind gift from Dr. P. 
Holthuizen (Department of Physiological Chemistry, University of Utrecht, the 
Netherlands). 
Table 1: Fibrinogen β promoter haplotypes present in pGL3-basic and their 



































Haplotype a G C G G C C ≈ 0.40
Haplotype b G C A G C C ≈ 0.20
Haplotype c G C G G T C ≈ 0.20
Haplotype d A T G A C T ≈ 0.20
Constructed haplotypes
Haplotype b’-148T G C A G C T
Haplotype d’-148C A T G A C C
 
Fibrinogen β promoter haplotypes are present as 1800 bp promoter fragment in 
pGL3-basic and frequency data are as reported 43. For easy comparison with the 
constructed haplotypes, in some of the figures the natural haplotype b is also called 
haplotype b-148C, and the natural haplotype d is also called haplotype d-148T. 
Luciferase-reporter gene assays 
TRANSFECTION CONDITIONS 
HepG2 and HuH7 cells were plated in 24-wells plates in DMEM with 10% FBS 
at a density of 1.0 *105 cells per well. After the cells had been allowed to attach 
overnight, the medium was replaced with serum-free medium supplemented 
with 0.1% human serum albumin (HSA, Cealb®). After 2 h, cells were 
transfected using FuGene 6 (Roche), according to the manufacturer’s protocol. 
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200 ng of pGL3 construct, and 4 ng of pRL-tk (Renilla luciferase expression 
construct, Promega), were used per well. If applicable, vector expressing HNF-
3α, HNF-3β, HNF-3γ or C/EBPβ, or a molar equivalent of the empty expression 
vector as control were added. The total amount of DNA was kept at 400 ng per 
well with carrier DNA (herring sperm, Invitrogen). The effect of the empty 
expression vectors on fibrinogen β promoter activity and on the Renilla 
luciferase expression was determined for all conditions tested in this study, and 
no effects of the empty control vectors were detected. For each construct at 
least two independent DNA preparations were used, and all DNA preparations 
were transfected at least twice in triplicate. 24 hrs after transfection, the 
medium was replaced with DMEM + 0.1% HSA, containing IL6 concentrations 
ranging from 0 to 15 ng/ml (recombinant human IL6, Pepro Tech). In healthy 
subjects systemic IL6 levels up to 0.1 ng/ml can be found and in subjects with 
signs of severe inflammation IL6 levels up to 1.4 ng/ml have been reported 15,35-
40. IL6 concentrations in both the physiological and supra-physiological ranges 
were used. 
LUCIFERASE ASSAY 
After the cells had been cultured for 24 hrs in the presence of IL6, they were 
washed once with 500 µl phosphate-buffered saline (PBS) and subsequently 
lysed for 15 minutes on a rotary platform at room temperature with 100 µl 
Passive Lysis Buffer (PLB, Promega). The Firefly luciferase reporter and Renilla 
luciferase internal control activities were measured in 10 µl lysate, using the 
Dual-Luciferase® Reporter Assay System (Promega). Luminescence was 
measured using a luminometer (Berthold). 
Electrophoretic Mobility Shift Assay (EMSA) 
PREPARATION OF NUCLEAR EXTRACTS 
HepG2 cells were cultured under serum-free conditions (DMEM P/S + 0.1% 
HSA) for 24h prior to the preparation of the nuclear extracts. For the 
preparation of nuclear extracts of IL6-stimulated cells, cells were incubated 
with 5 ng/ml IL6 for 15 minutes. Cells were washed and lysed, and nuclear 
extracts were prepared according to the method of Slomiany et al 41. Buffers 
were supplemented with protease inhibitor cocktail (CompleteTM Mini, Roche), 
and with phosphatase inhibitors (Na-orthovanadate, final concentration 250 
µM; β-glycerophosphate, final concentration 25 mM). The protein 
concentration in the nuclear extracts was estimated using the BCA micro kit 
(Pierce), and the samples were stored at –80°C for future use. 
OLIGONUCLEOTIDES 
Double-stranded 26 bp oligonucleotides were designed surrounding the 




-148C/T polymorphism, and included the HNF-3 site at –159/-151 (Table 2). 
Pairs of complementary oligonucleotides were annealed at equimolar amounts 
and radioactively labelled at the 5’ ends with γ-32ATP using T4 polynucleotide 
kinase (Invitrogen). The double-stranded and labelled oligonucleotides were 
purified using MicroSpin G-25 Columns (Amersham Pharmacia Biotech), and 
stored at –20°C for future use. 
Table 2: Sequence of the oligonucleotides used in the EMSAs 
Fibrinogen β promoter sequence
5' TATGACAAGTAAATAAGCTTTGCTGGGAAGATGTTGCTTAAATGA 3'
3' ATACTGTTCATTTATTCGAAACGACCCTTCTACAACGAATTTACT 5'
            HNF-3           IL6 RE     C/EBP
Fibrinogen β -148 C oligo
5’- TATGACAAGTAAATAAGCTTTGCTGG -3’




BINDING REACTION AND ELECTROPHORESIS 
For each binding reaction, 0.5-4 µg of nuclear extract was pre-incubated for 30 
minutes on ice with 5 µg poly dIdC (Amersham Pharmacia Biotech) in a 12 µl 
reaction mixture containing 10 mM Tris/HCl (pH 7.5), 100 mM KCl, 5 mM 
MgCl2, 1 mM dithiothreitol, 1 mM EDTA, 5% (v/v) glycerol, 250 µM Na-
orthovanadate and 25 mM β-glycerophosphate. Subsequently, the labelled 
oligonucleotides were added to the pre-binding reactions, and this mixture was 
incubated for another 30 minutes on ice. The reaction products were loaded 
onto 5% non-denaturing polyacrylamide gels and run in 0.25x TBE (1x TBE = 
0.1M Tris, 0.09M Boric Acid, 0.001M EDTA). Gels were blotted on Whatmann 
paper and exposed to autoradiograph film overnight at -80°C with intensifying 
screens. 
Statistical methods 
Firefly luciferase activity was normalized for transfection efficiency using 
Renilla luciferase activity as an internal standard. These normalized luciferase 
activity levels were expressed as a percentage of the normalized luciferase 
activity of pGL3-FGB haplo d or pGL3-FGB haplo b’-148T at baseline. 
Normalized expression levels of the different haplotype constructs were 
compared by ANOVA testing followed by LSD post hoc testing, or with 
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Student’s t-test; SPSS 11.0 for Windows was used. P-values are described in the 
results section or otherwise stated in the figure legends. 
RESULTS 
Identification of the functional polymorphism in the fibrinogen β 
promoter under IL6-induced conditions 
1800 bp fragments of the four common fibrinogen β promoter haplotypes were 
cloned into the luciferase expression vector pGL3-basic and sequenced (Table 
1). During this process the known polymorphisms in the fibrinogen β promoter 
were confirmed and no new polymorphisms were detected. IL6 treatment of 
HepG2 cells transfected with the constructs with the four natural promoter 
haplotypes resulted in a strong induction (up to 25-fold) of all four fibrinogen β 
promoter variants (Figure 1). 
 
 
Figure 1: IL6-induced expression of natural fibrinogen β promoter haplotypes 
in HepG2 cells. Fibrinogen β promoter constructs were transfected into HepG2 cells, and 
cells were subsequently treated with IL6. The IL6-induced promoter activity of haplotype d 
was significantly lower than the IL6-induced promoter activity of the other haplotypes 
(p<0.001 at all IL6 concentrations). Normalized luciferase activities are expressed in 
relation to baseline activity of the haplotype d construct and means (±SD) of triplicate 






Figure 2: IL6-induced expression of constructed fibrinogen β promoter 
haplotypes in HepG2 cells and identification of the functional polymorphism. 
Fibrinogen β promoter constructs were transfected into HepG2 cells, and cells were 
subsequently treated with IL6. The IL6-induced promoter activity of the haplotypes d-148T 
and b’-148T was significantly lower than the IL6-induced promoter activity of the 
haplotypes with C at position -148 (haplotype b-148C and d’-148C) (p<0.001 at all IL6 
concentrations). Normalized luciferase activities are expressed in relation to baseline 
activity of the haplotype d construct and means (±SD) of triplicate transfections are shown. 
However, the IL6-induced expression of promoter haplotype d was 
approximately 50% lower than the IL6-induced expression of haplotypes a, b 
and c. In addition, when the response of the promoter constructs to IL6 were 
expressed in relation to the baseline activity of the individual construct (as ‘fold 
induction’), also this relative induction haplotype d was substantially lower 
(35%-50%) than the relative induction of haplotypes a, b and c (data not 
shown). 
The -1420A, -993T, -455A and -148T alleles are all unique to haplotype d, and 
this implies that any of these base pair substitutions (or a specific combination) 
could be responsible for the haplotype-dependent difference in the response to 
IL6 observed. The -148C/T polymorphism is particularly interesting, as it is 
located between the HNF-3β site, and the IL6 RE and C/EBPβ site 17-19. To 
investigate the functionality of the -148C/T variation, artificial haplotypes that 
differed only at -148C/T from their natural counterparts were used in 
transfection experiments in hepatoma cells. IL6 treatment of HepG2 cells 
transfected with the artificial fibrinogen β promoter variants again resulted in a 
strong induction of these fibrinogen β promoter variants (Figure 2). The IL6-
induced expression of haplotypes b-148C and d’-148C was significantly higher 
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than the IL6-induced expression of haplotypes d-148T and b’-148T. In addition, 
when the response of the promoter constructs to IL6 were expressed in relation 
to the baseline activity of the individual construct (as ‘fold induction’), also this 
relative induction of constructs carrying T at position -148 was substantially 
lower (35%-50%) than the relative induction of haplotypes with a C at position 
-148 (data not shown). The approximately 50% lower IL6 induced promoter 
activity of haplotypes d-148T and b’-148T was confirmed in HuH7 cells, but the 
IL6 response of the fibrinogen β promoter variants was much smaller in HuH7 
cells than in HepG2 cells (data not shown). These results show that transition 
from C to T at -148 resulted in a strong decrease in IL6-induced expression, and 
vice versa. There were no significant differences between the activity of 
constructs carrying the same -148 allele, but differing at all other polymorphic 
sites (between haplotype b-148C and d’-148C, and between haplotype d-148T 
and b’-148T). This indicates that it is the -148C/T polymorphism that is the 




Figure 3: The response of fibrinogen β promoter haplotypes to physiological 
IL6 concentrations. Fibrinogen β promoter constructs were transfected into HepG2 
cells, and cells were subsequently treated with concentrations IL6 that occur in vivo. The 
IL6-induced promoter activity of haplotypes d-148T was significantly lower than the IL6-
induced promoter activity of haplotype d’-148C at 0.5 ng/ml IL6 (p=0.001) and at 1.0 
ng/ml (p=0.002). Normalized luciferase activities are expressed in relation to baseline 




The significance of the –148C/T polymorphism under physiological conditions 
was verified in an additional experiment in which low IL6 levels, as they occur 
systemically in vivo, were used. The fibrinogen β promoter responded to IL6 
concentrations as low as 0.25 ng/ml, and the difference in IL6-induced 
expression between the two promoter variants was already significant at these 
physiological IL6 concentrations (Figure 3). 
The -148C/T polymorphism influences basal fibrinogen β promoter activity 
In addition, the effect of the -148C/T variation on basal expression of the 
fibrinogen β promoter was determined. For this, the results from all 
experiments were pooled and analyzed together. This analysis showed that the 
basal expression levels of each individual construct with a C at -148 (haplotypes 
a, b and c and d’-148C) was approximately 30% higher than the basal 
expression levels of each individual construct with a T at -148 (haplotypes d and 
b’-148T) (Figure 4). 
 
Fibrinogen β promoter haplotypes
 
Figure 4: Basal expression levels of fibrinogen β promoter haplotypes in 
HepG2 cells. Fibrinogen β promoter constructs were transfected into HepG2 cells. Basal 
promoter activity of the haplotypes d and b’148 was significantly lower than the basal 
promoter activity of all other haplotypes (p<0.01 in all cases). Normalized luciferase 
activities are expressed in relation to the activity of the haplotype d construct. Means (±SD) 
of 12-24 transfections obtained in 7 independent experiments of triplicate transfections are 
shown. The labels in the bars indicate the nucleotide present at position -148. 
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However, in individual experiments, the effect of the -148C/T polymorphism on 
basal promoter activity was sometimes less clear. There were no significant 
differences in basal expression levels between any of the constructs with a C at 
position -148, or between those with a T at position -148. 
HNF-3β binds preferentially to the –148C allele under basal and IL6-
induced conditions 
The electrophoretic mobility shift assays (EMSAs) described in chapter 2 had 
shown that HNF-3β binds to the HNF-3 site 3 bp upstream of the –148C/T 
polymorphism. Therefore, EMSAs designed to evaluate the affinity of the -148C 
and -148T alleles for HNF-3β were performed. 
 
1    2    3    4        6  7    8     9        11   12   13   14       16 17   18   19
HNF-3β
NE
-148C                   -148T                 -148C                     -148T
 
Figure 5: The -148C/T polymorphism influences binding of HNF-3β to the 
fibrinogen β promoter. Labelled oligonucleotides representing the -148C allele (lanes 1 
to 4 and 11 to 14), or the -148T allele (lanes 6 to 9 and 16 to 19) were incubated with 
decreasing amounts of nuclear extracts (lanes 1, 6, 11, 16 all 4 µg, lanes 2, 7, 12, 17 all 2 µg, 
lanes 3, 8, 13, 18 all 1 µg, and lanes 4, 9, 14, 19 all 0.5 µg). Nuclear extracts derived from 
HepG2 cells cultured under basal conditions (lanes 1 to 9) and from HepG2 cells cultured 
under IL6-induced conditions (lanes 11 to 19) were used. 
A major complex, in chapter 2 identified as HNF-3β, bound to both alleles 
under basal- and IL6-induced conditions. The complex bound to the C allele at 
all amounts of nuclear extract, but disappeared from the T allele when less than 




preferentially to the C allele of the –148C/T polymorphism. No qualitative 
differences between the EMSA patterns of basal and IL6-induced conditions 
were observed. 
The –148C/T variation affects the response of the fibrinogen β promoter to 
HNF-3 
We observed that the –148C/T polymorphism influences binding of HNF-3β to 
the HNF-3 site in the fibrinogen β promoter. Next, we examined whether the 
-148C/T variation also affects the response of the fibrinogen β promoter to 
HNF-3, by transfection of fibrinogen β promoter haplotypes b and b’-148T in 
the presence of overexpressed HNF-3 isoforms. The -148C allele responded to 
overexpression of HNF-3α (50-500 pg) with a 2-fold increase in activity, 
whereas the -148T allele did not respond to HNF-3α (Figure 6). 
 
pg HNF-3 expression vector/ well
 
Figure 6: The -148C/T variation influences induction of the fibrinogen β 
promoter haplotypes by HNF-3 isoforms. Fibrinogen β promoter reporter gene 
constructs were transfected into HepG2 cells, in the presence of increasing amounts of 
HNF-3α, HNF-3β or HNF-3γ expression vector. The differences in response to HNF-3 
between the alleles were statistically significant at all HNF-3α concentrations (p<0.01 in all 
cases), when 125 or 250 pg of HNF-3β expression vector were cotransfected (p=0.037 and 
p=0.007 respectively), and when 125 and 250 pg of vector HNF-3γ expression vector were 
cotransfected (p=0.046 and p=0.011 respectively). Normalized luciferase activities are 
expressed in relation to baseline activity of the haplotype b (-148C) construct. Means (±SD) 
of triplicate transfections are shown. 
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The activity of the fibrinogen β promoter increased up to 9-fold in response to 
overexpression of HNF-3β, and up to 6-fold in response to overexpressed HNF-
3γ. The activity of the -148C allele was significantly higher than the activity of 
the -148T allele when 125 and 250 pg of vector expressing HNF-3β or HNF-3γ 
were cotransfected. At 50 pg HNF-3β or HNF-3γ, differences between the 
alleles could not be detected, and at 500 pg HNF-3β or HNF-3γ, the activity of 
the -148C allele did not increase any more. These results show that a change 
from C to T at position -148 results in a decreased response of the fibrinogen β 
promoter to HNF-3 isoforms. 
The –148C/T variation affects the response of the fibrinogen β promoter to 
C/EBPβ  
The effect of the -148C/T variation on the response of the fibrinogen β 
promoter to HNF-3 might be explained by an effect of this polymorphism on 
the adjacent HNF-3 site. Chapter 2 demonstrates that the response to the IL6-
activatable transcription factor C/EBPβ depends on the HNF-3 site, therefore 
the effect of the -148C/T variation on the response of the fibrinogen β promoter 
to overexpressed C/EBPβ was verified. 
 
 
Figure 7: The -148C/T variation influences C/EBPβ-induced activity of the 
fibrinogen β promoter. Fibrinogen β promoter reporter gene constructs were 
transfected into HepG2 cells, together with increasing amounts of C/EBPβ expression 
vector. The C/EBPβ-induced promoter activity of haplotype b-148C was significantly higher 
than the C/EBPβ-induced promoter activity of haplotype b’-148T (p<0.0005 at all C/EBPβ 
concentrations). Normalized luciferase activities are expressed in relation to baseline 





When fibrinogen β promoter constructs differing only at -148C/T (haplotype b 
and b’-148T) were transfected in the presence of overexpressed C/EBPβ, the 
activity of the C allele increased up to 7-fold, whereas the activity of the T allele 
increased only 4-fold (Figure 7). Similar differences were also present at lower 
C/EBPβ concentrations. Because the HNF-3 and the C/EBP sites interact and 
are both involved in the IL6 response of the fibrinogen β promoter (chapter 
2), a lower response of the -148T allele to C/EBPβ and HNF-3 may explain the 
decreased IL6-induced expression observed for the T allele. 
DISCUSSION 
In this study we show that the -148C/T variation in the fibrinogen β promoter is 
a strong determinant of both basal and IL6-induced promoter activity. We 
observed no indications of a functional role for any of the other promoter 
polymorphisms, since the -148C/T variation was able to explain the entire 
difference between haplotype d and the other haplotypes in our assay system. 
As the -148C/T variation significantly influenced basal promoter activity, and 
promoter activity under mild (physiological) and strong IL6-induced 
conditions, an effect of -148C/T on fibrinogen β expression in vivo is plausible. 
In addition, we provide evidence that the -148C/T variation influences the 
adjacent HNF-3 site, which can explain the functionality of the -148C/T 
variation at a molecular level. 
The -148C/T polymorphism is located in an evolutionarily conserved region of 
the fibrinogen β promoter. It is located 3 bp downstream of the HNF-3 site, 5 
bp upstream of the IL6 RE and 15 bp upstream of the C/EBPβ site 18,19. 
C/EBPβ is activated by phosphorylation upon IL6 stimulation, then 
translocates to the nucleus, binds to the C/EBP site in the promoter and 
induces promoter activity (reviewed by Poli 42). Binding of C/EBPα and 
C/EBPβ to the C/EBP site in the fibrinogen β promoter has been demonstrated 
18. The C/EBP site in the fibrinogen β promoter is necessary for the response of 
the fibrinogen β promoter to IL6, and it has been shown that mutation of the 
C/EBP site results in a moderate reduction of basal promoter activity 17-19. The 
HNF-3β site at -159/-151 has been discovered recently and the activity mediated 
by the C/EBP site depends on the integrity of the HNF-3 site. Mutation of the 
HNF-3 core sequence results in a diminished response of the fibrinogen β 
promoter to IL6, which can be explained by an interaction between the C/EBP 
site and the HNF-3 site (chapter 2). The results from the present study are in 
line with this interaction. Change from C to T at -148 resulted in a possibly 
weaker binding of HNF-3β to the HNF-3 site, a decreased responsiveness of the 
fibrinogen β promoter to overexpression of HNF-3, and also a lowered response 
to overexpressed C/EBPβ. Therefore, the effect of -148C/T on the activity of the 
adjacent C/EBP and HNF-3 sites provides an explanation for the significantly 
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lower IL6-induced and basal fibrinogen β promoter activity for the T allele that 
we observed in our promoter assays. 
The identification of -148C/T as the functional variation is important from an 
epidemiological point of view, as the degree of linkage disequilibrium between 
the fibrinogen β promoter polymorphisms may differ between ethnic groups. In 
Caucasians the linkage disequilibrium between -1420G/A, -993C/T, -455G/A 
and -148C/T is nearly complete, and thus each of the four variations can be 
used as a marker for the functional -148C/T polymorphism. In other ethnic 
groups however, the situation can sometimes be different. Cook et al showed 
that the -455G/A and the -148C/T variation were not in complete linkage 
disequilibrium in an Afro-American population 33. In this population, a 
stronger association was seen between -148C/T and plasma fibrinogen levels 
than between -455G/A and plasma fibrinogen levels. These data support our 
conclusion that -148C/T is a functional polymorphism, and this implies that 
determination of -148C/T instead of -455G/A should be used to study the 
associations with plasma fibrinogen levels in all populations. 
In our transfection assays, haplotype d, which includes -148T and -455A, 
showed weaker IL6-induced and basal expression. Surprisingly, in 
epidemiological studies, increased basal and increased acute phase-induced 
fibrinogen levels have generally been associated with -455A, which is contrary 
to our findings. In this respect, there are some issues that are worth 
considering. 
We performed our studies with both HepG2 and HuH7 cells. Although there are 
large differences between these cells with respect to the magnitude of their IL6 
response, fibrinogen β promoter fragments with haplotype d (-148T) had lower 
transcriptional activity in both HepG2 and HuH7 cells. A lower transcriptional 
activity of haplotype d in reporter gene experiments has also been observed in 
HepG2 and Hep3B cells by another research group 43,44. Similar results in three 
different hepatoma cell lines indicate that the discrepancy between the 
epidemiological reports and our experimental data is not caused by a 
peculiarity of any of the cell lines used. 
In our experiments, we used IL6 to mimic the acute phase response. In the case 
of an acute-phase event in vivo however, besides IL6, several other 
inflammatory mediators are expressed and IL6 interacts with numerous other 
inflammatory mediators. In the case of the acute phase response of fibrinogen, 
interactions between IL6 and interleukin-1β, interleukin-4, interleukin-10 and 
interleukin-13 are described, underlining the complexity of the inflammatory 
response of fibrinogen in vivo 45,46. 
A third possible explanation for the observed discrepancy between our in vitro 
data and the reported in vivo associations might involve the IL6 responsive 
element (IL6 RE). This sequence may only be required for the positioning of the 
HNF-3 and the C/EBP sites correctly to each other, but it is also possible that 




mechanism of the IL6 RE is still unclear. The HNF-3 site, the IL6 RE and the 
C/EBP site are all located within a region of only 35 base pairs, and the final 
output of the IL6 response of the fibrinogen β promoter may depend on a 
highly sensitive interplay between the transcription factors binding to this 
region. It is possible that the balance between the transcription factors is 
somewhat different in our experimental system from in vivo. A detailed picture 
of all the events and transcription factors involved in the regulation of the 
endogenous fibrinogen β gene, including the IL6 RE, needs to be established 
before we can better understand the presently observed discrepancy between 
the in vivo and in vitro effects. 
Another explanation for this apparent discrepancy between our in vitro results 
and the reported in vivo data could be the presence of a functional 
polymorphism located outside the fibrinogen β promoter fragment that we 
studied, which is responsible for elevated plasma fibrinogen level associated 
with the -148T allele in vivo. 
Despite the conclusion that parts of the acute phase regulation of the fibrinogen 
β gene still have to be elucidated, our results clearly identify -148C/T as a 
functional variation in the fibrinogen β promoter, and we provide a molecular 
mechanism. We recommend that the fibrinogen β -148C/T variation is 
determined in epidemiological surveys.  
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ABSTRACT 
The acute phase reaction is important in many disease processes. Habitual levels of 
the acute phase proteins fibrinogen, C-reactive protein (CRP) and interleukin-6 
(IL6) are associated with an increased risk of cardiovascular disease, but the 
dynamic variation of plasma levels of acute phase proteins may be of importance as 
well. The aim of this study was to document the variation in response by 
fibrinogen, CRP and IL6 levels to a mild inflammatory stimulus (yellow-fever 
vaccination) in 25 healthy individuals.  Plasma levels of fibrinogen, CRP and IL6 
were determined at baseline and 7 days after vaccination, and genetic 
polymorphisms in these genes were determined. After vaccination, fibrinogen 
levels had changed between -13% and +44% (p=0.003), CRP levels between -88% 
and +672% (NS), and IL6 levels between -55% and +448% (NS). Genetic variation 
partly explained the interindividual variation in response, as IL6-174G 
homozygotes showed a significantly stronger increase in CRP levels than IL6-174C 
allele carriers. In conclusion, this study suggests that a large interindividual 
variation exists in the acute phase response to yellow fever vaccination, indicating 
that individuals may be classified as hyper- or hypo-responders, and that genetic 





Inflammation plays an important role in many disease processes. There is a 
large variation in habitual plasma levels of inflammatory proteins 1. Increased 
plasma levels of the acute phase proteins fibrinogen, C-reactive protein (CRP) 
and interleukin-6 (IL6) have consistently been associated with an increased risk 
of cardiovascular disease 2-6. Increased levels of these acute phase proteins may 
be markers of the progression of atherosclerosis, but there is also evidence that 
acute phase proteins themselves participate in the development of vascular 
disease 7,8. Most studies on the relationship of fibrinogen, CRP and IL6 with 
cardiovascular risk have focused on basal levels of the acute phase proteins 2-6, 
but the dynamic variation in plasma levels of these proteins may be just as 
important. Individuals that respond to small inflammatory triggers with a 
strong rise in the plasma levels of these acute phase proteins (the hyper-
responders) are exposed to these higher levels regularly and they may therefore 
be at higher cardiovascular risk 9. Thus, the identification of the hyper- and 
hypo-responders to inflammatory stimuli could be of clinical relevance. 
Genetic variation is one of the factors that could predispose to a stronger 
response to acute phase triggers. Both population- and functional studies have 
been published supporting this hypothesis, showing that individuals carrying 
the A allele of the -455G/A variation in the fibrinogen β gene respond to 
inflammatory triggers with a stronger rise in fibrinogen plasma levels 10-12. 
Similar results have been reported for the effect of the IL6 -174G/C 
polymorphism on the response of CRP levels. IL6 is an important inducer of 
CRP expression, and subjects homozygous for the G allele of the -174G/C 
variation in the IL6 gene respond to inflammation with a stronger elevation of 
CRP levels 13,14. 
In this study, we explored the possibility of identifying individuals as hyper- or 
hypo-responders, using yellow fever vaccination as a standardized 
inflammatory stimulus. Vaccination with vaccines that are based on live 
attenuated viruses such as the yellow fever vaccine can be used as ethically 
acceptable and standardized inflammatory stimuli. These vaccines cause 
viraemia a few days after vaccination and viraemia can induce a mild acute 
phase response with flu-like symptoms 15,16. The primary aim of this study was 
to document the interindividual variation in the acute phase response. 
Secondly, it was investigated whether the fibrinogen β -455G/A and the IL6 
-174G/C polymorphisms could influence the response by fibrinogen, CRP and 
IL6 to an inflammatory trigger. Finally, in this study we evaluated whether an 
in vitro whole-blood bacterial lipo-polysaccharide (LPS) stimulation assay 
might provide an in vitro method for the identification of hypo- and 
hyperresponders to yellow fever vaccination. 
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METHODS 
Study design 
Twenty-five healthy individuals visiting the Vaccination Outpatient Clinic of the 
Leiden University Medical Center to receive vaccination against yellow fever 
prior to their travels participated in the study. On day 0, the travellers received 
0.5 ml Stamaril Pasteur heat-stable avian leucosis-free 17D yellow fever vaccine 
subcutaneously in the upper right arm (Pasteur Merieux, MSD). Blood was 
collected just before and 7 days after the subjects had received the vaccine. A 
pilot study had shown that fibrinogen and CRP levels peak 7 days after 
vaccination and that IL6 levels peak after 5 days 17. All the measurements could 
be obtained from 22 individuals. Because of our focus on CRP and fibrinogen, 
the participants were asked to return to the Vaccination Outpatient Clinic at 7 
days after vaccination. None of the subjects suffered from liver disease, auto-
immune diseases or other immune disorders, acute or chronic infectious 
diseases, or malignancy. None of the subjects had recently had trauma or 
surgery, and none of them had received recent vaccination or used medication 
that could affect the inflammatory response. None of the participants had 
received yellow fever vaccination before, and no other vaccinations were given 
simultaneously. The study was approved by the Medical Ethical Committee of 
the Leiden University Medical Center, and written informed consent was 
obtained from all participants. 
Blood sampling 
Blood was collected in tubes containing EDTA (final concentration 1.8 mg/ml, 
Greiner Labortechnik), and in tubes containing sodium citrate (final 
concentration 0.105 M, Becton Dickinson). EDTA anti-coagulated blood was 
used to determine plasma CRP- and IL6 levels, and for the-whole-blood LPS 
stimulation assay. Sodium citrate anti-coagulated blood was used for fibrinogen 
determination. Blood samples were either used immediately for the whole-
blood LPS stimulation assay, or centrifuged at 4°C, after which plasma was 
snap-frozen and stored at -80°C until analysis. Buffycoats were collected for 
DNA isolation. All samples were processed within 1 hour after venepuncture. 
Biochemical procedures 
Functional fibrinogen was determined according to the chronometrical clotting 
rate assay by Von Claus (Diagnostica Stago/ Roche Diagnostics). The CRP 
concentration was determined with an in-house high sensitivity enzyme 
immunoassay (EIA) 18. Polyclonal rat anti-human CRP antibodies were used as 
solid phase capture antibodies, and horseradish peroxidase conjugated 
polyclonal rabbit anti-human CRP antibodies were used as tagging antibodies 
(DAKO Diagnostics). Reference and control sera were obtained from Dade-




the whole-blood LPS stimulation assay, with an ultrasensitive EIA for human 
IL6 (R&D systems).  
Fibrinogen β -455G/A and IL6 -174G/C genotyping 
Fibrinogen β -455G/A genotype was determined by PCR on genomic DNA, 
followed by restriction enzyme analysis using HaeIII, as described previously 19. 
IL6 -174G/C genotype was determined by PCR on genomic DNA, followed by 
restriction enzyme analysis using Hsp 92 II, as described previously 13. 
In vitro whole-blood LPS stimulation assay 
For the whole-blood LPS stimulation assay, blood samples at day 0 were 
immediately stored at 37°C and the whole-blood stimulation assay was started 
within 60 minutes after blood sampling. 1 ml blood was added to 1 ml RPMI-
1640 culture medium (Bio Whittaker) in a culture plate. LPS was added to a 
final concentration of 10 ng/ml in duplicate, and the samples were incubated 
for 24 hours at 37°C. After incubation, samples were centrifuged for 20 minutes 
at 2000 rpm, plasma was collected, snap-frozen and stored at -80°C for IL6 
determination 9,20. 
Statistical analysis 
Because of the small sample size and because of the skewed distribution of the 
variables, all statistical analyses were performed using non-parametric 
methods. Plasma levels before and after vaccination were compared by the 
Wilcoxon Signed Rank Test, and relative changes in plasma levels between 
genotype groups were analyzed using the Mann-Whitney Test. The Spearman 
correlation coefficient was calculated to analyze correlation between variables. 
Data are presented as median values with the observed range, unless otherwise 
indicated. Genotype distributions were compared to those expected if the alleles 
were in Hardy-Weinberg equilibrium using the Chi-squared test. Statistical 
analyses were performed using SPSS for windows, release 11.0. 
RESULTS 
Characteristics of the study population at baseline 
13 males and 12 females were included in this study, and their median age was 
24 years (range 19 - 54). There was a significant correlation between CRP and 
fibrinogen levels for the whole group at baseline (r=0.54, p=0.006).  
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Changes in fibrinogen, CRP and IL6 plasma levels after yellow fever 
vaccination 
With respect to the response by the inflammatory markers to yellow fever 
vaccination, plasma levels of all markers were increased 7 days after 
vaccination, but this increase was only significant for fibrinogen (p=0.003) 
(Table 1). 
Table 1: Fibrinogen, CRP and IL6 levels at baseline and 7 days after yellow 
fever vaccination. 
t=0 t=7 % change
Fibrinogen (g/l) 2.8 (2.2, 3.5) 3.1 (2.2, 3.9) 9.4 (-12.5, 44.1)  *
CRP(mg/l) 0.8 (0.1, 4.1) 0.9 (<0.05, 4.8) 32.1 (-88.2, 672.2)
IL6 (pg/ml) 1.0 (0.5, 4.4) 0.8 (0.4, 4.1) 21.2 (-54.7, 447.7)
 
Data are median values (range), *p= 0.003 
There were no significant correlations between the relative changes of 
fibrinogen, CRP and IL6, but there was a significant correlation between CRP 
levels and IL6 levels after vaccination (r=0.42, p=0.05). For all three 
inflammatory markers, the plasma levels at baseline correlated significantly 
with the levels of these proteins at 7 days after vaccination (r=0.67 p=0.001 for 
fibrinogen, r= 0.68 p=0.001 for CRP, r=0.57 p=0.006 for IL6). 
 
 












































































































































Interindividual variation in the response by fibrinogen, CRP and IL6 
plasma levels to yellow fever vaccination 
Large interindividual variation was observed between the subjects with respect 
to the response by fibrinogen, CRP and IL6 levels to the yellow fever 
vaccination. For fibrinogen, the median increase in fibrinogen levels 7 days 
after vaccination was 9%, but varied between –13% and +44%. The median 
change in CRP levels was +32%, and showed a large variation between –88% 
and +672%. Finally, the median increase of IL6 levels was 21%, and varied 
between –55% and +448% (Table 1, Figure 1). All participants were healthy, 
and none of them had experienced illness during the study period, or reported 
other factors that could explain the large differences in response between the 
subjects. 
Genetic variation influences the response to vaccination 
We observed a significant association between the IL6 -174G/C genotype and 
the relative increase in CRP levels (Table 2, Figure 2). The CRP levels of 
subjects homozygous for the G allele of the -174G/C polymorphism showed a 
larger relative increase in response to the yellow fever vaccination than CRP 
levels of subjects carrying at least one C allele (p=0.032). For fibrinogen, there 
was a slightly stronger relative increase of fibrinogen levels in fibrinogen β 
-455A allele carriers compared to -455GG homozyotes, but the differences were 
not statistically significant (p=0.12). The genotype distributions of both 
polymorphisms were not different from those predicted by Hardy-Weinberg 
equilibrium. 
Table 2: Association of fibrinogen β -455G/A and IL6 -174G/C genotype with 
the response of fibrinogen, CRP and IL6 levels to vaccination. 
N Genotype t=0 t=7 % change
Fibrinogen (g/l) 16 Fbg β -455GG 2.9 (2.3, 3.5) 3.1 (2.2, 3.9) 7.5 (-12.5, 28.9)
6 Fbg β -455GA/AA 2.6 (2.2, 3.1) 3.0 (2.7, 3.7) 15.1 (5.9, 44.1)
CRP (mg/l) 7 IL6 -174GG 0.8 (0.1, 1.5) 1.3 (0.4, 4.8) 135.1 (-34.0, 672.2)*
15 IL6 -174GC/CC 0.6 (0.1, 4.1) 0.5 (<0.05, 4.1) -19.5 (-88.2, 563.6)*
IL6 (pg/ml) 6 IL6 -174GG 0.1 (0.5, 4.4) 1.1 (0.4, 4.1) 19.1 (-10.1, 86.3)
16 IL6 -174GC/CC 0.1 (0.5, 2.4) 1.0 (0.6, 2.9) 23.3(-54.7, 447.7)
 
Data are median values (range), * p=0.032 
In vitro whole-blood LPS stimulation assay 
After LPS stimulation, IL6 levels in the whole-blood samples strongly 
increased. The median IL6 level at baseline in the samples was 1.0 (0.5-4.4) 
(pg/ml), and after LPS treatment IL6 levels strongly increased to 607 (0-2536) 
pg/ml in response to 10 ng/ml LPS. 
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Figure 2: Relationships between genotype and inflammatory response. 
Association between fibrinogen β -455G/A genotype and the response of fibrinogen levels 
to vaccination (Figure 2a), between IL6 -174G/C genotype and the response of CRP levels to 
vaccination (Figure 2b), and between IL6 -174G/C genotype and the response of IL6 levels 




When the in vitro increase in IL6 levels in response to LPS was compared with 
the in vivo increases of fibrinogen, CRP or IL6 plasma levels after yellow fever 
vaccination, no significant correlations were observed. Finally, there also was 
no relationship between IL6-174G/C genotype and the in vitro increase in IL6 
levels in response to LPS. 
DISCUSSION 
This study shows that a large variation exists between individuals with respect 
to the response by fibrinogen, CRP and IL6 plasma levels to a mild, 
standardized inflammatory stimulus (yellow fever vaccination). Although the 
results may be limited by the small sample size of the population, this study 
indicates that genetic variation in the promoter regions of the inflammatory 
genes may contribute to the interindividual variation in response.  
It was expected that large differences could exist between individuals with 
respect to their response to inflammatory triggers 1,21,22, and our study is the 
first to document the interindividual variation in the response by acute phase 
reactants to a mild and standardized inflammatory stimulus. In our study, in 
which we used yellow fever vaccination as a mild acute-phase trigger, there was 
much variation between individuals in the magnitude of change of fibrinogen, 
CRP and IL6 levels. Fibrinogen levels changed between -13% and +44%, and 
CRP levels between –88% and +672%, and IL6 levels between -55% and 
+448%.  
In a previous pilot study, in which the plasma levels of fibrinogen, CRP and IL6 
were measured daily, we showed that CRP and fibrinogen levels peak 7 days 
after vaccination 17. This peak occurs ±3 days after the viraemia that results 
after the vaccination 15,16. In the present study, which has the same 
experimental design as the pilot study, moderate changes in the plasma levels 
of fibrinogen, CRP and IL6 were observed, and a significant increase of the 
average fibrinogen level was detected. 
We did observe significant relationships between baseline values and levels 
after vaccination for all three individual inflammatory markers. This suggests 
that subjects with higher basal levels are likely to have higher peak levels in 
response to inflammation. These findings are in line with another study, in 
which subjects with higher basal CRP and serum amyloid A (SAA) levels had 
higher peak levels of these proteins after angiography or PTCA 23. Associations 
between plasma levels of fibrinogen, CRP and IL6 have been reported on 
several occasions 6,24, and in our study we observed significant correlations 
between CRP and fibrinogen levels at baseline, and between CRP and IL6 levels 
at day 7. Correlations with the other inflammatory markers might have been 
expected since IL6 is a primary inducer of both CRP and fibrinogen release, but 
the small size of our study population may account for this lack of association. 
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An alternative explanation for the lack of correlation of IL6 levels at day 7 with 
CRP and fibrinogen may be the fact that at day 7 the CRP and fibrinogen levels 
were at their peak values, whereas the IL6 peak may have been slightly earlier. 
We observed that genetic variation contributes to the variation in response 
between individuals. CRP expression is strongly upregulated by IL6 25, and the 
IL6 -174G/C promoter polymorphism has been associated with basal plasma 
CRP levels 26. However, the results of the association studies published up until 
now are not consistent, as in some studies the -174G, and in other studies the 
-174C allele is associated with elevated basal CRP levels 26,27. In functional 
studies, IL6-promoter-reporter gene constructs with the -174G allele responded 
more strongly to LPS or interleukin-1 than constructs with the -174C allele in 
one study 13, but in another study, this was less evident 14. We observed that 
subjects homozygous for the G allele of the IL6 -174G/C polymorphism showed 
a significantly stronger response in CRP levels to yellow-fever vaccination, a 
mild acute phase trigger. For fibrinogen, we observed a trend towards a 
stronger response by fibrinogen levels to vaccination in -455A allele carriers, 
and a stronger response by fibrinogen levels in -455A allele carriers to 
inflammatory stimuli has been reported by others as well 10-12. Perhaps 
remarkably, we did not observe a relationship between the -174G/C genotype 
and the response by IL6 levels. We attribute this to the fact that IL6 levels peak 
5 days after vaccination, and we drew blood 7 days after vaccination. It is 
therefore probable that the peak in IL6 levels had already occurred at the time 
of the blood sampling, and that we were not able to detect an effect of the IL6 
-174G/C genotype on the response by IL6 levels because of this. However, since 
we did observe a relationship between the IL6 -174G/C polymorphism and the 
response by CRP levels, we should expect that the -174G/C polymorphism had 
also affected the IL6 response. 
A whole-blood in vitro LPS stimulation assay has been used previously to study 
the intensity of the response of an individual to potential inflammatory stimuli, 
and an association between the in vitro IL6 production after LPS-challenge and 
circulating CRP levels in patients with unstable angina has been reported 9. 
However, in our LPS stimulation assays with blood samples from healthy 
subjects we did observe a strong response by IL6 expression to LPS treatment, 
but the increase in IL6 in response to LPS in vitro did not correlate with the 
response by fibrinogen, CRP and IL6 to vaccination in vivo. This indicates that 
this whole-blood stimulation assay is not a representative model for the in vivo 
response to yellow fever vaccination. This may be explained by the fact that LPS 
and yellow fever activate different receptors. The yellow fever virus has a single-
stranded, positive polarity RNA genome of 10,862 nucleotides 28 and it has 
been shown recently that toll-like receptor 3 (TLR 3) is the receptor for viral 
RNA 29. LPS however activates the TLR 4 30, and therefore activation of 
different receptors by yellow fever and LPS could explain the lack of association 




In conclusion, this study shows that there are large differences between 
individuals regarding the intensity of the response by CRP, fibrinogen and IL6 
plasma levels to yellow fever vaccination, and that genetic variation may be one 
of the factors determining the responsiveness of an individual. This is a 
potentially relevant conclusion for several diseases that have an inflammatory 
component such as cardiovascular disease, but also for sepsis, malignancies, 
and infectious diseases. This study shows that individuals can be classified as 
hyper- or hypo-responders, which may be useful, as individuals hyper-
responsive to inflammatory triggers may have a different disease risk profile. 
This work indicates that yellow fever vaccination provides an interesting tool 
for investigating the inflammatory response under standardized conditions, in 
larger studies. A relevant research aim in such future studies would be to study 
the biological mechanisms of acute-phase reactions. More understanding of the 
biological mechanisms of different acute-phase reactions would help in 
choosing the appropriate model system, for instance the in vivo yellow fever 
vaccination model or the in vitro whole-blood LPS stimulation assay, described 
in this study. 
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ABSTRACT 
Elevated plasminogen activator inhibitor-1 (PAI-1) concentrations are associated 
with cardiovascular diseases. PAI-1 antigen levels are influenced by environmental 
factors such as body mass index (BMI), and by genetic factors. The -844A/G and 
the -675(4G/5G) polymorphisms are present in the PAI-1 promoter and they are in 
linkage disequilibrium. The 4G allele of the -675(4G/5G) variation has been 
associated with elevated PAI-1 concentrations and on some occasions with an 
increased risk of cardiovascular disease. The aim of our study was to investigate the 
effect of the PAI-1 promoter haplotype on PAI-1 concentrations and to determine 
the role of BMI. The association between the PAI-1 promoter haplotype and PAI-1 
antigen levels was investigated in two populations, each including 600 healthy 
Caucasians. To assess the direct effect of the PAI-1 promoter haplotype on PAI-1 
promoter activity, in vitro reporter gene assays were performed in HepG2 and 
BAEC cells. We observed significantly higher PAI-1 concentrations in A-4G 
homozygotes than in G-5G carriers, in the lowest BMI quartile. In these lean 
subjects, the PAI-1 concentrations of A-4G/G-5G heterozygotes were reduced to 
60-75%, and the concentrations of G-5G homozygotes to 45-55%, compared to the 
PAI-1 concentrations of A-4G homozygotes. PAI-1 concentrations increased 
approximately 4-fold from the lowest to the highest BMI quartile. The in vitro 
reporter gene assays did not indicate a direct effect of the PAI-1 promoter 
haplotype on promoter activity. Our study suggests that the PAI-1 promoter 
haplotype and BMI affect PAI-1 concentrations and that BMI is a stronger 






Plasminogen activator inhibitor-1 (PAI-1) is a 50 kD plasma glycoprotein and a 
member of the serpin family. PAI-1 is produced in several tissues including 
liver, endothelium, adipose tissue, and vascular smooth muscle cells 1-3. PAI-1 
controls fibrinolysis by the inhibition of the tissue-type- and urokinase-type 
plasminogen activators, and increased PAI-1 plasma levels result in impaired 
fibrinolytic capacity 4. Elevated PAI-1 levels have been associated with an 
increased risk of cardiovascular disease in epidemiological studies 5. Moreover, 
elevated PAI-1 levels are associated with an elevated body mass index (BMI), 
hypertension, hyperinsulinaemia, lipid disorders and increased cytokine levels, 
together referred to as the metabolic syndrome 6. This shows that PAI-1 levels, 
cardiovascular disease and several traditional risk factors (e.g. BMI, 
hyperinsulinaemia and hypertension), are tightly interrelated. 
PAI-1 levels are also partly determined by genetic variables, and the heritability 
of PAI-1 levels in the normal population is estimated at 50-60% 7. Two common 
polymorphisms have been described in the promoter region of the PAI-1 gene: 
the -844A/G (XhoI) polymorphism, and the -675(4G/5G) polymorphism. These 
polymorphisms are in strong, but not complete, positive linkage disequilibrium 
in the Caucasian population 8. The 4G allele of the -675(4G/5G) variation is 
associated with elevated PAI-1 levels, and an association of the 4G allele with an 
increased risk of coronary artery disease and myocardial infarction has been 
reported on some occasions 9-12. Functional studies have indicated that the 
-675(4G/5G) polymorphism may directly affect PAI-1 gene transcription, 
especially in response to factors such as cytokines, lipoproteins and hormones 
13,14. In addition, some association studies suggest that the relationship between 
PAI-1 levels and metabolic factors such as BMI and plasma lipids, may be 
influenced by the -675(4G/5G) polymorphism 9,15,16. However, this interaction 
was not observed in other epidemiological studies 3,8. In addition, it has been 
suggested that the -844A/G polymorphism may also be relevant. The -844A 
allele has been associated with an increased risk of venous thrombosis in 
carriers of the Factor V Leiden mutation, and it has been shown in vitro that 
the -844A/G variation can affect the binding of nuclear proteins to the PAI-1 
promoter 17,18. However, as the two variations are in linkage disequilibrium, the 
relevance of the individual -844A/G and -675(4G/5G) variations is still under 
discussion. Therefore, a haplotype-based approach was used in this study. 
The aim of this study was to determine the contribution of the PAI-1 promoter 
haplotype to PAI-1 plasma levels, and the modification of this relationship by 
BMI. In addition, we performed in vitro functional assays to determine the 
direct effect of PAI-1 promoter haplotype on PAI-1 promoter activity. Besides 
the -675(4G/5G) variation, these functional assays also included the less-well 
characterized -844A/G variation. 
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METHODS 
Study populations 
Analyses were performed separately in two populations which have been 
described in more detail elsewhere 19,20. Briefly, the first population was 
originally designed to investigate the Gly972Arg polymorphism in the insulin 
receptor-substrate-1 (IRS-1) gene. Therefore, carriers of the rare 972Arg allele 
were oversampled from two cohorts of healthy Caucasians: the Maastricht area 
of the Cardiovascular Disease Risk Factor Monitoring Project and the Dutch 
Monitoring Project on Risk Factors for Chronic Diseases (MORGEN) 21, and 
this combined population will be referred to as the MORGEN sample 20. DNA 
and plasma samples were available from 564 subjects, and PAI-1 promoter 
haplotype combinations and PAI-1 antigen (ag) levels could be obtained from 
561 subjects. As the IRS-1 gene and the PAI-1 gene are located on different 
chromosomes, no effect of oversampling of the IRS-1 972Arg allele on the PAI-1 
haplotype frequencies was expected. 
The second population is the Glostrup study, a cohort of healthy individuals 
(n=1198) born in 1936 and living in the area served by the Glostrup Hospital in 
Copenhagen, Denmark, which has been followed since 1976 19,22. In 1996, the 
cohort was re-examined with a participation rate of 65% (695 subjects). DNA 
and plasma samples were available from 664 subjects, and PAI-1 promoter 
haplotype combinations and PAI-1 antigen levels could be obtained from 631 
subjects. 
For both the MORGEN sample and the Glostrup study, the subjects provided 
informed consent and the study protocols were approved by the local medical 
ethical committees. 
Blood sampling, DNA extraction, biochemical procedures 
Collection of samples and biochemical procedures in the MORGEN sample and 
the Glostrup study are described in more detail elsewhere 19,20. Briefly, fasting 
blood samples were drawn into tubes containing citrate in the MORGEN 
sample, and in Stabylite tubes (Biopool) in the Glostrup study. PAI-1 antigen 
concentrations in plasma were measured using EIA (MORGEN: Elitest PAI-1, 
Hyphen Biomed and Glostrup: Imulyse PAI-1:Ag, Biopool). DNA was isolated 
from buffy coats. Triglyceride, total cholesterol, HDL cholesterol, pro-insulin 
and glucose plasma levels were measured in the MORGEN sample as described 
previously 20, and enzymatic methods were used to assess the serum 
concentrations of triglycerides,  total cholesterol, HDL cholesterol and LDL 





Haplotyping of the PAI-1 promoter 
To determine the PAI-1 promoter haplotypes in the MORGEN sample, a PCR 
was designed with primers specific to either the -675(4G) or the -675(5G) allele 
(Figure 1). In this reaction, 0.4 µM forward primer (5’-GCT TGA ATC ATC CCG 
AAA CCA TCC C-3’), 0.4 µM reverse allele specific primer (4G allele: 5’-TAC 
ACG GCT GAC TCC CCA-3’, 5G allele: 5’-TAC ACG GCT GAC TCC CCC-3’), and 
0.04 µM reverse control primer (5’-TGC AGC CAG CCA CGT GAT TGT CTA-3’), 
were used at an annealing temperature of 66ºC. Separate reactions were carried 
out with the 4G- and 5G-specific primers for each DNA sample and the control 
primer was included to avoid false negatives. PCR products were digested with 
XhoI (Invitrogen) and the restriction patterns on agarose gel revealed the PAI-1 
promoter haplotype.  
As the G-4G haplotype occurred at a frequency of only 0.4% in the MORGEN 
sample, it was investigated whether two single genotypes can be used reliably to 
construct the haplotype. In the MORGEN sample, an Expectation-
Maximization algorithm was used to estimate the haplotypes based on the 
frequencies of the individual genotypes. It was calculated that the chance of 
mistyping an individual heterozygous at both polymorphic sites was 0.1%. 
Because of this low chance of mistyping, for the Glostrup study haplotype 
combinations were constructed based on the individual 844A/G and 
-675(4G/5G) genotypes, and subjects heterozygous at both polymorphic sites 
were assigned the haplotype combination A-4G/G-5G. Previously described 
methods to determine the -675(4G/5G) and the -844A/G polymorphisms 












R4G or R5G RC
control band -844A
control band -844G
allele spec. band -844A
allele spec. band -844G
 
Figure 1: The promoter region of the PAI-1 gene. The -844A/G and the -675(4G/5G) 
variations and the locations of the haplotype-specific PCR primers are shown. The bottom 
part shows the fragments formed after digestion of the PCR products with XhoI. 
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Functional PAI-1 promoter assays 
CELLS AND REAGENTS 
HepG2 hepatoma cells were obtained from American Type Culture Collection, 
and maintained in Dulbecco’s Modified Eagle’s medium (DMEM, Invitrogen) 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin (Bio 
Whittaker Europe) and 10% foetal bovine serum (FBS, Invitrogen). Bovine 
aorta endothelial cells (BAECs) were isolated by scraping the inner surface of 
calf aortas with a scalpel, and maintained in HepG2 culture medium 
supplemented with 5 IE/ml heparin (Leo Pharma BV) in plates or flasks coated 
with 1% gelatin. 
REPORTER GENE CONSTRUCTS, TRANSFECTION AND LUCIFERASE ASSAY 
2.0 kb of the promoter region of the PAI-1 gene (-1979 to +23, relative to the 
transcription start site) was amplified by PCR (forward primer: 5’-TCT AAC 
GCG TCA TCC ACA ACA TCC AGA CCA-3’, reverse primer: 5’-TAC TAG ATC 
TCC CTG CAG CCA AAC ACA G-3’). PCR products were digested with MluI and 
BglII and cloned into pGL3-basic (Promega), resulting in PAI-1 promoter-
reporter gene constructs with the A-4G haplotype or the G-5G haplotype. By the 
exchange of the MluI-Bsu36I restriction fragment between these haplotype 
constructs, constructs with the G-4G and the A-5G haplotypes were derived. 
Constructs were sequenced and no additional polymorphisms were detected. 
HepG2 cells were plated in 24-well plates. After an overnight incubation, 
medium was replaced with DMEM supplemented with penicillin and 
streptomycin and 0.1% human serum albumin (HSA, Cealb®). After 2h, cells 
were transfected using FuGene 6 (Roche). 25 ng pGL3 construct, 250 ng carrier 
DNA (herring sperm, Invitrogen) and 0.25 ng pRL-SV40 (Renilla luciferase 
expression construct, Promega) were used per well. 24h after transfection, 
medium was replaced and cells were cultured for an additional 24h. BAEC cells 
were plated in 24-wells plates. After an overnight incubation, cells were 
transfected by calcium phosphate precipitation 23. 500 ng pGL3 construct and 
50 ng pRL-SV40 construct were used per well. Transfection medium was 
removed 6h after transfection, cells were washed and DMEM supplemented 
with penicillin, streptomycin and 0.25% HSA was added. For each construct 
two independent DNA preparations were transfected twice in triplicate. After 
culturing the cells for 48h following transfection, cells were washed, lysed and 
Firefly luciferase and Renilla luciferase activities were measured in lysates 
using the Dual-Luciferase® Reporter Assay System (Promega). 
STATISTICAL ANALYSIS 
Variables with a skewed distribution (PAI-1 antigen, triglycerides, glucose and 
pro-insulin) were logarithmically (ln) transformed. PAI-1 antigen data are 





calculated between PAI-1 concentrations and the metabolic variables. In both 
populations BMI had the highest correlation coefficient with PAI-1 
concentrations, therefore the population was divided into quartiles according to 
BMI. Comparisons were performed by one-way ANOVA. If applicable, Least-
significant difference (LSD) post hoc tests were performed. P<0.05 was 
considered statistically significant. For the sake of clarity, PAI-1 antigen levels 
are expressed in relation to the geometric mean of the populations in the 
figures. 
In the functional assays, firefly luciferase activity was normalized for 
transfection efficiency using Renilla luciferase activity as internal standard, and 
expressed as a percentage of normalized luciferase activity of haplotype A-4G. 
Normalized expression levels were compared by ANOVA testing.  
For all the analyses described above, SPSS 11.5 for Windows was used. An 
Expectation-Maximization algorithm, incorporated in Arlequin, was used to 
estimate the PAI-1 promoter haplotype combinations in the Glostrup 
population 24. 
RESULTS 
PAI-1 promoter haplotypes and PAI-1 antigen levels  
BASELINE CHARACTERISTICS 
The baseline characteristics of the MORGEN and the Glostrup study 
populations are shown in Table 1. 
Table 1: Baseline characteristics of the MORGEN and Glostrup populations 
Mean (±SD) Range Mean (±SD) Range
Age (years) 54.2 (±10.0) 28.0-73.0 60 ‡
Men 45.30% 46.80%
BMI (kg/m2) 26.6 (±5.2) 17.8-41.0 26.5 (±3.9) 17.3-46.9






‡ All subjects in the Glostrup study were of the same age, * because of the skewed 
distribution, the geometric means (±SD) of PAI-1 antigen levels (MORGEN: Elitest, 
Glostrup: Imulyse) are shown. 
Mean PAI-1 antigen level in the MORGEN sample was 78.7 ng/ml (Elitest PAI-
1, Hyphen Biomed), and in the Glostrup study 10.1 ng/ml (Imulyse PAI-1:Ag, 
Biopool). The difference in absolute PAI-1 concentrations between the 
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populations can be attributed to the different assays used in the studies. In both 
study populations, the range of the PAI-1 levels was over two orders of 
magnitude, and the PAI-1 concentrations of men were significantly higher than 
those of women (in both cases p<0.01). 
DISTRIBUTION OF PAI-1 PROMOTER HAPLOTYPES AND ASSOCIATION WITH PAI-1 
ANTIGEN LEVELS 
The frequencies of the four PAI-1 promoter haplotypes in both populations are 
shown in Table 2. The -675(4G) allele was almost completely associated with 
the -844A allele, whereas the -675(5G) allele occurred with both -844A and G 
alleles, although the combination with the -844G allele was more frequent. 
As BMI was the strongest metabolic contributor to PAI-1 antigen levels (Table 
3), the relationship between the PAI-1 promoter haplotype and PAI-1 
concentrations were investigated in the two populations as a whole, and by BMI 
quartiles in the MORGEN sample and the Glostrup study separately (Figures 2 
and 3). 
Table 2: PAI-1 promoter haplotype frequencies in the MORGEN and Glostrup 
populations 
MORGEN Glostrup
Full name Abbrev. N N
-844A/-675(4G) A-4G 595 (52.7%) 705 (53.1%)
-844G/-675(4G) G-4G 4 (0.4%) 5 (0.4%)
-844A/-675(5G) A-5G 67 (5.9%) 68 (5.1%)





Table 3: Pearson correlation coefficients between PAI-1 ag levels, metabolic 
variables and age. 
R p R p
Age 0.34 <0.001 ND *
BMI 0.63 <0.001 0.44 <0.001
pro insulin ‡ 0.5 <0.001 ND
Glucose ‡ 0.48 <0.001 0.29 <0.001
TG ‡ 0.48 <0.001 0.37 <0.001
VLDL cholesterol ND 0.33 <0.001
HDL cholesterol -0.44 <0.001 -0.32 <0.001
LDL cholesterol ND 0.14 <0.001






PAI-1 antigen levels and ‡ levels were ln-transformed prior to analysis, * All subjects in the 
Glostrup study were of the same age, therefore no correlation between age and PAI-1 
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Figure 2: PAI-1 antigen levels of the haplotype combinations in the overall 
MORGEN sample (Figure 2A) and in BMI Quartiles of the MORGEN sample 
(Figure 2B). Bars represent the geometric means (+SD) of the PAI-1 antigen levels 
expressed as a percentage of the geometric mean of the overall population, for each 
haplotype combination separately. Relative geometric means and number of subjects are 
indicated. Rare haplotype combinations are not shown, their relative PAI-1 antigen levels 
are: Quartile 2: (5A/5A: 148.9(n=1)), Quartile 3: (4A/4G: 92.3(n=1)), (4G/5G: 
163.1(±55.7)(n=2)), Quartile 4: (4G/4G: 184.1(n=1)), (5A/5A: 227.7(n=1)). 
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Figure 3: PAI-1 antigen levels of the haplotype combinations in the overall 
Glostrup population (Figure 3A) and in BMI Quartiles of the Glostrup 
population (Figure 3B). Bars represent the geometric means (+SD) of the PAI-1 antigen 
levels expressed as a percentage of the geometric mean of the overall population, for each 
haplotype combination separately. Relative geometric means and number of subjects are 
indicated. Rare haplotype combinations are not shown, their relative PAI-1 antigen levels 
are: Quartile 1: (4A/4G: 28.6(±6.5)(n=2)), Quartile 3: (4A/4G: 82.3(±18.1)(n=3)), (5A/5A: 





In the MORGEN sample overall, there were no significant differences in PAI-1 
concentrations between the haplotype combinations (Figure 2A). However, in 
the lowest BMI quartile of the MORGEN sample (BMI< 22.0 kg/m2), PAI-1 
antigen levels differed significantly between the promoter haplotype 
combinations (p<0.05). The PAI-1 concentrations of A-4G homozygotes were 
significantly higher than those of A-4G/G-5G heterozygotes (p<0.05), and than 
those of G-5G homozygotes (p<0.01). The geometric mean PAI-1 
concentrations of A-4G/G-5G heterozygotes and G-5G homozygotes were 
respectively 76% and 56% of the geometric mean PAI-1 levels of A-4G 
homozygotes (Figure 2B). 
In the Glostrup population overall, significant differences in PAI-1 
concentration between the haplotype combinations were observed (p<0.05). 
The PAI-1 antigen levels of A-4G homozygotes were significantly higher than 
those of A-4G/G-5G heterozygotes (p<0.01), and than those of G-5G 
homozygotes (p<0.001) (Figure 3A). When the population was divided into 
BMI quartiles however, these differences were only present in the lowest BMI 
quartile (BMI< 23.8 kg/m2) (p<0.05), similarly to the observations in the 
MORGEN sample.The PAI-1 levels of A-4G homozygotes were significantly 
higher than those of A-4G/G-5G heterozygotes (p<0.05), and than those of 
G-5G homozygotes (p<0.001). In the lowest BMI quartile, the geometric mean 
PAI-1 antigen level of A-4G/G-5G heterozygotes and G-5G homozygotes were 
respectively 61% and 45% of the geometric mean PAI-1 levels of A-4G 
homozygotes (Figure 3B).  
In both the MORGEN sample and the Glostrup study, no significant differences 
in PAI-1 antigen level between the haplotype groups were detected in the 2nd, 
3rd and 4th BMI quartiles (Figures 2 and 3). 
Table 4: PAI-1 promoter activity in hepatoma and endothelial cells 
Full name Abbrev. HepG2 BAEC
-844A/-675(4G) A-4G 100 (±10.3) 100 (±21.9)
-844G/-675(4G) G-4G 95 (±9.0) 104 (±20.7)
-844A/-675(5G) A-5G 88 (±7.6) 93 (±50.1)
-844G/-675(5G) G-5G 91 (±16.7) 123 (±27.3)
p=0.08 p=0.44
Haplotype PAI-1 promoter activity
Anova  
Normalized luciferase activities are expressed in relation to the activity of the A-4G 
haplotype construct. Means (±SD) of 12 transfections obtained in four independent 
experiments are shown. 
Functional PAI-1 promoter assays 
To investigate whether PAI-1 promoter variation directly affects PAI-1 promoter 
activity, reporter-gene assays were performed, with constructs representing the 
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four different PAI-1 promoter haplotypes. No significant differences between 
the basal promoter activity of the four PAI-1 promoter haplotypes were 
observed in hepatoma (HepG2) or endothelial (BAEC) cells (Table 4), although 
the lowest promoter activity was seen for the G-5G and A-5G promoter 
haplotypes. 
DISCUSSION 
In this study we observed associations between PAI-1 promoter haplotypes and 
PAI-1 concentrations, which were most pronounced in subjects in the lowest 
BMI quartile. In vitro reporter gene assays showed no clear indications of a 
direct effect of the PAI-1 promoter variation on PAI-1 promoter activity. 
To study the relationship between PAI-1 promoter haplotype and PAI-1 antigen 
levels, we determined the PAI-1 promoter haplotypes in two different 
populations of healthy individuals, and in both populations the frequencies of 
the haplotypes were similar. The A-4G haplotype had a frequency of 
approximately 53%, the G-4G haplotype a frequency of 0.4%, the A-5G 
haplotype a frequency of approximately 6%, and the G-5G haplotype a 
frequency of approximately 41%. This is the first time that the frequencies of 
the PAI-1 promoter haplotypes have been reported. The haplotype frequencies 
are in accordance with the reported allele frequencies of the individual 
-844A/G and -675(4G/5G) variations 8,17,25. 
In both populations, homozygotes for the A-4G haplotype had higher PAI-1 
concentrations than A-4G/G-5G heterozygotes and G-5G homozygotes. In the 
MORGEN sample, this association was only significant in the lowest BMI 
quartile (BMI<22.0). In the Glostrup study the association was also present in 
the whole population, but when the population was divided into BMI quartiles, 
the association between PAI-1 plasma levels and PAI-1 promoter haplotypes 
was only significant in the lowest quartile (BMI<23.8). These results indicate 
that the association between PAI-1 promoter variation and PAI-1 levels is most 
prominent in lean individuals. To our knowledge, this is the first report on the 
relationship between PAI-1 promoter variation and PAI-1 concentrations in this 
subgroup. As expected, PAI-1 concentrations did tightly correlate with BMI in 
our populations, and mean PAI-1 antigen levels increased approximately four-
fold from the lowest up to the highest BMI quartile. The confinement of the 
association between PAI-1 promoter haplotype and PAI-1 concentrations to the 
lowest BMI quartile suggests that that the effect of genetic variation of the PAI-
1 promoter on PAI-1 concentrations is lost to the background of the (stronger) 
effect of BMI on these levels in the 2nd, 3rd and 4th BMI quartiles. More 
generally, metabolic factors such as BMI, are more important determinants of 
PAI-1 concentrations than genetic variation of the PAI-1 promoter, and this 





indications of a synergistic interaction between PAI-1 promoter genotype and 
PAI-1 antigen levels, which was suggested by some studies 9,16, but not by others 
8,26.  
The differences in PAI-1 levels between the PAI-1 promoter haplotype groups 
are fairly large (approximately 50% between A-4G homozygotes and G-5G 
homozygotes in the lowest BMI quartile). Therefore it is interesting to 
hypothesize how this compatible is with previous reports on the relationships 
between PAI-1 promoter variation, PAI-1 concentrations and the risk of 
cardiovascular disease. The reported relationships between PAI-1 promoter 
variation and PAI-1 antigen levels, and between PAI-1 antigen levels and the 
risk of cardiovascular disease are consistent, but the relationship between PAI-1 
promoter variation and the risk of cardiovascular disease is debatable 27. Our 
study indicates that the influence of genetic variation of the PAI-1 promoter on 
PAI-1 concentrations is reasonably strong mainly in lean individuals, i.e. 
individuals with a favourable status with respect to the important 
cardiovascular risk factor BMI. This could explain the reported weak (or 
absent) relationship between variation of the PAI-1 gene and the risk of 
cardiovascular disease 12,25. 
It would be interesting to evaluate the individual effects of the -675(4G/5G) and 
the -844A/G polymorphisms. However, due to the low frequency of the G-4G 
and A-5G haplotypes in our populations, we could not discriminate between the 
effects of the -675(4G/5G) and -844A/G polymorphisms in vivo. The in vitro 
reporter gene assays with the four different PAI-1 promoter haplotypes 
provided an alternative approach to answering this question. In our in vitro 
studies, we did not find any clear indications of a direct effect of the PAI-1 
promoter variation on basal PAI-1 promoter activity. These observations are in 
line with the findings of others 13,28, but in contrast to one positive report 10. In 
this latter study constructs with two tandem copies of a 30 bp DNA segment 
containing either the 4G or the 5G allele upstream from a minimal promoter 
were used. In all the studies including ours which did not find any effect of 
promoter variation on basal PAI-1 promoter activity, a larger part of the 
proximal PAI-1 promoter with the -675(4G/5G) polymorphism in its natural 
context was used. This different design of the constructs which is used, is a 
plausible explanation for the inconsistency in the reported results. With the 
present work we confirm previous findings that -675(4G/5G) does not affect 
basal PAI-1 promoter activity in HepG2 and endothelial cells, and we show that 
also the -844A/G variation does not directly affect basal PAI-1 promoter activity 
in these cell types. However, we need to make the proviso that the cell culture 
conditions may not accurately represent the situation in the human body, and 
therefore we may have to be careful with the interpretation of these results.  
We observed an association between PAI-1 promoter variation and PAI-1 
plasma levels in vivo, in line with previous reports. Our in vitro observation 
that the PAI-1 promoter polymorphisms do not directly affect basal PAI-1 
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promoter activity also is consistent with the findings of others. This apparent 
discrepancy between the in vivo and in vitro results could be explained by a 
functional PAI-1 polymorphism located outside the promoter region of the 
gene, which was not included in our functional assays, but is responsible for the 
effects observed in vivo. For example, this additional polymorphism could be 
located in the 3’ region of the gene and influence mRNA stability, or it could be 
located in the introns of the gene in the vicinity of splicing sites.  
Another explanation for the lack of effect of genetic variation on PAI-1 
promoter activity in HepG2 and BAEC cells could be that in vivo tissues other 
than liver and endothelium are responsible for the genotype-dependent PAI-1 
expression. This is a relevant issue, as the transcriptional regulation of many 
genes, including the PAI-1 gene, can be highly dependent on the cell type 29. 
Because of the relationship between BMI and PAI-1 plasma levels, there is 
much interest in the role of adipose tissue in the production of PAI-1. However, 
also for adipose tissue, no effect of the -675(4G/5G) polymorphism on the 
endogenous PAI-1 production could be detected 3, and therefore it is not yet 
clear which tissue is responsible for the genotype-dependent PAI-1 production 
in vivo. 
In this study we observed a great difference between the average PAI-1 
concentrations in the two populations, which can be attributed to the different 
PAI-1 immunoassays used. The PAI-1 antigen levels in the MORGEN sample 
(measured with Elitest) are in accordance with reported levels obtained with 
this assay 30, and this is also the case for the PAI-1 antigen levels in the Glostrup 
study (measured with Imulyse) 11,15. The two assays differ in their specificity for 
the different PAI-1 forms, as Elitest recognizes all PAI-1 forms (active, in 
complex, inactive) equally well, whereas Imulyse is relatively insensitive to 
inactive PAI-1 31.  
In conclusion, in this study we observed an association between the PAI-1 
promoter haplotype and PAI-1 antigen levels, which was most prominent in 
lean individuals. Our results indicate that both genetic variation and BMI 
influence PAI-1 levels, but that BMI is a more important determinant of PAI-1 
concentrations. In vitro we did not observe any direct effect of the PAI-1 
promoter haplotype on basal PAI-1 promoter activity in hepatoma and 
endothelial cells.  
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ABSTRACT 
Plasminogen activator inhibitor type 1 (PAI-1) is a main inhibitor of fibrinolysis 
and increased plasma PAI-1 levels are associated with an increased risk of 
cardiovascular disease. PAI-1 concentrations are regulated by environmental and 
genetic factors, and are associated with plasma levels of inflammatory factors and 
with features of the metabolic syndrome. The aim of this study was to describe the 
relationships between environmental and genetic factors and PAI-1 antigen levels, 
with a focus on the metabolic syndrome and inflammation. PAI-1 antigen levels, 
metabolic and inflammatory parameters, and the PAI-1 -675(4G/5G), insulin 
receptor substrate-1 (IRS-1) Gly972Arg, tumor necrosis factor-α (TNF-α 
-308G/A), and interleukin-6 (IL6) -174G/C genotypes were determined in a 
population of 600 healthy Caucasian subjects. Strong correlations were present 
between PAI-1 antigen levels and the plasma levels of several metabolic factors, 
and C-reactive protein. In addition, we observed that high body mass index (BMI) 
and low physical activity were associated with elevated PAI-1 concentrations (in 
both cases p<0.001). Concerning the genetic factors, a significant relationship with 
PAI-1 antigen levels was observed for the PAI-1 -675(4G/5G) polymorphism after 
adjustment for age, sex, the metabolic syndrome and environmental factors 
(p=0.011), and for the IRS-1 Gly972Arg polymorphism (p=0.008). In addition, our 
data indicate an interaction between the TNF-α -308G/A polymorphism and 
physical activity on plasma PAI-1 concentrations (p for interaction = 0.05), with 
higher PAI-1 concentrations in physically inactive subjects homozygous for the 
TNF-α-308A allele. This study demonstrates the effects of physical activity, BMI 
and the PAI-1 -675(4G/5G) and the IRS-1 Gly972Arg polymorphisms on plasma 
PAI-1 levels. We also obtained indications for an interaction between the TNF-α 
-308G/A polymorphism and physical activity. Our study suggests that these factors 





Plasminogen activator inhibitor-1 (PAI-1) is a 50 kD plasma glycoprotein and a 
member of the serpin family. PAI-1 is produced in several tissues, including 
liver, endothelium, adipose tissue, and vascular smooth muscle cells 1-5. PAI-1 
controls fibrinolysis by inhibition of both tissue-type- and urokinase-type 
plasminogen activators. Increased PAI-1 plasma levels result in impaired 
fibrinolytic capacity 6, and elevated PAI-1 plasma levels are associated with an 
increased risk of cardiovascular disease 7,8. 
The PAI-1 plasma concentration is determined by metabolic, environmental 
and genetic factors. The main determinant of the plasma PAI-1 concentration is 
the metabolic syndrome 9. Elevated PAI-1 concentration in the metabolic 
syndrome may be the result of enhanced PAI-1 production in response to 
substances such as insulin, glucose, fatty acids or lipoproteins 10-14. There is a 
strong relationship between body mass index (BMI), which is a major feature of 
the metabolic syndrome, and PAI-1 plasma levels. In addition, it has been 
demonstrated that weight reduction is effective in lowering PAI-1 levels 15. 
Adipose tissue is an important source of PAI-1 in the circulation 16,17, which 
might explain the relationship between BMI and the PAI-1 plasma 
concentration. Insulin resistance also is an important feature of the metabolic 
syndrome, and several studies have indicated a relationship between insulin 
resistance and PAI-1 levels 9,18. In addition, it has been reported that genetic 
variation of the insulin receptor substrate-1 (IRS-1) gene, which plays a key role 
in the cellular response to insulin, was associated with PAI-1 plasma levels 19. 
Environmental factors such as smoking, physical activity and alcohol 
consumption also influence the PAI-1 concentration 20,21. However, it is unclear 
if these variables influence PAI-1 concentrations independently of the insulin 
resistance syndrome. PAI-1 expression is also controlled by inflammatory 
factors, and tumor necrosis factor-α (TNF-α) is a key player in both 
inflammation and the obesity-linked elevation of plasma PAI-1 22,23. 
The heritability for the PAI-1 concentration is estimated at 50-60% 24,25. Several 
polymorphisms in the PAI-1 gene have been described. The -675(4G/5G) single 
base pair insertion-deletion polymorphism has been studied on many 
occasions, and several studies have indicated that the 4G allele of this 
polymorphism is associated with elevated PAI-1 plasma levels 26-29. It can also 
be anticipated that polymorphisms in genes upstream in the regulatory 
pathway of PAI-1 production may affect PAI-1 concentrations. Polymorphisms 
in genes regulating the inflammatory response (e.g. TNF-α or interleukin-6 
(IL6)), or in genes important in the metabolic syndrome (IRS-1), could 
therefore be particularly interesting. 
Therefore, the aim of this study was to describe the impact of environmental 
and genetic factors on the PAI-1 concentration, in a representative sample of 
the Dutch population. 
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METHODS 
Subjects 
Briefly, the study population of healthy individuals was selected from 
participants of the Maastricht area of the Cardiovascular Disease Risk Factor 
Monitoring Project and the Dutch Monitoring Project on Risk Factors for 
Chronic Diseases (MORGEN) 30,31. All participants of these two studies were re-
approached in 1998 with a self-administered questionnaire with questions on 
general health. This study was designed to study the (relatively rare) IRS-1 
Gly972Arg polymorphism. Therefore, the IRS-1 Gly972Arg polymorphism was 
determined in all subjects and a subset of carriers of the rare Arg allele (n=519), 
and a random sample of the wild-type subjects (n=497) were selected, and 
invited for a new physical examination. Sixty percent of the invitees 
participated, and subjects with diagnosed diabetes were excluded 32. All 
individuals for which the PAI-1 antigen level and the PAI-1 -675(4G/5G) 
genotype were available, were included in the analysis (n=561). Participants 
filled in an informed consent form, and the protocol was approved by the 
Medical Ethical Committee of TNO Prevention and Health, Leiden, the 
Netherlands. 
Clinical measurements 
After an overnight fast, measurements for the determination of BMI and waist-
to-hip ratio (WHR) were obtained. Blood was drawn between 8.00 and 10.30 in 
the morning, into tubes containing K3EDTA and in tubes containing sodium 
citrate. Subjects also handed in a general health questionnaire, which included 
questions about smoking behavior, alcohol consumption and physical activity. 
Subjects were classified as smokers or non-smokers. Alcohol consumption was 
categorized as follows: no alcohol, 0-1 glasses a day, or more than 1 glass a day. 
Bouts of exercise, biking, gardening, etc. were included to assess physical 
activity if they lasted 30 minutes per day or more. Subjects who reported such 
activities on three or more days a week were considered to be physically active, 
others were classified as non-active. 
Laboratory measurements 
PAI-1 antigen concentrations were determined using an enzyme immunoassay 
(EIA, Elitest PAI-1, Hyphen Biomed, France) in citrated plasma. In EDTA-
plasma, triglyceride, HDL cholesterol, insulin and glucose levels were measured 
as described previously 32, and C-reactive protein (CRP) was determined with 
an in-house highly sensitive EIA, using polyclonal antibodies to human CRP as 
catching and tagging antibodies (DAKO Diagnostics) 33. Genomic DNA was 
extracted from white blood cells, and the PAI-1 -675(4G/5G) polymorphism 




elsewhere 34. The IRS-1 Gly972Arg, the TNF-α -308G/A, and the IL6 -174G/C 
polymorphisms were determined as described previously 32,35. 
Statistical analysis 
Variables with a skewed distribution (PAI-1 antigen, insulin, triglycerides, 
glucose, CRP), were logarithmically (ln) transformed prior to analysis, and they 
are presented as geometric means and SDs. Pearson correlation coefficients 
were calculated between PAI-1 concentrations and the metabolic variables and 
CRP levels. Differences between subgroups were analyzed with analysis of 
variance, after adjustments for only age and sex (simple model), and after 
adjustments for age, sex, the metabolic syndrome (WHR, insulin and 
triglycerides were taken as characteristics), and the other environmental factors 
(smoking, alcohol intake, physical activity, BMI) (extensive model). Differences 
between genotype groups were analyzed similarly (ANOVA with adjustments as 
in the simple model, or the extensive model). An interaction term in this model 
was used to evaluate possible interactions between environmental and genetic 
variables. A p-value smaller than 0.05 was considered statistically significant. 
All analyses were performed using SPSS 11.5 for Windows. 
RESULTS 
Table 1. Baseline characteristics of the study population 
Mean (±SD)
n=561
Age (yr) 52.7 (±10.0)
Men (%) 44.90%
BMI (kg/m2) 26.6 (±5.2)
WHR 0.87 (±0.11)
PAI-ag (ng/ml) ‡ 78.7 (±31.6)
Insulin (pmol/l) ‡ 42.8 (±7.3)
Triglycerides (mmol/l) ‡ 1.1 (±0.06)
Glucose (mmol/l) ‡ 5.2 (±0.05)
HDL-cholesterol (mmol/l) 1.3 (±0.36)
CRP (mg/l) ‡ 2.12 (±0.74)
Smoking (% yes) 28.20%
Alcohol use (%)          0 glass/day 24.40%
                                      0-1 glass/day 41.00%
                                        >1 glass/day 34.60%
Physical activity (% > 2 days/week) 64.40%
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Baseline characteristics 
The baseline characteristics of the study population are shown in Table 1. The 
population included 252 men and 309 women aged 26 to 71 years. The 
geometric mean PAI-1 antigen level was 78.7 ng/ml, and the PAI-1 antigen 
levels were higher in men than in women (105.3 ng/ml versus 62.1 ng/ml, 
p<0.001). PAI-1 antigen levels were strongly and positively associated with age, 
BMI, waist-hip ratio (WHR), and with glucose, insulin, triglyceride and CRP 
levels, and were inversely associated with HDL-cholesterol levels (p<0.001 in 
all cases) (Table 2). 
Table 2: Spearman correlation coefficients of PAI-1 antigen levels with 





Glucose ‡ 0.5 <0.001
Insulin ‡ 0.48 <0.001
Triglycerides ‡ 0.51 <0.001
HDL-cholesterol -0.48 <0.001
CRP ‡ 0.32 <0.001
 
PAI-1 antigen levels and ‡ levels were logarithmically (ln) transformed prior to analysis 
Environmental factors and PAI-1 antigen concentrations 
The PAI-1 antigen concentration was related to several environmental factors in 
our population. PAI-1 antigen levels were significantly lower in subjects that 
had a BMI below the mean (26.6 kg/m2) compared to individuals with a BMI 
above the mean after adjustment for age and sex (51.1 (±13.2) ng/ml versus 
122.0 (±31.3) ng/ml p<0.001) (Table 3a), and when additional adjustment for 
the metabolic syndrome (WHR, insulin and triglycerides) and the other 
environmental factors (smoking, alcohol intake, physical activity) were applied 
(67.1 (±20.5) ng/ml versus 94.1 (±28.5) ng/ml, p<0.001). In addition, PAI-1 
concentrations were significantly higher in physically inactive subjects after 
adjustment for age and sex (92.7 (±29.0) ng/ml versus 70.9 (±22.6) ng/ml, 
p<0.001). When the metabolic syndrome (WHR, insulin and triglycerides) and 
the other environmental factors (smoking, alcohol intake, BMI) were taken into 
account, this relationship was maintained (85.8 (±15.2) ng/ml versus 76.1 
(±13.9) ng/ml, p=0.032). Smoking and alcohol intake were not significantly 





Table 3a: PAI-1 antigen levels according to environmental factors 
PAI-1 ag PAI-1 ag
(ng/ml) (ng/ml)
§  ¶
<26.6 (n=282) 51.1 (±13.2) <0.001 67.1 (±20.5) <0.001
>26.6 (n=279) 122.0 (±31.3) 94.1 (±28.5)
0-2 (n=190) 92.7 (±29.0) <0.001 85.8 (±15.2) 0.032
3-7 (n=343) 70.9 (±22.6) 76.1 (±13.9)
No (n=395) 81.4 (±25.7) 0.075 78.81 (±14.2) 0.68
Yes (n=155) 71.2 (±23.1) 80.88 (±15.2)
0 (n=132) 75.1 (±24.1) 0.6 71.4 (±13.0) 0.082
0-1 (n=222) 80.7 (±25.5) 81.0 (±14.6)










Values are presented as geometric means (±SD). PAI-1 levels adjusted for age and sex (§), 
and PAI-1 levels adjusted for age, sex, the metabolic syndrome (WHR, insulin, 
triglycerides) and the other environmental variables tested (physical activity, smoking, 
alcohol consumption and BMI) (¶) are shown. 
 
Table 3b: PAI-1 antigen levels according to genetic variation 
PAI-1 ag PAI-1 ag
(ng/ml) (ng/ml)
§ ¶
PAI-1 -675(4G5G) 4G4G (n=144) 87.8 (±28.1) 0.14 89.3 (±9.8) 0.011
4G5G (n=307) 75.3 (±24.6) 77.8 (±13.5)
5G5G (n=110) 77.5 (±25.2) 71.4 (±12.4)
IRS-1 Gly 972Arg GG (n=335) 84.6 (±27.6) 0.008 83.8 (±15.0) 0.014
GA/AA (n=226) 70.8 (±22.8) 73.3 (±12.9)
TNF-α -308G/A GG (n=386) 76.9 (±25.0) 0.45 77.1 (±13.2) 0.22
GA (n=156) 81.9 (±26.7) 84.4 (±15.1)
AA (n=19) 92.7 (±30.0) 88.7 (±15.9)
IL6 -174G/C GG (n=209) 82.8 (±26.5) 0.37 81.9 (±14.3) 0.7
CG (n=278) 78.3 (±25.3) 78.3 (±13.9)
CC (n=70) 71.24 (±23.2) 77.8 (±13.9)
p p
 
Values are presented as geometric means (±SD). PAI-1 antigen levels adjusted for age and 
sex (§), and PAI-1 antigen levels adjusted for age, sex, the metabolic syndrome (insulin, 
triglycerides, WHR) and environmental variables (physical activity, smoking, alcohol 
consumption and BMI) (¶) are shown. 
 106
 
Determinants of PAI-1 concentrations 
Genetic variation and PAI-1 antigen concentrations 
The relationships between PAI-1 plasma concentrations and several genetic 
factors were also investigated. After adjustment for age, sex, the metabolic 
syndrome (WHR, insulin and triglycerides) and the environmental factors 
(smoking, alcohol intake, physical activity, BMI), there was a significant 
relationship between the -675(4G/5G) polymorphism in the PAI-1 promoter 
and PAI-1 antigen levels, and higher PAI-1 antigen levels were associated with 
the 4G allele (4G4G: 89.3 (±9.8) ng/ml, 4G5G: 77.8 (±13.5) ng/ml, 5G5G: 71.4 
(±12.4) ng/ml, p=0.011) (Table 3b). Concerning the IRS-1 Gly972Arg 
polymorphism, the PAI-1 antigen levels of subjects homozygous for the Gly 
allele were significantly higher than the PAI-1 antigen levels of carriers of the 
Arg allele after adjustment for age and sex (84.6 (±27.6) ng/ml versus 70.8 
(±22.8) ng/ml, p=0.008), and also after additional adjustments for the 
metabolic syndrome (WHR, insulin and triglycerides) and environmental 
factors (smoking, alcohol intake, physical activity, BMI) (83.8 (±15.0) ng/ml 
versus 73.3 (±12.9) ng/ml, p=0.014). No significant relationships between PAI-
1 antigen levels and the TNF-α -308G/A and the IL6 -174G/C polymorphisms 
were observed. 
Table 4: Significance levels of gene-environment interactions on PAI-1 antigen 
levels 
Smoking Alcohol  Phys. act BMI 
Yes /no 0, 0-1, >1 High/ low High/ low
PAI-1 -675(4G/5G) 0.04* 0.86 0.97 0.72
IRS-1 Gly972Arg 0.32 0.41 0.19 0.63
TNF-α -308G/A 0.2 0.63 0.17 0.86
IL6 -174G/C 0.29 0.33 0.09 0.61
PAI-1 -675(4G/5G) 0.23 0.6 0.45 0.91
IRS-1 Gly972Arg 0.3 0.71 0.95 0.25
TNF-α -308G/A 0.4 0.71 0.05* 0.44
IL6 -174G/C 0.26 0.74 0.07 0.41
 Extensive adjustments (¶)
Adjusted for age and sex (§)
 
Models adjusted for age and sex (§), and adjusted for age, sex, metabolic syndrome and 
environmental factors (¶) are shown. * p<0.05 
Gene-environment interactions 
As it is biologically plausible that the effects of genetic variation may be 
particularly relevant under specific conditions, interactions between the 
environmental factors (smoking, alcohol intake, physical activity and BMI) and 




1 -675(4G/5G) polymorphism and smoking was observed (p=0.04), after 
adjustment only for age and sex (Table 4). However, this interaction 
disappeared when additional adjustments were made for the metabolic 
syndrome (WHR, insulin and triglycerides) and the other environmental 
factors (alcohol intake, physical activity, BMI) (p=0.23). In addition, a 
significant interaction was observed between the TNF-α -308G/A 
polymorphism and physical activity after adjustments for age, sex, the 
metabolic syndrome (WHR, insulin and triglycerides) and the other 
environmental factors (smoking, alcohol intake, BMI) , (p=0.05), and the PAI-1 
antigen levels were increased in physically inactive subjects homozygous for the 
TNF-α-308A allele (Figure 1). This interaction was not present when only age 
and sex were taken into account (p=0.17). 
 
 
Figure 1: PAI-1 antigen levels of the different TNF-α-308G/A genotypes, in 
physically inactive and physically active subjects. Bars represent the geometric 
means (±SD) of the PAI-1 antigen levels. The number of subjects in the subgroups is 
indicated on the bars. 
DISCUSSION 
Elevated PAI-1 plasma levels are associated with an increased risk of 
cardiovascular disease 7,8. In this study we describe the relationship between 
several environmental and genetic factors, and PAI-1 antigen levels. We focused 
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on the metabolic syndrome and inflammation, as both these biological 
processes are important for PAI-1 concentrations and also for cardiovascular 
disease. We were also interested in identifying factors that influenced PAI-1 
concentrations independently of the metabolic syndrome. 
We have observed tight correlations between PAI-1 antigen levels and several 
features of the metabolic syndrome, e.g. BMI, WHR, glucose levels, insulin 
levels, triglyceride levels, and HDL cholesterol levels. This confirms that PAI-1 
antigen levels are related to the metabolic syndrome, and this conclusion is in 
accordance with the literature 18,36. In addition we observed a tight correlation 
between PAI-1 antigen levels and the sensitive acute-phase marker CRP, and 
with this finding we confirm the relationship between PAI-1 and inflammation 
that had been suggested before 22,37. PAI-1 transcription is under direct control 
of several cytokines including TNF-α and transforming growth factor-β (TGF-
β). Elevated plasma levels of these cytokines are also a feature of the metabolic 
syndrome 23,38, which might explain the interrelationships between the 
metabolic syndrome, inflammation and PAI-1 plasma concentrations 22,39 
In this study, we evaluated the relationships between PAI-1 concentrations and 
the environmental factors BMI, physical activity, smoking and alcohol intake. 
First of all, we observed significantly higher PAI-1 concentrations in subjects 
with a BMI above the mean, which was expected based on the results of others 
18,21. We observed that subjects that were physically active had lower PAI-1 
concentrations than subjects that were inactive (p<0.001 adjusted for age and 
sex, and p=0.032 after adjustment also for the metabolic syndrome and the 
other environmental factors). In a previous study, it was shown that after a six-
month intervention in which the participants underwent a controlled exercise 
program, PAI-1 levels were moderately decreased. Our results support this 
conclusion that regular physical exercise has a beneficial, reducing effect on 
PAI-1 plasma concentrations. 40. We did observe slightly higher PAI-1 antigen 
levels in non-smokers compared to smokers, and this might be explained by the 
fact that in general non-smokers have a higher BMI than smokers, which also 
was the case in our population (the average BMI was 27.3 in non-smokers and 
24.5 in smokers, p<0.001). This is underlined by the fact that after additional 
adjustment for the metabolic syndrome and the other environmental factors 
(including BMI), the PAI-1 antigen levels in non-smokers and smokers were 
similar (Table 3a). Finally, we did not observe a strong relationship between 
PAI-1 concentrations and alcohol intake, although PAI-1 antigen levels seemed 
to increase with increasing alcohol consumption, which is in line with the 
results of others 41, and this elevated PAI-1 production might be related to 
increased cytokine production in the early stage of many liver diseases, 
including alcoholic steatohepatitis 42. However, our results may also rely on 
chance as they were not significant and in some other studies no clear 
relationship between PAI-1 concentrations and alcohol intake could be detected 




strongest effector of PAI-1 antigen levels, also independent of the other 
environmental factors (smoking, alcohol intake, physical activity), and the 
metabolic syndrome (WHR, insulin and triglycerides) (67.1 (±20.5) ng/ml 
versus 94.1 (±28.5) (ng/ml, p<0.001). The PAI-1 antigen levels of subjects with 
a BMI above the mean was 1.4 fold increased compared to the PAI-1 antigen 
levels of subjects with a BMI below the mean. This indicates that the 
relationship between PAI-1 plasma concentrations and BMI might be 
independent of the other characteristics of the metabolic syndrome, and this is 
an interesting observation that should be confirmed in other studies. 
We also investigated the relationship between several genetic factors and PAI-1 
antigen levels, and also in this analysis we were interested in the effect of the 
metabolic syndrome on these relationships. Generally, the 4G allele of the 
-675(4G/5G) polymorphism in the PAI-1 gene is associated with elevated PAI-1 
levels 27-29. Also in our population, higher PAI-1 antigen levels were observed 
associated with the -675(4G) allele, and this relationship was significant when 
adjustments were made for age, sex, the metabolic syndrome and 
environmental factors (p=0.011). This indicates that in our population the 
-675(4G/5G) polymorphism influences PAI-1 antigen levels, but the metabolic 
syndrome and environmental factors need to be taken into account in order to 
detect this relationship, which is in line with other studies 29,36. Our results 
could indicate that BMI and the -675(4G/5G) variation influence PAI-1 antigen 
levels independently, and that in order to detect the relatively small effect of the 
-675(4G/5G) polymorphism, adjustment for BMI needs to be made. We have 
obtained similar results in another population of healthy Caucasians as well, 
and this has been described elsewhere (chapter 5). Secondly, we observed 
lower PAI-1 plasma levels in carriers of the rare Arg allele of the Gly972Arg 
polymorphism in the insulin-receptor substrate-(IRS)-1 gene, which is in line 
with findings of Clausen et al 19. However, this relationship disappeared when 
the metabolic syndrome (WHR, insulin and triglycerides) and environmental 
factors (smoking, alcohol intake, physical activity) were also considered, 
indicating that the effect of the IRS-1 polymorphism on PAI-1 levels might work 
through the metabolic syndrome. This is biologically plausible, as IRS-1 is 
important in the cellular response to insulin, and insulin is a key player in the 
metabolic syndrome. In this population, carriers of the rare IRS-1 972Arg allele 
indeed have higher insulin levels, particularly when they are also overweight 32. 
Therefore, higher insulin levels in carriers of the IRS-1 972Arg allele are a 
plausible explanation for the relationship between the IRS-1 972Arg allele and 
elevated PAI-1 antigen levels that we describe in the present work. We did not 
observe significant relationships between the functional TNF-α -308G/A and 
IL6 -174G/C polymorphisms and PAI-1 antigen levels, although in both cases 
there was a trend towards higher PAI-1 antigen levels in the carriers of the 
alleles associated with high cytokine production (the -308A allele of the TNF-α 
polymorphism, and the -174G allele of the IL6 polymorphism 44,45). However, 
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the relevance of these two polymorphisms for PAI-1 plasma levels in the general 
healthy population is probably limited. 
It is biologically plausible that effects of genetic variation are particularly 
relevant under specific (environmental) conditions. Therefore we have 
investigated the interactions between the environmental factors and genetic 
factors, on PAI-1 concentrations. We observed two possible interactions that 
deserve further discussion. Firstly, we observed an interaction between the PAI-
1 -675(4G/5G) polymorphism and smoking status after adjustment for age and 
sex only, but this interaction disappeared when also the environmental and 
metabolic factors were taken into account. This can be explained by the fact 
that smoking often coincides with low BMI, suggesting that this interaction 
does not influence PAI-1 concentrations independently of other metabolic and 
environmental factors. Therefore, this interaction may be less relevant for PAI-1 
plasma concentrations from a biochemical point of view. Secondly, we observed 
an interaction between the TNF-α -308G/A polymorphism and physical activity 
on PAI-1 antigen levels after adjustment for age, sex, the metabolic syndrome 
and the other environmental factors. This interaction is biologically possible, as 
it has been shown that physical activity can reduce inflammation 46. We 
observed that the PAI-1 antigen levels in physically inactive subjects 
homozygous for the TNF-α-308A allele were approximately 2.2 fold higher 
than the PAI-1 antigen levels in others. The TNF-α-308A allele is associated 
with increased TNF-α promoter activity in vitro 44. Our results suggest that the 
effect of this polymorphism on TNF-α expression might be strong enough to 
influence PAI-1 expression under the relatively pro-inflammatory conditions 
present in physically inactive subjects. However, this hypothesis is based on a 
small number of subjects in this subgroup, and this association should 
therefore be verified in other studies. 
In summary, this study describes effects of several environmental and genetic 
factors on PAI-1 antigen levels. In this population, BMI, physical activity and 
the PAI-1 -675(4G/5G) and the IRS-1 Gly972Arg polymorphisms affect PAI-1 
levels independent of the metabolic syndrome. In addition, we observed 
indications for an interactive effect between the TNF-α -308G/A polymorphism 
and physical activity on PAI-1 plasma concentrations. 
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General Discussion and Conclusions 
THIS CHAPTER 
The overall aim of the studies described in this thesis was to investigate the 
effects of common genetic variations in the promoter regions of the fibrinogen β 
and plasminogen activator inhibitor-1 (PAI-1) genes on promoter activity and 
plasma protein levels. This chapter contains the general discussion of issues 
concerning the functional studies of the fibrinogen β promoter (chapter 2 and 
3), and a discussion of the studies on the relationship between PAI-1 promoter 
variation and PAI-1 antigen levels (chapter 5 and 6). Additionally, some 
general issues concerning the role of genetic variation in the promoter regions 
of genes (chapter 4) and its relationship with cardiovascular disease are 
discussed. 
REGULATION OF FIBRINOGEN β CHAIN GENE EXPRESSION 
In chapter 2 we describe the identification of a functional hepatocyte nuclear 
factor-3 (HNF-3) element located at position -159/-151 in the fibrinogen β 
promoter. Promoter-reporter gene assays showed that this site plays an 
important role in the interleukin-6 (IL6) response of the fibrinogen β gene, and 
supershift assays demonstrated that in HepG2 nuclear extracts, HNF-3β did 
bind to this sequence under basal and IL6-induced conditions. In addition, we 
observed that the IL6-responsive CCAAT box/ enhancer-binding protein 
(C/EBP) site at -133/-125 in the fibrinogen β promoter interacts with the novel 
HNF-3 element, which is a plausible explanation for the importance of this 
HNF-3 element in the IL6 response of the fibrinogen β promoter. 
Interestingly, inspection of the promoter regions of genes encoding other acute-
phase proteins, revealed that the promoters of the fibrinogen α and C-reactive 
protein (CRP) genes also contain a putative HNF-3 site located adjacent to IL6-
responsive C/EBP elements (MatInspector Professional) 1,2. This suggests that a 
regulatory pathway involving HNF-3 and C/EBP might be important in the IL6 
response of a number of acute phase genes, and this increases the relevance of a 
detailed understanding of the role of HNF-3 in the acute phase response of the 
fibrinogen β gene. 
With our identification of the HNF-3 element at -159/-151 in the fibrinogen β 
promoter, three major elements important in the IL6 response of this gene have 
now been described: the HNF-3 site, the C/EBP site and the IL6 responsive 
element (IL6 RE). The IL6 RE is located at position -143/-137, between the 
HNF-3 and the C/EBP sites, and its role is not yet understood 3,4. For a good 
understanding of the mechanism of the IL6 response of the fibrinogen β gene 
and the role of the HNF-3 site, the functioning of the IL6 RE needs to be 




discussed in the following paragraphs, including their implications for the role 
of HNF-3. 
First of all, the sequence of the IL6 RE represents a perfect half-site for the IL6-
activatable transcription factor signal transducer and activator of transcription-
3 (STAT3) 5, and therefore the most straightforward hypothesis is that STAT3 
binds this IL6 RE in the fibrinogen β promoter. Surprisingly, binding of STAT3 
to the IL6 RE or transactivation of the fibrinogen β promoter by overexpression 
of STAT3 could not be detected, neither in the presence nor in the absence of 
IL6 (Gervois, personal communication and our unpublished data). However, it 
is possible that STAT3 requires the presence of other transcription factors, and 
therefore no effect of STAT3 may be detectable in experiments that focus on the 
isolated effect of STAT3. This theory is supported by the results of Duan et al, 
which show that STAT3 does bind weakly to the identical IL6 REs in the 
fibrinogen γ promoter, and that other nuclear factors are also present in the 
transcriptional complex 6. The presence of both STAT3 and HNF-3 in the same 
transcriptional complex is plausible, as direct interaction of these two 
transcription factors has been reported 7. However, an argument against the 
involvement of STAT transcription factors in the regulation of the fibrinogen β 
promoter may be that the IL6 RE in the fibrinogen β promoter does not 
represent a complete STAT site but only a half-site. Until now, it had been 
thought that STAT transcription factors bind as dimers, and consequently 
should require a complete STAT site instead of a half-site. 
Therefore, a second hypothesis is that the IL6 RE does not bind a transcription 
factor of its own and that its similarity to a STAT half-site is a coincidence. Then 
the IL6 RE, which is located between the HNF-3 and C/EBP binding sites, may 
only be required to correctly position HNF-3 and C/EBPβ in relation to each 
other. Mutations in the IL6 RE sequence might slightly change the position of 
the HNF-3 and C/EBPβ sites in relation to each other, resulting in a decreased 
interaction between these two transcription factors, explaining the loss of IL6 
response observed after the mutation of the IL6 RE 3,4. If indeed the IL6 RE 
does not bind a transcription factor of its own, HNF-3 and C/EBP may interact 
either directly or indirectly through an intermediating protein, which does not 
bind to the DNA itself, but does physically interact with HNF-3 and C/EBP. 
Then again, there are also arguments that oppose the above-mentioned 
hypothesis, and that do suggest binding of a specific transcription factor to the 
IL6 RE. For instance, the three fibrinogen chains are coordinately expressed 
during the acute-phase response, and functional IL6 REs with identical 
sequences have been identified in the promoter regions of all three fibrinogen 
genes. However, the organization of the regulatory elements in the vicinity of 
the IL6 REs is different. A functional C/EBP site and a putative HNF-3 site are 
also present in the fibrinogen α promoter, but not in the fibrinogen γ promoter. 
In addition, in the fibrinogen β promoter the IL6 RE is located between the 
C/EBP and HNF-3 sites, whereas in the fibrinogen α promoter the IL6 RE is 
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located just downstream of the C/EBP and HNF-3 sites 1,8. Identical sequences 
but different locations relative to other regulatory elements in the three 
fibrinogen promoters, argue against the hypothesis that the IL6 RE is only 
required for the positioning of other regulatory elements, but suggest that there 
is a specific factor binding the IL6 REs.  
Therefore, a third hypothesis is that the IL6 RE in the fibrinogen β promoter 
does bind a specific transcription factor other than STAT3. As HNF-3 has been 
shown to interact with a variety of different transcription factors including 
C/EBPβ, STAT3, HNF-4, and p53 7,9,10, HNF-3 may also interact with this 
putative transcription factor binding to the IL6 RE. 
POLYMORPHISMS IN THE FIBRINOGEN β PROMOTER 
Six polymorphisms have been described in the proximal 2000 bp of the 
fibrinogen β promoter: the -1420G/A, -993C/T, -854G/A, -455G/A, the 
-249C/T and the -148C/T variations. The -1420G/A variation is in (nearly) 
complete linkage disequilibrium with the -993C/T, -455G/A and -148C/T 
variations in Caucasians 11. Our study shows that the change from C to T at 
position -148 decreases basal and IL6-induced fibrinogen β promoter activity 
by influencing the adjacent HNF-3 site and its interaction with the C/EBP 
element. This explains the lowering effect on promoter activity of this 
nucleotide change, at the molecular level (chapter 3).  
Identification of the functional fibrinogen β promoter variation has also been 
the aim of functional promoter-reporter gene studies from several other groups, 
and the results of these studies are not always in accord with ours. Using 
promoter fragments of 640 bp of the proximal fibrinogen β promoter cloned in 
a reporter gene vector, Brown et al showed that a change from G to A at 
position -455 resulted in increased basal and IL6-induced expression 12. A year 
later, van ’t Hooft et al demonstrated with fragments of 1100 bp of the proximal 
fibrinogen β promoter cloned in a reporter gene vector, that the -854A (unique 
for haplotype b) and -455A (unique for haplotype d) alleles were associated 
with increased basal fibrinogen β promoter activity 13, whereas in our 
experiments with 1800 bp fibrinogen β promoter fragments, only the -148C/T 
variation affected basal and IL6-induced fibrinogen β promoter activity 
(chapter 3). In another study, functional effects were indicated for the 
-1420G/A polymorphism, and the involvement of a putative HNF-3 element 
located just downstream of the -1420G/A polymorphism was suggested. In this 
study, Wragg et al showed with promoter-reporter gene assays including 1480 
bp fibrinogen β promoter fragments that the -1420G/A polymorphism 
influenced the response of the promoter to HNF-3 14. Also in our experiments 
HNF-3 turned out to be a key player, and therefore we extended our 




polymorphism. In addition to the fibrinogen β promoter haplotype constructs 
described in chapter 3, we created haplotype constructs that differed only at 
position -1420G/A from their natural counterparts. Using these constructs, we 
could not detect any effect of the G to A change at position -1420 on basal, IL6-
induced, or HNF-3-induced fibrinogen β promoter activity in our assay system 
(data not shown). We also mutated the putative HNF-3 consensus sequence 
located at -1418/-1410, just downstream of the -1420G/A variation by 
disrupting the core sequence, analogous to the mutant promoter-reporter gene 
constructs that we created to investigate the HNF-3 site adjacent to the -148C/T 
polymorphism (chapter 2). Mutation of the putative HNF-3 site at -1418/-
1410 did not affect basal, IL6-induced, or HNF-3-induced fibrinogen β 
promoter activity, indicating that in our assay system the putative HNF-3 site at 
-1418/-1410 is not an important regulatory element (data not shown).  
In conclusion, some controversy still exists about the functional effects of the 
different variations in the fibrinogen β promoter. This may partly be explained 
by differences in experimental design for instance with respect to the length of 
the fibrinogen β promoter fragments used. However there are three reasons 
why we believe that we have strong evidence for a functional role of the -148C/T 
variation. Firstly, decreased IL6-induced and basal fibrinogen β promoter 
activity by a change from C to T at position -148, has been confirmed by others 
11,15. Secondly, in ethnic groups with incomplete linkage disequilibrium between 
the -455G/A and -148C/T variations (both located on haplotype d), a stronger 
association was seen between -148C/T and plasma fibrinogen levels than 
between -455G/A and plasma fibrinogen levels 16. Thirdly, following the 
identification of the -148C/T variation as the functional variation, we have been 
able to explain the effects of this variation on fibrinogen β promoter activity, at 
the molecular level. Therefore, we suggest that the -148C/T variation is selected 
to investigate genetic variation of the fibrinogen β gene in epidemiological 
studies.  
FIBRINOGEN β PROMOTER ACTIVITY IN RELATION TO PLASMA 
FIBRINOGEN LEVELS 
With our in vitro luciferase assays we identified the -148C/T polymorphism as 
the functional variation in the fibrinogen β promoter, and we observed that the 
T allele of the -148C/T polymorphism was associated with decreased IL6-
induced and basal promoter activity, which has also been observed in vitro by 
others 11,14. However, in population-based association studies, the -148T allele 
generally is related to elevated basal and acute phase-induced plasma 
fibrinogen levels (chapter 3) 17-20. This apparent discrepancy between in vitro 




General Discussion and Conclusions 
There are several technical issues, peculiar to the in vitro experiments as we 
performed them, which may have contributed to this in vivo - in vitro 
discrepancy. Firstly, we chose a hepatoma cell line (HepG2) as model system, 
since no relevant sources of fibrinogen other than the liver had been described. 
A reduced basal and IL6-induced promoter activity associated with the -148T 
allele has been observed in two additional hepatoma cell lines (HuH7 and 
Hep3B) by others and by us, and therefore it is unlikely that the cell types used 
were responsible for the inconsistency with the results from in vivo association 
studies 14.  Secondly, the situation in the human body is different from the 
conditions in our cell cultures. For instance, we used only IL6 to mimic the 
acute phase response, but in the case of an acute-phase event in vivo several 
inflammatory mediators besides IL6 are expressed. Different inflammatory 
mediators will activate different transcription factors that can have opposite 
effects, especially when these factors bind to adjacent or overlapping DNA 
elements. In this respect, our inadequate knowledge of the IL6 RE in the 
fibrinogen β promoter may be a complicating factor. The IL6 RE is located 
between the HNF-3 and the C/EBP sites; a putative third transcription factor 
binding the IL6 RE might compete for binding with HNF-3 or C/EBPβ. Such 
competition has been described on several occasions, and it often represents a 
mechanism of inhibition of gene induction 9,21. As the mechanism of the IL6 RE 
is still unclear, and the -148C/T polymorphism is located right between the IL6 
RE and the HNF-3 site, the net effect of the polymorphism on fibrinogen β 
promoter activity can probably only be fully explained if the IL6 RE is 
completely understood. A third issue concerning the experimental conditions is 
that in vivo interaction between hepatocytes and other cell types could be 
important, whereas these interactions were absent in our HepG2 tissue 
cultures. A fourth technical point to consider is the DNA fragment selected. We 
used a 1800 bp fragment of the fibrinogen β promoter because a fragment of 
this size is expected to include all major regulatory sequences, and because 
larger DNA fragments become increasingly unpractical. This means that there 
is always a risk of missing important regulatory elements. For instance, the 
sequences responsive to glucocorticoids have been mapped between -2900 and 
-1500 relative to the transcription start site in the fibrinogen β promoter, but 
their exact location is not known 22. Therefore, these responsive elements may 
not have been present in our 1800 bp fragments. This could be relevant because 
of the synergistic effect that glucocorticoids and IL6 have on fibrinogen 
expression 23. To summarize, the in vitro model system is simpler in design 
than the naturally occurring systems in the human body, and this may have 
contributed to the discrepancy between our in vitro results and the in vivo 
results published by others. 
An alternative explanation is that another functional polymorphism located 
outside the promoter region, but in linkage disequilibrium with the -148C/T 
polymorphism, is the actual cause of the increased fibrinogen levels associated 




in association studies. The relevance of linkage disequilibrium is illustrated by 
the following example. On some occasions, a relationship between the promoter 
haplotype d (including the -455A and -148T alleles) and an increased risk of MI 
has been reported, which has been attributed to the higher plasma fibrinogen 
levels associated with the haplotype d 24,25.  However, the promoter haplotype d 
extends into the coding region of the gene and is also characterized by the rare 
allele of the 448Arg/Lys polymorphism 26. Substitution of the arginine for a 
lysine at position 448 in the fibrinogen β molecule results in thinner fibrin 
fibres and a more tightly packed clot, and it has been proposed that this change 
in clot structure might influence the clinical outcome 27. Although the relevance 
of the 448Arg/Lys polymorphism is not yet clear, and the relationship between 
the haplotype d and the risk of MI is far from certain, this example shows that 
different polymorphisms unique to the same functional haplotype (-455G/A 
and -148C/T versus 448Arg/Lys) can potentially influence the same events (e.g. 
MI) through different mechanisms (increased plasma levels versus clot 
structure). 
The issues discussed in the preceding paragraphs underline the difficulty of 
extrapolating results from functional in vitro assays on the effect of a single 
polymorphism, and applying them to the results of population-based 
association studies that represent the net result of numerous genetic and 
environmental factors. Epidemiological association studies are powerful in 
detecting associations and therefore they can offer a framework for the 
interpretation of results obtained in in vitro experiments and in animal studies, 
but they cannot provide evidence of the underlying molecular mechanisms. For 
this, in vitro experiments and animal experiments are necessary, even though 
they also have their limitations. Multiple model systems should then be used to 
tackle research questions from different angles, and together they should help 
to elucidate the biological mechanisms. 
FUTURE RESEARCH ON THE FIBRINOGEN β CHAIN GENE 
PROMOTER 
On the basis of the results described in chapters 2 and 3 of this thesis, there 
are several research lines that can be investigated further. 
Firstly, it would be interesting to investigate whether HNF-3 is a general 
regulator of the acute phase response. The presence of putative HNF-3 sites in 
the vicinity of functional C/EBP elements also in the promoter regions of other 
acute-phase genes, could indicate that the cooperation between HNF-3 and 
C/EBP in the IL6 response is a more general mechanism regulating the 
(hepatic) acute phase response (chapter 2). In addition, further understanding 
of the cooperation between C/EBP and HNF-3 in the IL6-mediated regulation 
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of the fibrinogen β gene will be increasingly relevant if indeed this cooperation 
turns out to be a general mechanism regulating the acute phase response. 
Furthermore, for a complete picture of the regulation of IL6-induced fibrinogen 
β expression by HNF-3 and C/EBP, and the effect of the -148C/T variation, the 
role of IL6 RE in the fibrinogen β promoter needs to be clarified. 
As a secondary aim, the effects of fibrates can also be investigated in the 
experiments suggested in this section. These hypolipidaemic and anti-
inflammatory drugs specifically reduce plasma levels of fibrinogen by 
decreasing the activity of the C/EBP element, and the nuclear receptor 
peroxisome proliferator-activated receptor-α (PPARα) plays a crucial role in 
this mechanism 28,29. Research into the role of the IL6 RE and the HNF-3 site in 
the interaction of PPARα with the C/EBP element, could provide further 
understanding of the mechanism by which fibrates influence plasma protein 
levels. Finally, also the effect of the -148C/T polymorphism should be 
addressed in these experiments as it is likely to modulate these events. 
GENETIC VARIATION OF THE PAI-1 GENE AND PLASMA PAI-1 
LEVELS 
We have observed that PAI-1 promoter haplotypes, determined by the -844A/G 
and the -675(4G/5G) polymorphisms, are associated with PAI-1 antigen levels, 
most prominently in lean individuals. In these lean subjects, the PAI-1 antigen 
levels of A-4G/G-5G heterozygotes were reduced to approximately 60-75% and 
the G-5G homozygotes to approximately 45-55%, compared to the PAI-1 
antigen levels of A-4G homozygotes. However, we also observed that the effect 
of BMI on PAI-1 concentrations was much stronger than the effect of PAI-1 
promoter variation, as PAI-1 plasma levels increased approximately fourfold 
from the lowest to the highest BMI quartile (chapter 5). To our knowledge this 
is the first study that has investigated the relationship between PAI-1 promoter 
variation and PAI-1 antigen levels in quartiles according to BMI. However, our 
conclusion that metabolic factors (e.g. BMI) are more important determinants 
of PAI-1 levels than genetic variation, is supported by others 30. 
It is interesting to hypothesize how our observation that PAI-1 promoter 
variation is relevant for PAI-1 antigen levels in lean individuals, connects to the 
reported relationships between PAI-1 promoter variation, PAI-1 antigen levels 
and cardiovascular risk. In general, the reported relationships between PAI-1 
promoter variation and PAI-1 antigen levels, and between PAI-1 antigen levels 
and cardiovascular risk are consistent, but the relationship between PAI-1 
promoter variation and cardiovascular risk is much weaker 31,32. Our study 
demonstrates that the influence of genetic variation on PAI-1 antigen levels is 
primarily relevant in individuals with low BMI, which means that these 




factor. The relevance of genetic variation to PAI-1 levels primarily in a subgroup 
in an advantageous position to other (risk) factors, might explain the weak 
relationship between the genetic variation of the PAI-1 promoter and the risk of 
cardiovascular disease. 
GENETIC VARIATION OF THE PAI-1 PROMOTER UNDER BASAL 
CONDITIONS IN VITRO 
One aim of this thesis was to identify the functional polymorphism(s) in the 
promoter region of the PAI-1 gene. In the MORGEN and Glostrup populations 
we observed higher PAI-1 levels associated with the -844A/-675(4G) haplotype, 
and lower PAI-1 antigen levels associated with the -844G/-675(5G) haplotype 
(chapter 5). However, due to the low number of the other haplotypes in our 
populations, we could not discriminate between the effects of the -844A/G and 
the -675(4G/5G) polymorphisms. To identify the functional polymorphism in 
the PAI-1 promoter and to elucidate the underlying molecular mechanisms, we 
performed in vitro promoter-reporter gene assays with the four different PAI-1 
promoter haplotypes. In these assays we could not detect a direct effect of PAI-1 
promoter variation on basal PAI-1 promoter activity in hepatoma or endothelial 
cells, and these in vitro observations are consistent with the in vitro findings 
under basal conditions of others (Schoenhard et al personal communication) 
33,34. However, we did observe a relationship between PAI-1 promoter variation 
and PAI-1 antigen levels in our in vivo association studies (chapters 5 and 6), 
and the apparent discrepancy with the in vitro findings could be caused by 
technical limitations in our experimental model, similar to the ones listed in the 
previous section on the fibrinogen β promoter. Another possible explanation is 
that the actual functional PAI-1 polymorphism is located outside the promoter 
region that we included in the functional assays. In that case, the PAI-1 
promoter haplotype would only be a marker of this functional polymorphism. 
PAI-1 expression is highly regulated at the post-transcriptional level by 
sequences located at the 3’ end of the gene, and it has been shown previously 
that changes in the 3’ sequence of the gene can affect mRNA stability 35-38. In 
the 3’ untranslated region (UTR) of the PAI-1 gene several variations are 
present, including the +10707C/T and the 11053G/T polymorphisms. These two 
variations are both in nearly complete linkage disequilibrium with the promoter 
polymorphisms, and could be very interesting candidates for further 
investigation (http://pga.gs.washington.edu/data/serpine1/) 39 
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GENETIC VARIATION OF THE PAI-1 PROMOTER UNDER 
INDUCED CONDITIONS IN VITRO 
It has been reported that the relationship between PAI-1 concentrations and 
plasma triglyceride levels is modified by the genetic variation of the PAI-1 gene, 
indicating that the regulation of PAI-1 expression might be influenced by 
genotype 40,41. Since then, many in vitro studies have been performed, 
investigating the influence of the -675(4G/5G) polymorphism on the response 
of the PAI-1 promoter to a variety of inducers. In these investigations, either the 
endogenous PAI-1 promoter or transfected PAI-1 promoter fragments were 
studied in several different cell types (endothelial cells, adipocytes, hepatocytes, 
smooth muscle cells). In some of these studies, the response of the PAI-1 
promoter to interleukin-1 (IL1), transforming growth factor-β (TGF-β), very-
low-density lipoprotein (VLDL) and insulin, was dependent on the 
-675(4G/5G) genotype 34,42,43. However, additional studies have not been able 
to confirm these effects of the -675(4G/5G) polymorphism on the response of 
the PAI-1 promoter (Schoenhard et al personal communication and our 
unpublished data) 33,34,44-46. Because of the conflicting results it is unclear which 
inducer stimulates PAI-1 expression genotype-dependently, if any. 
A relationship between the -675(4G/5G) polymorphisms and the circadian 
variation of PAI-1 plasma concentrations levels has also been suggested. Two 
epidemiological studies have reported that the circadian oscillation of PAI-1 
antigen is more prominent in carriers of the -675(4G) allele than in -675(5G) 
homozygotes 47,48. In addition, it has been shown in vitro that the circadian 
oscillation of PAI-1 expression is mediated by an E-box element located just 
upstream of the -675(4G/5G) polymorphism 49. However, when these in vitro 
experiments were repeated with the -675(4G/5G) polymorphism taken into 
account, no effect of the polymorphism on the transcriptional regulation of the 
circadian expression could be detected (Schoenhard et al personal 
communication). Therefore, it is not certain whether the more pronounced 
circadian oscillation observed in -675(4G) carriers is caused by the 
-675(4G/5G) polymorphism itself, or that the oscillation is merely more evident 
in -675(4G) carriers as they generally have higher PAI-1 plasma levels than 
-675(5G) homozygotes. 
FUTURE RESEARCH ON GENETIC VARIATION OF THE PAI-1 
PROMOTER 
First of all, our conclusion that the relationship between PAI-1 promoter 
haplotype and PAI-1 plasma levels is most prominent in lean individuals 
deserves to be re-established in other populations, although the relevance of the 
genetic variation of the PAI-1 gene for cardiovascular disease is probably 




functional effects of the PAI-1 promoter polymorphisms does not seem relevant 
at this moment, as we did not find clear indications of a functional effect of the 
-844A/G and -675(4G/5G) polymorphisms on PAI-1 promoter activity. On the 
other hand, the regulation of PAI-1 mRNA levels by sequences located at the 3’ 
end of the PAI-1 gene is a relatively unexplored research area that is worth 
further investigation. In such studies, the polymorphisms located in the 3’ 
region of the PAI-1 gene should be taken into account. If indeed these 
polymorphisms do affect PAI-1 expression levels, they might explain the 
association between PAI-1 promoter variation and PAI-1 antigen levels 
observed in vivo. 
DIFFERENTIAL EFFECTS OF GENETIC VARIATION ON GENE 
EXPRESSION 
The effects of genetic variation on gene expression can vary greatly among the 
different genes. The fibrinogen β and PAI-1 genes, which are described in this 
thesis, vary in this respect. 
For fibrinogen, the most important inducer is IL6. We show with functional 
assays that genetic variation of the fibrinogen β promoter interacts with the IL6 
response of the gene (chapter 3). In addition, it has been reported that in the 
presence of a strong acute-phase trigger, the average plasma fibrinogen level 
was ±12%, ±15% and ±30% higher in carriers of the -455A (and -148T) allele 
compared to -455GG (and -148CC) homozygotes, in groups of 250, 45 and 60 
individuals respectively. This indicates that fibrinogen β promoter variation can 
be relevant for plasma fibrinogen levels, particularly in the presence of a strong 
acute-phase stimulus 19,20,50. 
In the case of PAI-1, the situation is different. Our study shows that genetic 
variation is relevant for PAI-1 concentrations, as we observed that PAI-1 
antigen levels are approximately 50% lower in G-5G homozygotes than in A-4G 
homozygotes. However, this was confined to lean individuals, and in more 
obese subjects the effect of genetic variation on PAI-1 concentrations is easily 
overruled by the effect of BMI (chapter 5). This can be explained by the way 
the PAI-1 gene is regulated. PAI-1 expression is under the influence of many 
(metabolic syndrome-related) substances, including insulin, transforming 
growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), VLDL, fatty acids, 
glucose, angiotensin II, and hypoxia. These inducers regulate PAI-1 expression 
by distinct mechanisms through response elements mostly located at different 
sites in the PAI-1 promoter 44,51-57. Therefore, the effect of genetic variation of 
the PAI-1 promoter on PAI-1 expression is probably limited, because of the 
overriding signals of several inducers. This is supported by our results 
described in chapter 5, showing that the effect of genetic variation on PAI-1 
levels is less prominent in subjects with increased BMI, which are the 
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individuals who generally have increased levels of the many factors associated 
with the metabolic syndrome. 
These examples of fibrinogen and PAI-1 show that the relevance of genetic 
variation to gene expression and plasma protein levels is dependent on the 
importance of the genotype-dependent trigger relative to other triggers, and on 
the mechanism by which genetic variation influences the plasma protein levels. 
Another possibility is that the genetic variation of regulating factors influences 
the expression of the gene of interest. In this thesis, two examples of this 
principle are indicated. Firstly, in chapter 4 we show that the response to 
vaccination by CRP plasma levels in vivo, is influenced by the -174G/C 
polymorphism in the promoter region of its inducer; IL6. Secondly, in chapter 
6 we show that the Gly972Arg polymorphism in the insulin-receptor substrate-
1 (IRS-1) gene, which is important in the cellular response to insulin, is 
associated with PAI-1 antigen levels. However, we need to make provisos in 
both these cases. Firstly, the effect of the IL6 -174G/C polymorphism on the 
response of CRP levels was statistically significant and therefore detectable, but 
fairly small with respect to the absolute effect on plasma levels. In the case of 
the IRS-1 Gly972Arg polymorphism, only a few subjects (1.8% of the 
population) were homozygous for the rare Arg allele, therefore they were 
pooled and analysed together with the Gly/Arg heterozygotes. However, the 
PAI-1 antigen levels of the Arg/Arg homozygotes were in fact lower than those 
of Gly/Arg heterozygotes, whereas assuming an allele-dosage effect, their levels 
were expected to be higher than those of Gly/Arg heterozygotes. Therefore, 
although the biological mechanisms in both these examples are plausible, their 
effects may be small (in the case of the IL6 -174G/C polymorphism and CRP 
levels), and we might have to be careful with the interpretation of the results (in 
the case of the IRS-1 Gly972Arg polymorphism and PAI-1 levels). 
RELEVANCE OF GENETIC VARIATION TO THE RISK OF 
CARDIOVASCULAR DISEASE 
There is evidence that both PAI-1 and fibrinogen can directly contribute to 
cardiovascular disease, but increases in their plasma levels also coincide with 
incidence of the disease. Therefore, their association with cardiovascular risk 
could largely rely on the latter. Many biological processes are involved in the 
development of cardiovascular disease, including blood coagulation, 
fibrinolysis, inflammation, lipid metabolism, glucose metabolism, and blood 
pressure. Therefore, the importance for disease risk of a polymorphism with a 
mild or moderate effect on the plasma levels of a single factor in one of these 
several biological events, is expected to be small. In fact, this theory is 
supported by the results of many epidemiological studies that have reported 




cardiovascular disease 31,33,58-60. In general it can be concluded that genetic 
variation may be relevant for the levels of plasma proteins, and the effects of 
genetic variation on plasma concentrations may be enhanced by environmental 
factors. However, the relevance of genetic variation to the risk of cardiovascular 
disease is probably much more limited. Therefore, future in vivo and in vitro 
studies on the role of genetic variation are important for a further 
understanding of the biological mechanisms, but such studies are less relevant 
to the risk of multicausal diseases with a strong environmental contribution, 
such as arterial diseases. 
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Cardiovascular diseases account for approximately 35% of the mortality in the 
Netherlands. Cardiovascular diseases can be divided into arterial and venous 
diseases, and atherosclerosis and myocardial infarction are well-known 
examples of arterial diseases. Cardiovascular diseases are caused by a 
combination of lifestyle and genetic factors. Elevated plasma levels of the 
coagulation factor fibrinogen, and of the fibrinolytic factor PAI-1 are associated 
with an increased risk of (arterial) cardiovascular diseases. 
In the promoter regions of the genes encoding the fibrinogen β and the PAI-1 
proteins, genetic variations (polymorphisms) are located. Relationships 
between these polymorphisms and the fibrinogen and PAI-1 plasma protein 
levels have been described on many occasions, and a relationship with the risk 
of arterial diseases has also been suggested. Polymorphisms in the promoter 
regions can affect the habitual fibrinogen β and PAI-1 levels, but they may also 
affect the response of the genes to the environment. The aim of the studies 
described in this thesis is to identify the functional polymorphisms in the 
fibrinogen β and PAI-1 promoters, to determine their effect on the response of 
the genes to modulating factors, and to elucidate the underlying molecular 
mechanisms. 
Fibrinogen is an acute-phase protein, and plasma fibrinogen levels strongly 
increase in response to inflammatory stimuli.  In addition, genetic variation of 
the fibrinogen β gene influences plasma fibrinogen levels, and there are 
indications from population-based studies that inflammation and genetic 
variation of the fibrinogen β promoter interact.  In chapter 2 and 3, studies 
are described that further elucidate the molecular regulation of the fibrinogen β 
gene, and the interaction of genetic variation with the regulation of 
transcription. Using luciferase reporter gene assays in hepatoma cells, mutation 
analysis, and electrophoretic mobility shift assays, we identified a hepatocyte 
nuclear factor-3 (HNF-3) site located just upstream of a previously identified 
interleukin-6 (IL6) -responsive sequence in the fibrinogen β promoter. Our 
results show that this HNF-3 site is essential for a full response of the promoter 
to IL6. The activity of the CCAAT box/enhancer-binding protein (C/EBP) site 
(located 18 nucleotides downstream of the HNF-3 site and important to the IL6 
response), depends on the integrity of the HNF-3 site and vice versa, 
explaining the necessity of HNF-3 in the IL6 response of the fibrinogen β 
promoter. Such involvement of HNF-3 in the inflammatory gene response has 
not been described before, but the collaborative action of these two 
transcription factors might be more commonly employed as putative HNF-3 





In addition, we showed that among six polymorphisms in the fibrinogen β gene 
(-1420G/A, -933C/T, -854G/A, -455G/A, -249C/T, -148C/T), only the –148C/T 
variation affected IL6-induced and basal fibrinogen β promoter activity in our 
assay system. Our results indicate that the -148C/T polymorphism, which is 
located between the binding sites of HNF-3 and C/EBP, interferes with the 
interaction between these two transcription factors, which explains its 
functional effects at the molecular level. 
The acute phase reaction is important in many disease processes. Habitual 
levels of the acute phase proteins fibrinogen, C-reactive protein (CRP) and 
interleukin-6 (IL6) are associated with an increased risk of cardiovascular 
disease, but the dynamic variation of plasma levels of acute phase proteins may 
be of importance as well. The aim of chapter 4 was to document the variation 
in fibrinogen, CRP and IL6 levels in response to yellow-fever vaccination (a 
mild inflammatory stimulus), in 25 healthy individuals. Plasma levels of 
fibrinogen, CRP and IL6 were determined at baseline and 7 days after 
vaccination, and polymorphisms in the promoter regions of these genes were 
determined.  After vaccination, fibrinogen levels had changed between -13% 
and +44%, CRP levels between -88% and +672%, and IL6 levels between -55% 
and +448%. The change in fibrinogen levels was statistically significant. 
Genetic variation partly explained the interindividual variation in response, as 
IL6-174G homozygotes showed a significantly stronger increase in CRP levels 
than IL6-174C allele carriers. In conclusion, this study suggests that a large 
interindividual variation exists in the acute phase response to yellow fever 
vaccination. This study indicates that individuals may be classified as hyper- or 
hypo-responders, and that genetic variation may influence the responsiveness 
of an individual. Finally, this study identifies vaccination as a useful model 
system to investigate the inflammatory response under standardized 
conditions. 
PAI-1 antigen levels are influenced by acquired factors such as body mass index 
(BMI), and by genetic factors. Chapter 5 and 6 describe in vivo and in vitro 
studies on genetic variation of the PAI-1 promoter, and the relationship with 
environmental factors, in the first place with BMI. Two polymorphisms have 
been described in the PAI-1 promoter; the -844A/G and the -675(4G/5G) 
variations. The 4G allele of the -675(4G/5G) variation has been associated with 
elevated PAI-1 concentrations and on some occasions with an increased risk of 
cardiovascular disease. The associated –844A/G variation however, has been 
investigated less extensively. 
In chapter 5, the association between the PAI-1 promoter haplotype and PAI-1 
antigen levels was investigated in two populations, each including 
approximately 600 healthy Caucasians. We observed significantly higher PAI-1 
concentrations in A-4G homozygotes than in G-5G carriers, but this 
relationship was restricted to the lowest BMI quartile. In these lean subjects, 




and the concentrations of G-5G homozygotes to 45-55%, compared to the PAI-1 
concentrations of A-4G homozygotes. PAI-1 concentrations increased 
approximately 4-fold from the lowest to the highest BMI quartile. To assess the 
direct effect of the PAI-1 promoter haplotype on PAI-1 promoter activity, in 
vitro reporter gene assays were performed in HepG2 and BAEC cells. These 
assays however, did not indicate a direct effect of the PAI-1 promoter haplotype 
on promoter activity. Therefore it is not clear whether one of the variations in 
the promoter region is responsible for the observed effects, or that the 
functional variation should be found outside of the promoter region of the PAI-
1 gene. Concluding, the study described in chapter 5 suggests that the PAI-1 
promoter haplotype and BMI affect PAI-1 concentrations, but that BMI is a 
stronger determinant than PAI-1 promoter variation. 
Chapter 6 is a description of the relationship between PAI-1 antigen levels, 
several metabolic and inflammatory parameters and several genetic variations, 
in a population of approximately 600 healthy Caucasian subjects. Positive 
correlations were present between PAI-1 antigen levels and the plasma levels of 
several metabolic factors, C-reactive protein, and low physical activity. In 
addition, the previously reported relationship between PAI-1 antigen levels and 
the PAI-1 -675(4G/5G) polymorphism was detected also in this population. 
Finally, a relationship between the insulin receptor substrate-1 (IRS-1) 
Gly972Arg polymorphism and PAI-1 antigen levels was observed, which may be 
explained by the elevated insulin levels associated with the IRS-1 Gly972Arg 
polymorphism, which on their turn increase PAI-1 production. In general, this 
study demonstrates that PAI-1 plasma levels are under control of several 
environmental and genetic factors. 
This thesis provides more information on the relationships between genetic 
variation of the fibrinogen β and PAI-1 promoters their respective plasma 
protein levels. In addition, these studies provide further insight into the 
mechanisms behind these relationships, which contributes to the 













Hart- en vaatziekten veroorzaakten ongeveer 35% van de sterfgevallen in 
Nederland in 2001, en kunnen ruwweg opgedeeld worden in twee categorieën, 
de arteriële en de veneuze ziekten. Van de arteriële (=slagaderlijke) ziekten zijn 
het hartinfarct en atherosclerose de bekendste verschijningsvormen. Hart- en 
vaatziekten zijn multifactoriële ziekten, en worden veroorzaakt door een 
combinatie van omgevings- en genetische factoren. Omgevingsfactoren 
betreffen vaak leefstijlfactoren (rook- en eetgewoonten, lichamelijke activiteit), 
of de gevolgen hiervan (overgewicht, diabetes). Verscheidene biologische 
processen in het lichaam kunnen, als ze verstoord zijn, bijdragen aan het 
ontstaan van hart- en vaatziekten. Voorbeelden zijn bloedstolling, fibrinolyse 
(de tegenhanger van bloedstolling), ontsteking, de vetstofwisseling en de 
glucosehuishouding. Genetische factoren kunnen bijdragen aan de kans op 
hart- en vaatziekten, doordat ze bovengenoemde biologische processen kunnen 
beïnvloeden. Er bestaan zeldzame genetische afwijkingen met soms zeer 
ernstige gevolgen voor hart en/of bloedvaten, maar er bestaan ook 
veelvoorkomende genetische veranderingen met mildere effecten. Over deze 
laatste categorie gaat dit proefschrift. Deze veranderingen in de genen worden 
ook wel genetische variaties of polymorfismen genoemd. Polymorfismen 
leveren een bijdrage aan het totale risico op hart- en vaatziekten van een 
individu. Polymorfismen komen onder meer voor in de promoter, het deel van 
het gen dat de genactiviteit onder verschillende omstandigheden reguleert. Het 
is waarschijnlijk dat polymorfismen in de promoters van genen de reactie van 
een individu op omgevingsfactoren kan beïnvloeden. 
Verhoogde bloedniveaus van de bloedstollingsfactor fibrinogeen of de 
fibrinolytische factor ‘plasminogen activator inhibitor-1’ (PAI-1) zijn 
geassocieerd met een verhoogd risico op arteriële hart- en vaatziekten, daarom 
staan fibrinogeen en PAI-1 in dit proefschrift centraal. 
Fibrinogeen is een stollingsfactor die in de laatste stap van het 
bloedstollingsproces omgezet wordt in fibrine. Fibrine vormt samen met de 
bloedplaatjes het bloedstolsel. Fibrinogeen wordt gemaakt in de lever, en het 
fibrinogeen molecuul bestaat uit twee sets van drie eiwitketens: 2 α, 2 β en 2 γ 
ketens. Tijdens de synthese van het fibrinogeen molecuul is de aanmaak van de 
β keten snelheidsbepalend, daarom richtten wij ons in ons onderzoek op de 
regulatie van het fibrinogeen β gen. Fibrinogeen is een acuut-fase eiwit, wat 
betekent dat de productie van fibrinogeen sterk stijgt in reactie op een 
ontstekingsstimulus zoals infectie, verwonding, zware fysieke inspanning, of 
roken. Tijdens een acuut-fase reactie worden allerlei ontstekingsstoffen 
gemaakt, onder andere interleukine-6 (IL6). IL6 stimuleert vervolgens de 
productie van fibrinogeen. 




bloed leiden tot het vertraagd oplossen van bloedstolsels. PAI-1 wordt 
geproduceerd op verschillende plaatsen in het lichaam, waarvan het endotheel 
(vaatwand), de lever en het vetweefsel de belangrijkste zijn. PAI-1 bloedniveaus 
zijn sterk geassocieerd met het metabool syndroom, wat een overkoepelende 
term is voor een cluster symptomen die vaak samen voorkomen, te weten; 
overgewicht, verhoogde lipide- en cholesterolniveaus in het bloed, verhoogde 
bloeddruk, en verhoogde insuline- en glucosespiegels. 
In de promoters van zowel het fibrinogeen β als het PAI-1 gen komen 
polymorfismen voor die in populatiestudies samengaan met verhoogde 
bloedniveaus van fibrinogeen of PAI-1. Daarnaast is in enkele onderzoeken ook 
een verband tussen de polymorfismen in de fibrinogeen β en PAI-1 promoters 
en een verhoogd risico op (arteriële) hart- en vaatziekten gevonden. In ons 
onderzoek waren wij dus geïnteresseerd in het mogelijke directe effect van deze 
polymorfismen op fibrinogeen en PAI-1 bloedniveaus, en in de verklarende 
moleculair-biologische mechanismen. 
Tot nu toe zijn in de fibrinogeen β promoter zes polymorfismen beschreven; 
-1420G/A, -993C/T, -854G/A, -455G/A, -249C/T en -148C/T, en ook de meest 
voorkomende combinaties (haplotypen) zijn bekend. Het haplotype -1420A, 
-993T, -455A en -148T heeft een frequentie van 20% in de populatie, en is 
geassocieerd met verhoogde fibrinogeen niveaus in het bloed. 
Hoofdstuk 2 en 3 beschrijven de resultaten van laboratoriumonderzoek die 
het functionele polymorfisme in dit haplotype identificeren en het 
biochemische mechanisme ophelderen. Wij hebben met moleculaire technieken 
verscheidene fibrinogeen β promoter haplotypen (zowel natuurlijk 
voorkomende als kunstmatige combinaties) gekoppeld aan het luciferase gen. 
Deze fibrinogeen β promoter-luciferase constructen zijn in HepG2 cellen (een 
humane levercellijn) getransfecteerd. Deze cellen produceren vervolgens 
luciferase onder controle van de fibrinogeen β promoter, en de hoeveelheid 
geproduceerd luciferase is een maat voor de activiteit van de fibrinogeen β 
promoter. In onze experimenten beïnvloedde alleen het -148C/T polymorfisme 
de activiteit van de fibrinogeen β promoter, en dit effect was zeer duidelijk in 
aanwezigheid van de ontstekingsmediator IL6. Deze conclusie heeft gevolgen 
voor epidemiologische onderzoeken. In epidemiologische studies wordt om 
historische redenen vaak het –455G/A polymorfisme bepaald. Deze studies 
betroffen tot nu toe vrijwel altijd Caucasiërs (mensen van West-Europese of 
West-Aziatische oorsprong). In deze groep bevinden zich de -455G/A en 
-148C/T polymorfismen altijd op hetzelfde haplotype. Bepaling van het 
-455G/A of het -148C/T polymorfisme levert dus hetzelfde resultaat op. In 
andere etnische groepen zijn deze polymorfismen echter niet altijd 
geassocieerd, en het is inmiddels aangetoond dat in Afro-Amerikanen 
fibrinogeen bloedniveaus een sterkere relatie vertonen met het -148C/T 
polymorfisme dan met het -455G/A polymorfisme. Dit ondersteunt onze 






Om het mechanisme van het effect van het -148C/T polymorfisme op de IL6-
respons van de fibrinogeen β promoter te begrijpen, hebben we eerst de 
omringende DNA sequentie nauwkeurig bestudeerd. Naast het -148C/T 
polymorfisme in het DNA ligt een (al bekende) herkenningsplaats voor de 
transcriptiefactor CCAAT-box/enhancer-binding protein β (C/EBPβ). C/EBPβ 
kan door IL6 geactiveerd worden, en brengt vervolgens het IL6 signaal op de 
fibrinogeen β promoter over, waardoor deze gestimuleerd wordt. Aan de andere 
kant van het -148C/T polymorfisme bleek een DNA sequentie te liggen die sterk 
leek op een bindingsplaats voor de leverspecifieke transcriptiefactor 
hepatocyte-nuclear factor-3 (HNF-3). Naar deze mogelijke HNF-3 site hebben 
wij verder onderzoek gedaan. Electrophoretic mobility shift assays (Eiwit-DNA 
bindingsassays) toonden aan dat HNF-3 inderdaad kan binden op deze positie 
naast het -148C/T polymorfisme. Om het belang van deze HNF-3 site voor de 
activiteit van de fibrinogeen β promoter te onderzoeken, hebben we transfectie 
assays gedaan met een fibrinogeen β promoter variant met een gemuteerde 
HNF-3 site. Mutatie van de HNF-3 site leidde tot een sterk verminderde reactie 
van de promoter op tot overexpressie gebracht HNF-3, wat aangeeft dat het 
hier inderdaad een functionele site betreft. Daarnaast bleek de gemuteerde 
promoter verzwakt te reageren op IL6 en C/EBPβ, de overbrenger van het IL6 
signaal. Deze proeven bewezen dat de HNF-3 site belangrijk is voor de reactie 
van de fibrinogeen β promoter op IL6, waarschijnlijk omdat HNF-3 door 
binding aan deze site samenwerkt met C/EBP. In de literatuur is HNF-3 
beschreven als een ‘opener’ van het DNA. Het is daarom mogelijk dat in geval 
van de fibrinogeen β promoter, HNF-3 het DNA toegankelijk maakt voor 
C/EBPβ, de overbrenger van het IL6 signaal. Een rol voor HNF-3 in de 
regulatie van genen door IL6 is nog niet eerder beschreven, en wij hebben 
aanwijzingen dat dit een algemener genregulatie mechanisme zou kunnen zijn. 
Tenslotte bleek het -148C/T polymorfisme de interactie tussen de HNF-3 site 
en de C/EBPβ site te beïnvloeden, wat het effect van dit polymorfisme op de 
IL6-respons van de fibrinogeen β promoter kan verklaren. 
Er bestaan aanzienlijke verschillen tussen mensen in de mate waarin ze op 
specifieke omgevingsfactoren reageren, en het is waarschijnlijk dat genetische 
variatie in het promoter gebied van genen bijdraagt aan deze interindividuele 
variatie. Het kan lastig zijn om deze hypothese in een populatie te onderzoeken, 
omdat het in sommige gevallen onethisch is de onderzoeksgroep bloot te stellen 
aan de (mogelijk schadelijke) omgevingsfactoren. Dit geldt zeker voor de voor 
ons onderzoek interessante ontstekingsstimuli, zoals verwonding en infecties. 
Het is bekend dat sommige vaccins (o.a. het gele koorts vaccin), een milde 
ontstekingsreactie kunnen oproepen, en daarmee zou vrijwillige vaccinatie dus 
een ethisch aanvaardbaar acuut-fase-onderzoeksmodel kunnen zijn. In 
hoofdstuk 4 hebben we bepaald in hoeverre mensen verschillen in hun reactie 
op gele koorts vaccinatie, en daarmee onderzocht of vaccinatie een bruikbaar 




genetische variatie de variatie in ontstekingsrespons tussen mensen deels kan 
verklaren. Bij mensen die werden gevaccineerd tegen gele koorts in verband 
met een voorgenomen reis naar Azië of Zuid-Amerika, werd bloed afgenomen 
voorafgaand aan de vaccinatie en 7 dagen daarna. Vervolgens zijn de niveaus 
van fibrinogeen en van ontstekingsmarker C-reactief proteïne (CRP) bepaald. 
Tenslotte hebben we de polymorfismen in de fibrinogeen β- en de IL6 -
promoter bepaald. De IL6 promoter werd betrokken in het onderzoek omdat 
IL6 de belangrijkste stimulator van zowel CRP als fibrinogeen is, en omdat er in 
het verleden relaties zijn gevonden tussen polymorfismen in de IL6 promoter 
en CRP bloedniveaus. Uit statistische analyse van de resultaten bleek dat er 
tussen mensen inderdaad een zeer grote variatie in de reactie van fibrinogeen 
en CRP bloedniveaus op gele koorts vaccinatie bestaat. Daarnaast was er ook 
een verband tussen genetische variatie en de mate van reactie op de vaccinatie. 
Genetische variatie in de IL6 promoter bleek gerelateerd aan de mate van 
stijging van CRP bloedniveaus na gele koorts vaccinatie. Een dergelijke trend 
bleek er ook te bestaan tussen polymorfismen in de fibrinogeen β promoter en 
de reactie van fibrinogeen bloedniveaus op vaccinatie. Concluderend geeft onze 
studie aan dat gele-koorts vaccinatie een bruikbaar model is om de 
interindividuele variatie in ontstekingsreactie te bestuderen. Daarnaast 
ondersteunen onze onderzoeksresultaten de hypothese dat genetische variatie 
in de promoters van genen de genrespons mede bepaalt. Wel moeten we 
opmerken dat de absolute effecten van de onderzochte polymorfismen op de 
bloedniveaus vrij klein waren, wat aangeeft dat het belang van de individuele 
polymorfismen voor het individu waarschijnlijk vrij beperkt zijn. 
Verscheidenen populatiestudies hebben aangetoond dat de –675(4G) variant 
van het  -675(4G/5G) polymorfisme in de PAI-1 promoter gerelateerd is aan 
verhoogde PAI-1 bloedniveaus. Echter, in deze studies is een ander 
polymorfisme in de PAI-1 promoter (-844A/G) buiten beschouwing gelaten. In 
onze studies hebben we ook het –844A/G polymorfisme, en de PAI-1 promoter 
haplotypen in beschouwing genomen (hoofdstuk 5). Hiervoor hebben wij een 
nieuwe, haplotype-specifieke PCR methode ontwikkeld, waarmee we de PAI-1 
promoter haplotypen bepaald hebben in twee onderzoeksgroepen van elk 
ongeveer 600 gezonde Caucasiërs. Vervolgens hebben we in deze mensen ook 
de PAI-1 bloedniveaus bepaald. Uit statistische analyse van de resultaten bleek 
in beide populaties een relatie te bestaan tussen het PAI-1 promoter haplotype 
en PAI-1 bloedniveaus. Hogere PAI-1 niveaus gaan samen met het 
-675(4G)/-844A haplotype, en lagere PAI-1 niveaus met het -675(5G)/-844G 
haplotype. Echter, deze relatie was alleen te detecteren in slanke mensen. Dit is 
te verklaren uit het feit dat PAI-1 bloedniveaus zeer sterk stijgen met 
toenemend lichaamsgewicht, en het is waarschijnlijk dat in mensen met 
overgewicht het effect van het PAI-1 haplotype op PAI-1 bloedniveaus 
overschaduwd wordt door het sterkere effect van een hoger lichaamsgewicht. 
Deze bevinding kan het belang van het PAI-1 promoter haplotype voor het 





slanke mensen lijkt het PAI-1 haplotype een meetbaar effect op PAI-1 levels te 
hebben, en dit zijn nu juist de mensen die vanwege hun lage lichaamsgewicht 
sowieso al een lager risico op (arteriële) hart- en vaatziekten hebben. Onze 
bevinding stemt overeen met die van eerdere onderzoeken, waarin meestal 
slechts een zwak of geen verband tussen PAI-1 promoter polymorfismen en 
risico op hart- en vaatziekten gevonden is. Over de rol van de andere twee PAI-1 
promoter haplotypen (-675(4G)/-844G en -675(5)/-844A) hebben we geen 
uitspraak kunnen doen omdat deze twee haplotypen vrij zeldzaam bleken te 
zijn. Hierdoor was de statistische zekerheid te laag om over de relatie van deze 
twee haplotypen met PAI-1 bloedniveaus een uitspraak te kunnen doen. 
Om toch meer te weten te komen over de (effecten van de) twee zeldzame 
haplotypes en over de polymorfismen afzonderlijk, hebben we ook PAI-1 
promoter-luciferase experimenten gedaan. Hiervoor hebben we HepG2 cellen 
en BAEC cellen (endotheelcellen geïsoleerd uit kalfsaorta’s) gebruikt. In deze 
experimenten hebben wij geen effect van de -844A/G en -675(4G/5G) 
polymorfismen, in welke combinatie dan ook, op PAI-1 promoter activiteit 
gevonden. Dit lijkt verrassend vanwege de aanwezigheid van de relatie tussen 
PAI-1 promoter haplotypen en PAI-1 bloedniveaus in de onderzoeksgroepen, 
maar de afwezigheid van een direct effect van de haplotypen op PAI-1 promoter 
activiteit in de experimenten is verklaarbaar. Mogelijk is een ander 
polymorfisme dan -675(4G/5G) of -844A/G, gelegen buiten de promoter maar 
wel samen voorkomend met de promoter polymorfismen, verantwoordelijk 
voor de effecten op bloedniveaus. Dit veronderstelde polymorfisme zou dus 
aanwezig zijn in de PAI-1 genen van de mensen in de onderzoeksgroep, maar 
ontbreekt in de luciferase experimenten die alleen de polymorfismen in de 
promoter in beschouwing namen. In andere delen van het PAI-1 gen zijn 
inderdaad polymorfismen aanwezig die (vrijwel) volledig samen voorkomen 
met de -675(4G/5G) en -844A/G polymorfismen. In het bijzonder de 
polymorfismen aan het uiteinde van het gen (het zogenaamde 3’ deel) kunnen 
erg interessant zijn, omdat er steeds meer bewijs komt dat behalve de promoter 
ook het 3’ deel van genen bepalend is voor de expressieniveaus van genen. Het 
is dus mogelijk dat de polymorfismen in het 3’ gebied de PAI-1 expressie 
beïnvloeden. 
Hoofdstuk 6 beschrijft de relaties van verscheidene omgevings- en genetische 
factoren met PAI-1 bloedniveaus in een populatie van 600 gezonde Caucasiërs. 
Dit hoofdstuk geeft meer achtergrondinformatie, en mogelijk nieuwe 
aanknopingspunten voor verder onderzoek. In onze onderzoeksgroep bleken 
PAI-1 plasma niveaus gerelateerd te zijn aan de verscheidene facetten van het 
metabool syndroom, en aan een verhoogde ontstekingsstatus (gereflecteerd 
door verhoogde bloedniveaus van de ontstekingsmarker CRP). Daarnaast 
vonden we verhoogde PAI-1 niveaus in mensen met overgewicht, in mensen die 
meer dan twee glazen alcohol per dag dronken, in mensen die lichamelijk 
minder actief zijn, en in niet-rokers (waarschijnlijk omdat de niet-rokers 




gerapporteerde resultaten. Wat betreft genetische variatie, vonden we de 
verwachte relatie tussen het -675(4G/5G) polymorfisme en PAI-1 bloedniveaus, 
en een relatie tussen het insuline receptor substraat-1 (IRS-1) Gly972Arg 
polymorfisme en PAI-1 plasma levels. IRS-1 is een belangrijke schakel in de 
overdracht van het insuline-signaal, en het is gebleken dat dragers van de IRS-1 
972Arg variant een verhoogd insuline bloedniveau hebben. Omdat insuline ook 
een belangrijke stimulator van PAI-1 expressie is, kan de verhoogde 
insulinespiegel in dragers van de IRS-1 972Arg variant het hogere PAI-1 
bloedniveau verklaren. 
De effecten van genetische variatie in de promoter gebieden van de fibrinogeen 
β en PAI-1 genen stonden centraal in het onderzoek dat in dit proefschrift 
beschreven is. Dit proefschrift geeft nieuwe inzichten in de relatie tussen 
genetische variatie van de fibrinogeen β en PAI-1 promoters en de fibrinogeen 
en PAI-1 bloedniveaus, en de onderliggende (moleculaire) mechanismen. 
Vanwege de sterke relatie tussen fibrinogeen en PAI-1 bloedniveaus en hart- en 
vaatziekten, draagt dit bij aan de basiskennis die noodzakelijk is voor het beter 











Dit proefschrift is het resultaat van vier jaar onderzoek uitgevoerd bij TNO 
Preventie en Gezondheid in Leiden en bij de sectie Hemostase van het Leids 
Universitair Medisch Centrum, onder begeleiding van Dr. Moniek de Maat en 
Dr. Hans Vos. Promoveren doe je niet alleen, dus op deze plaats wil ik graag 
aandacht geven aan een paar mensen in het bijzonder. 
Ten eerste ben ik natuurlijk diegenen dankbaar, die direct aan de resultaten 
beschreven in dit boekje hebben bijgedragen. Dus Antoine, Daniëlle, Hester en 
Martha: bedankt voor de inzet tijdens afstudeerprojecten en stages, en de 
interessante discussies. Dan wil ik Maureen in het bijzonder bedanken. Twee 
jaar lang hebben wij ons vastgebeten in de fibrinogeen en PAI-1 promoters, en 
de mooie resultaten van dit werk zijn zeker ook het gevolg van heel goed 
teamwork: 1+1=3! Ik ben dan ook heel gelukkig dat jij mij tijdens de officiële 
verdediging van ons werk als paranimf bijstaat. 
En natuurlijk wil ik ook alle andere collega’s op TNO en het LUMC bedanken, 
met name Monique, Simone, Ana, Nancy, Marlien, en René: heel veel dank voor 
alle gezelligheid en steun op TNO. En de andere AIO’s van ‘mijn generatie’ op 
het LUMC: Huib, Elaine, Cocky, Pernilla, Marieke, Marijn; dank voor alle hulp, 
maar zekere ook voor de ‘buitenschoolse’ activiteiten. De TNO-ers en LUMC-ers 
samen hebben mijn promotietijd behalve leerzaam en productief, ook heel 
aangenaam gemaakt.  
Tenslotte natuurlijk dank aan mijn vrienden en vriendinnen, mijn ouders, mijn 
broertje en de rest van mijn familie, die aan de zijlijn als betrokken supporters 
het hele tafereel hebben aanschouwd. Soms was ik onder de indruk hoe jullie, 
met beperkte achtergrondkennis, toch heel goed begrepen waar ik mee bezig 
was. Soms echter, leverden mijn verhalen ‘uit het lab’ enkel mistige blikken op, 
wat dan wel onmiddellijk weer de broodnodige relativering bracht…… 











De schrijfster van dit proefschrift werd op 12 februari 1975 geboren te 
Wageningen. 
Na het behalen van haar VWO diploma in 1993 aan Scholengemeenschap 
Durendael in Oisterwijk, ging zij Bioprocestechnologie studeren aan 
Wageningen Universiteit. Tijdens de studie werden twee afstudeervakken en 
een stage uitgevoerd. Tijdens het eerste (7-maands) afstudeervak bij de 
vakgroep Virologie werd een moleculair-biologisch onderzoek gedaan naar een 
vaccin tegen mond- en klauwzeer, onder begeleiding van Dr. D. Zuidema. 
Tijdens een tweede (5-maands) afstudeervak bij de vakgroep Communicatie en 
Innovatie studies werden de dilemma’s die leven rond biotechnologie bij dieren 
in kaart gebracht, met discursieve psychologie als onderzoeksperspectief. Dit 
onderzoek werd begeleid door Dr. H. F.M te Molder. Tenslotte werd een 5-
maands stage uitgevoerd aan the University of British Columbia in Vancouver 
B.C., Canada, in ‘the Laboratory of Marine Virology’ onder leiding van Prof. Dr. 
C.A. Suttle. Tijdens deze stage werd onderzoek gedaan naar de moleculaire 
biologie en de moleculaire ecologie van mariene virussen. 
Na het behalen van het doctoraal examen in september 1999, begon de 
schrijfster van dit proefschrift in november van datzelfde jaar aan haar 
promotieonderzoek onder leiding van Dr. M.P.M. de Maat (afdeling Biomedical 
Research, TNO Preventie en Gezondheid in Leiden) en Dr. H.L. Vos (sectie 
Hemostase en Trombose onderzoek, afdeling Hematologie van het Leids 
Universitair Medisch Centrum). De resultaten van dit onderzoek zijn te lezen in 
dit proefschrift. 
Sinds mei 2004 is de schrijfster van dit proefschrift werkzaam als Scientist op 
de afdeling Up Stream Processing van Crucell in Leiden, waar zij bijdraagt aan 
de ontwikkeling van vaccins.

 
 
 
